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SUMMARY 
Insulin plays an essential role in the maintenance of homeostasis of blood glucose, 
which relies on an adequate mass and functional insulin secretion in pancreatic β-
cells. It has been proven that the small G-protein Rac1 participates in glucose- and 
cAMP-induced insulin secretion. This effect is accomplished probably through 
maintaining a functional actin structure for recruitment of insulin granules. Both 
phosphatidylinositol-4-phosphate 5-kinase Iα (PIP5K-Iα) and p21-activated kinase 
1 (PAK1), the downstream effectors of Rac1, are suggested to be involved in 
mediating the action of Rac1 on actin cytoskeleton remodeling. In this thesis study, 
their potential roles in insulin secretion and cell survival were investigated in INS-1 
cell line, a widely-used pancreatic β-cell model. Using RNA interference technique, 
effective knockdown of PIP5K-Iα and PAK1 was achieved by reverse transfection 
of the targeting siRNA duplexes.  
PIP5K-Iα knockdown disrupted F-actin structure and caused changes in cell 
morphology. In addition, the content of its product, phosphatidylinositol-4,5-
bisphosphate (PIP2), on plasma membrane was reduced and the glucose effect of 
PIP2 hydrolysis was abolished by PIP5K-Iα knockdown. Although total insulin 
secretion in response to glucose and other stimuli was increased in PIP5K-Iα 
knockdown cells, the incremental insulin release over basal (2.8 mM glucose) 
stimulated by high glucose and forskolin was inhibited. However, at resting status, 
PIP5K-Iα knockdown increased glucose metabolism, depolarized membrane 
potential, raised cytoplasmic free Ca2+ levels ([Ca2+]i), and doubled insulin secretion. 
In contrast, metabolism and [Ca2+]i rises at high glucose were diminished. These 
results indicate that PIP5K-Iα may play a complex role in both the proximal and 
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distal steps of signaling cascades towards insulin secretion in β-cells, besides 
mediating the effect of Rac1 on actin cytoskeleton organization.  
On the other hand, PAK1 knockdown had no apparent effect on both F-actin 
cytoskeleton and insulin secretion by various stimuli. However, PAK1 knockdown 
attenuated INS-1 cell apoptosis and caspase-3 activation due to prolonged exposure 
to high (20 or 30 mM) glucose (glucotoxicity). In addition, glucotoxicity also led to 
activation of caspase-8 and -9, suggesting the involvement of both extrinsic and 
intrinsic apoptotic pathways. Prolonged exposure to high glucose activated PAK1 
and several mitogen-activation protein kinases (MAPKs), including p44/42 MAPK, 
p38 MAPK and c-jun-N-terminal kinase (JNK). However, it appeared that only  
p38 MAPK was activated downstream of PAK1 upon glucotoxicity. Moreover, both 
inhibitors for p38 MAPK and JNK were able to alleviate INS-1 cells from 
glucotoxicity-induced apoptotic death. This suggests that p38 MAPK, at least 
partially, mediated the protective role of PAK1 from glucotoxicity induced 
apoptosis.  
The data from this thesis work has demonstrated that both PIP5K-Iα and PAK1 play 
important roles in β-cells. The former may function as a downstream effector to 
mediate Rac1-induced organization of F-actin structure and regulation of insulin 
secretion, whereas the latter may be involved in the control of β-cell apoptosis and 
glucotoxicity. These results improved the understanding of β-cell biology and the 
molecular mechanism for pathogenesis of diabetes. 
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1. Introduction 
1.1 General background 
1.1.1 Diabetes mellitus and β-cell malfunction 
Diabetes mellitus is a disease characterized by chronic hyperglycemia and insulin 
deficiency with or without insulin resistance. It affects more than 170 million people 
worldwide in 2000, and the number is expected to be more than doubling by the end 
of 2030 as estimated by world health organization (WHO) (1). Type 1 diabetes 
(insulin-dependent diabetes mellitus) and type 2 diabetes (non-insulin-dependent 
diabetes mellitus) represent the two major types of diabetes mellitus. Although, from 
the epidemiological point of view, they are two distinct diseases, it is difficult to draw 
a line between them. On the other hand, from a clinical point of view, type 1 and type 
2 diabetes mellitus are often viewed as the two ends of spectrum with some 
similarities overlapping in the middle. The middle-overlapping portion is the 
dysfunction of insulin secretion, which is present in both types of diabetes to varying 
degree.  
Acting as insulin secreting cells, pancreatic β-cells play a critical role in the 
development and progression of diabetes mellitus. Thousands of pancreatic β-cells are 
located in a spherical cluster called islet of Langerhans (named after the discoverer in 
1869), which scatter throughout the pancreas especially at the pancreas tail. Besides 
pancreatic β-cells, the islet of Langerhans comprises a small quantity of other 
endocrine cells (i.e. α, δ, and pp) (20-40%). In type 1 diabetes mellitus (T1DM), 
autoimmune attack mediated by cytotoxic T-lymphocytes destroys pancreatic β-cells 
thereby interrupting insulin secretion. Although the type 2 diabetes mellitus (T2DM) 
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is mainly due to insulin resistance, β-cell destruction by hyperglycemia is also 
believed to be a critical etiological factor for its development (2). However, the β-cell 
failure is not attributed solely to the loss of β-cell mass, but also the abnormal 
function of the remaining β-cells. Hyperinsulinemia evoked by prolonged 
hyperglycemia results in pancreatic β-cells exhaustion in type 2 diabetes. Thereafter, 
the glucose stimulated insulin secretion (GSIS) is diminished and β-cell 
dedifferentiated (3).  
1.1.2 Effect of hyperglycemia on β-cells 
Diabetes is the major risk factor for various cardiovascular complications. Chronic 
hyperglycemia can cause not only vascular dysfunctions (4-6) but also deteriorate 
functions of pancreatic β-cells (7-9). Elevated glucose concentrations can induce 
impaired insulin biosynthesis and secretion and ultimately lead to β-cell death. This is 
known as glucotoxicity (7-9). In fact, high concentrations of glucose have a dual 
effect on β-cell mass turnover (10;11). Short-term exposure of human islets to 
increased concentrations of glucose enhances insulin production and β-cell 
proliferation, whereas prolonged exposure has toxic effects leading to impaired 
insulin secretion (12;13) and β-cell apoptosis (14;15). A loss of β-cell mass is 
implicated in both type 1 and type 2 diabetes; the former is due to autoimmune 
destruction of islet β-cells whereas the latter is attributable to glucotoxicity to a large 
extent. 
1.1.3 Insulin biosynthesis  
The physiological glucose homeostasis is maintained within a narrow range, which 
mainly owes to the precise regulation of insulin secretion. The discovery of insulin 
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was awarded the Nobel Prize in 1921. Ever since the discovery, the insulin has 
attracted interest of scientists from various fields of research. 
Insulin is naturally created from the translation of insulin mRNAs (messenger 
ribonucleotide acid). Initially, the insulin is in an inactive form, known as 
preproinsulin, which is a single chain precursor, composed of 110 amino acids at 
rough endoplasmic reticulum (RER). A signal peptide region of 24 amino acids 
enriched with hydrophobic residues (at the amino terminus of preproinsulin) enables 
it to translocate into the RER lumen via a series of interactions of the signal peptide 
with the signal recognition particle (SRP) and the SRP-receptor in the RER membrane 
(16). Consequently, the signal peptide is cleaved by a signal peptidase located on the 
luminal side of RER membrane, and a prohormone of 86 amino acids, known as 
proinsulin, is produced. Within the cisternae of RER, proinsulin is folded and 
disulfide bonds are formed to generate the native tertiary structure. The structure 
consists of a C-peptide (35 amino acids) at the center of the proinsulin sequence with 
A-chain (21 amino acids) and B-chain (30 amino acids) at the two ends separately 
(17). The two disulfide bonds between A-chain and B-chain enable them to remain 
connected. In the native tertiary structure, proinsulin is transported to the Golgi 
apparatus and then packed to clathrin-coated secretory granules budding from the 
trans-Golgi. Within the Golgi apparatus and immature granules, proinsulin undergoes 
a series of maturation steps. First, the prohormone convertases, PC1/3, clips off the C-
peptide from proinsulin to produce the biologically active insulin (51 amino acids), 
comprised of the A-chain and the B-chain.  Afterwards, an equal amount of C-peptide 
and mature insulin are stored in secretary granules and secreted together upon 
stimulation (18).  
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1.1.4 Regulation of insulin secretion 
Pancreatic β-cells are able to secrete insulin appropriately in response to a wide range 
of glucose levels. From the biochemical standpoint, the β-cells are specialized in their 
high rate of glycolytic and insulin-independent glucose metabolism. These β-cells 
have a unique ability that allows the cells to control the secretion using the available 
metabolizable nutrients, without mediating the ligand-specific cell surface. The two 
important glucose sensors, glucose transporter-2 (Glut2) and glucokinase, are critical 
for glucose metabolism in β-cells (19). Upon diffused into β-cells through Glut2, 
glucose is phosphorylated by glucokinase and metabolized into acetyl-coenzyme A 
(Ac-CoA) through the glycolytic pathway. Ac-CoA is then further metabolized in 
mitochondria, resulting in a rise of cellular ATP-to-ADP ratio, followed by closure of 
ATP-sensitive K+ (KATP) channels, and hence leading to the depolarization of 
membrane potential. Thereafter, the opening of voltage-operated Ca2+ channels (20-
22) ensues and the increased of Ca2+ influx elevates the cytoplasmic free Ca2+ 
concentrations ([Ca2+]i). It is believed that such an increase of [Ca2+]i is  the trigger 
signal for insulin secretion. (23;24).  
Besides glucose, the primary physiological stimulator for insulin secretion, there are 
many other factors that are involved in the complex insulin secretion process. All of 
these factors can be generally categorized into three groups: initiators, potentiators 
and inhibitors (24). The initiator group consists of many nutrients, such as other 
carbohydrates, amino acids and fatty acids. These nutrients are capable of initiating 
insulin secretion on their own through metabolic coupling factors (MCF). Arginine, 
on the other hand, initiates insulin secretion by depolarizing the plasma membrane in 
a KATP-channel independent manner due to its transport in a positive charge form (24-
27). In addition, typical pharmacological agents: sulphonylureas, e.g. tolbutamide and 
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glibenclamide, used for clinical treatment of diabetes, are potent KATP-channel 
blocker, and thereby able to initiate insulin secretion in the presence of moderate 
glucose (24;28;29). Potentiators are secretagogues that are not able to initiate insulin 
secretion directly by themselves, but they do enhance secretion in the presence of an 
initiator. For instance, acetylcholine and cholecystokinin are able to promote 
phosphoinositide breakdown and result in the mobilization of Ca2+ from intracellular 
stores and the activation of protein kinase C (PKC) (24;30). Other potentiators, gastric 
insulinotropic polypeptide (GIP) (31), the intestinal glucoincretin hormones 
glucagons-like peptide 1(GLP-1) (32), and pituitary adenylate cyclase activating 
protein (PACAP), activate adenylate cyclase. This causes the rise in cyclic AMP 
(cAMP) levels, which activate cAMP-dependent protein kinase A (PKA) followed by 
potentiation of insulin secretion (24;31;33-35). In contrast, inhibitors are able to 
reduce activation of adenylate cyclase, modify Ca2+ and K+ channel gating or directly 
affect exocytosis to suppress insulin secretion. Inhibitors are comprised of 
neurotransmitters and hormones such as somatostatin, glanin and adrenalin 
(34;36;37).  
1.1.5 Insulin granules exocytosis  
Pancreatic β-cells show a biphasic insulin secretion process when exposed to abrupt 
and sustained increase in the ambient glucose concentration. The biphasic pattern of 
secretion starts with a rapid and transient increase of secretion (first phase) and then 
followed by a slow and sustained secretion (second phase). There are two mechanism 
models underlying this biphasic response: the “storage-limited model” and “the 
signal-limited model” (20;33;38). According to the “storage-limited model”, insulin 
granules are located in geographically and functionally distinct pools. They are the 
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readily releasable pool and the reserve pool. Release of insulin granules from readily 
releasable pool gives rise to the first phase, followed by energy-consuming 
recruitment of granules from reserve pool to the plasma membrane. The release of 
these granules corresponds to the second phase of insulin secretion. However, 
according to the “signal-limited model”, the biphasic response is a result of biphasic 
triggering signals. In this model, the Ca2+ influx acts as the triggering signal with 
some unclear biochemical mechanisms amplifying the Ca2+ efficacy.  While these two 
models have their own unique point of view, they are however not mutually exclusive 
and both ideas could coexist (38-41). 
Insulin stored in large dense core vesicles (LDCV), the secretory granules (diameter ≈ 
0.3 µm), is released by a series of steps in terms of exocytosis, involving the approach 
of vesicles to the plasma membrane, followed by docking, priming, fusion with the 
plasma membrane and finally release to the extracellular space. Upon stimulations, 
even at the maximal stimulatory conditions, only a small proportion of insulin is 
released by aforementioned exocytosis, whereas most of insulin is stored in secretory 
granules (41). A healthy β-cell contains more than 13,000 insulin-containing granules. 
However, only a small fraction, as low as 0.05% of granules, stay in the primed ready 
releasable pool (RRP) (39;41). The recruitment of the insulin granules from 
biosynthetic or storage pools in the cytoplasm to the plasma membrane is facilitated 
by cytoskeleton including microtubules and microfilament. After reaching the plasma 
membrane, insulin granules interact with plasma membrane reversibly in close 
proximity to the exocytotic site, named docking. The priming of insulin granules is an 
ATP-dependent irreversible process, in which, soluble N-ethylmaleimide-sensitive 
factor attachment protein receptor (SNARE) complex is formed and the generation of 
phosphoinositol-4,5-bisphosphate (PIP2) is needed. Although, SNAREs were 
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originally identified as synaptic proteins, β-cells express a full repertoire of SNAREs 
proteins. Synaptobrevin [vesicle-attached membrane protein (VAMP-2)] and 
cellubrevin are expressed on the β-granules as v-SNAREs, whereas syntaxin I and 
soluble N-ethylmaleimide-sensitive factor attachment protein-25 (SNAP-25) are 
expressed on the plasma membrane as t-SNAREs. The primed granules are fused with 
plasma membrane by Ca2+ binding to sensor proteins such as synaptotagmin. In 
addition, PKA takes effect at the post-priming step, perhaps by increasing the number 
of granules in ready releasable granules in response to Ca2+ (23;42;43). 
1.2 Rho GTPases, cytoskeleton, insulin secretion and 
viability of β-cells 
1.2.1 Re-organization of cytoskeleton in exocytosis 
The recruitment of insulin granules from biosynthetic or storage pools to the 
exocytotic sites needs the reorganization of cytoskeleton. Based on the fluorescence 
microscopy, the actin filament is visualized mainly as a cortical network beneath the 
plasma membrane (44). The secreting cell population preferentially displays 
relocalization and polymerization of actin, suggesting a strong correlation between 
them (45;46). By using a new technique, transmitted light images, F-actin 
cytoskeleton dynamics was observed directly in neuroendocrine cells and the notion 
that F-actin cytoskeleton acted simultaneously as a barrier and carrier system during 
secretion was supported (44).  
As for pancreatic β-cell models, it is interesting that disruption of the actin 
cytoskeleton by using cytochalasin B or latrunculin B enhanced insulin secretion from 
MIN6 cells or islet (47-49). On the other hand, by using Clostridium botulinum C2 
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which also reduces F-actin filaments, the insulin secretion was inhibited (50). It 
suggests that actin cytoskeleton may also play a role in facilitating the recruitment of 
granules. Glucose, the most important physiological secretogogue for insulin 
secretion was found to modulate cortical actin organization and disrupt its interaction 
with the plasma membrane t-SNARE complex at a distal regulatory step of insulin 
secretion (49).  Taken together, actin cytoskeleton dynamic is critical for insulin 
granule transportation. The actin cytoskeleton may act as a barrier to obstruct the 
access of insulin secretory granules and re-organization of cortical actin skeleton may 
facilitate the approach of granules. However, the mechanism underlying the 
reorganization of actin-cytoskeleton in insulin secretion remains unclear. 
1.2.2 Regulators of cytoskeleton involved in exocytosis 
There are at least sixty members of small monomeric [20-30 kDa (kilo-Dalton)] GTP-
binding proteins (G-proteins) in mammals, which fall into five major groups: Ras, 
Rho, Rab, Arf and Ran. There are >20 members of Rho GTPases family in 
mammalian cells, including Rho (three isoforms; A, B, C), Rac (1 to 5), Cdc42, 
TC10, TCL, Chp, Rho G, Rnd, RhoBTB, Rho D, Rif and TTF. The most extensively 
characterized members are Rho, Rac and Cdc42 (51;52). Rho family is related to the 
reorganization of the cytoskeleton. Rho has been shown to regulate the formation of 
actin stress fibers and focal adhesion (53). On the other hand, Rac1 specifically 
induces membrane ruffling and lamellipodia formation (53-55) while Cdc42 mediates 
the formation of filopodia and actin microspikes (54;56).  
Since some small G-proteins are the major regulators for actin cytoskeleton, a variety 
of studies have been carried out for their roles in insulin secretion (46;57;58). 
Monomeric G-protein (GTPase) acts as a molecular switch, cycling between an active 
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(GTP-bound) and an inactive (GDP-bound) conformation (51). These G-proteins 
possess GTPase activity to various degrees. Several studies have also established a 
permissive role for GTP in insulin secretion elicited by glucose (59-62). Depletion of 
cellular GTP in islet β-cells might cause inactivation of some small G-proteins (63) 
and inhibited insulin release stimulated by glucose and other secretagogues 
(59;61;64). Recently the increasing number of evidence suggests that G-proteins play 
various important regulatory roles in physiological insulin secretion from the islet β-
cells (65;66). Besides the critical role in regulation of cytoskeletal organization, Rac 
and Rho have also been linked to the signaling cascades towards exocytosis 
(45;46;57;58;66;67). 
1.2.3   insulin-secreting cell models for pancreatic β-cell  
As for pancreatic β-cells, the study is limited by the availability of primary cells. 
Isolation of islets of Langerhans to obtain pancreatic β-cells is a labor-intensive and 
technique-demanding procedure. Moreover, it is difficult to maintain the primary 
culture of β-cells for a long period of time as β-cells are highly differentiated and not 
able to proliferate in vitro and their ability to synthesize insulin is rapidly decreased. 
As a result, several insulin-secreting cell lines have been established from induced 
insulinomas, viral transformation, transgenic mice or other methods as reviewed in 
(68) and compared in (69). Currently, there are a number of widely used insulin-
secreting cell lines. These includes RIN (70), HIT (71), BRIN-BD11 (72), MIN6 (73) 
and INS-1 cells (74). In 1992, Asfari et al established a highly differentiated insulin-
secreting cell line, INS-1, from cells isolated from X-ray-induced rat insulinoma (74). 
INS-1 cells, containing the highest insulin content (around 8 µg/106cells, 
corresponding to 20% of the native β cell content) among the widely-used β-cell 
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models, have been studied thoroughly in various aspects and reported in more than 
2000 published journal papers. INS-1 cells express glucokinase predominantly, and 
are able to synthesize proinsulin I and II. Glucose stimulation depolarizes INS-1 cell 
plasma membrane and raises cytosolic Ca2+ concentrations, thereby induce insulin 
secretion in a dose-dependent manner with a Km similar to that in native β cells. In 
addition, INS-1 cells give significant insulin secretion in response to non-glucose 
secretagogues for instance carbachol and glibenclamide (69). Furthermore, INS-1 
cells are stable in culture for many passages (74). All of abovementioned 
characteristics make INS-1 cells a suitable model for β-cell function study at various 
aspects. 
1.2.4   Role of Rho GTPases in exocytosis 
In some other secretory cells, it has been reported that the activation of RhoA, Rac1 
and Rho GDI could be induced in Ca2+-dependent exocytosis at least partly through 
the reorganization of actin filaments in PC12 cells (46). Cdc42 and Rac stimulated 
exocytosis of secretory granules by activating the IP3/Ca2+ pathway in RBL-2H3 Mast 
cells (57). Secretory stimuli could activate Rac1 and modulated the secretory pathway 
downstream of Ca2+ influx, partly through regulation of cytoskeletal organization in 
bovine chromaffin cells (58). Rac on vesicles has been reported to be required for the 
fusion competence of exocytotic sites after docking of synaptic vesicles in ganglion 
(75). 
In some β-cell models, Cdc42 was shown to bind directly to VAMP2 independent of 
its activation in vitro (76), and GDP-bound Cdc42 was required for glucose induced 
insulin secretion in MIN6 cells (77). In contrast, a recent report has shown that Cdc42 
deletion mediated by small interfering RNA resulted in the selective loss of second-
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phase insulin release in isolated islets (78). Furthermore, deletion of PAK1 abolished 
glucose-stimulated insulin release in MIN6 cells (78). As for INS-1 β cell model, 
earlier studies from this lab have reported that Rac1 is involved in signal cascade of 
glucose-stimulated insulin secretion in INS-1 cells (66). Transfection of a dominant-
negative Rac1 mutant (N17Rac1) (66) abolished glucose-induced Rac1 activation and 
inhibited glucose- and forskolin-stimulated insulin secretion, especially the late phase 
of secretion, in addition of leading to morphological changes and disruption of F-actin 
structure. However the active-mutant (V12Rac1) had no effect on both basal and 
stimulated insulin secretion (66), suggesting an essential but not sufficient role of 
Rac1 activation in the process of insulin secretion possibly at the level of recruitment 
of secretory granules through actin cytoskeletal network reorganization. However, the 
precise mechanism of Rac1 involved in cortical actin remodeling and insulin secretion 
remains uncertain. 
1.2.5   Role of Rac in cell viability 
Besides a role in the regulation of secretory events, Rac1 is believed to play dual roles 
in cell growth and apoptosis depending on the cell type and the extracellular stimuli. 
Upon UV-irradiation (79;80), death receptor activation (81), or growth factor 
deprivation (82-84), Rac1 was activated in fibroblasts and hematopoietic cells. 
Overexpression of constitutive-active Rac1 induced apoptosis in fibroblasts (84;85), 
neurons (86), and epithelial cells (87), whereas RNA interference-mediated 
knockdown of Rac greatly reduced Fas-dependent, TCR-induced apoptosis in T 
lymphocytes (88). However, the pro-apoptotic mechanism of Rac1 was not 
explicated. Rac was capable of stimulating the activation of stress kinase pathways 
through JNK (Jun amino terminal kinase) and p38 MAPK, which was involved in 
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apoptosis induced by UV radiation, osmotic shock or inflammatory cytokines (80;89). 
Additionally, Rac1 has been reported to be cleaved by caspase-3 in lymphoma cells 
and may be implicated in morphological changes during apoptosis (90).  On the other 
hand, Rac promoted cell survival primarily through its effects on cell proliferation. 
Rac was able to activate several critical cell-cycle checkpoint factors, c-Jun (91;92), 
E2F-1 (93), cyclinD1 (94;95), and nuclear factor NF-κB (96). Furthermore, Rac could 
promote cell survival through its downstream effectors, PAK or protein kinase A 
(PKA), which was reported to phosphorylate BAD, a proapoptotic member of Bcl 
family (97-101).   
The deleterious effect of hyperglycemia has been explored extensively in endothelial 
cells, and accumulating evidence suggests an involvement of Rac.  Rac activation due 
to prolonged exposure to elevated glucose levels was found in HUVECs (human 
umbilical vein endothelial cells) (102), pericytes (103) and human aortic endothelial 
cells (HAEC) (104). Expression of dominant negative mutant of Rac1 (N17-Rac1) 
prevented hyperglycemia caused caspase-3 activity and apoptosis in pericytes (PCs) 
(103). Endothelial cells treated with high glucose is associated with an increased 
activation of the pathway Rac/Pak1/NADPH oxidase (nicotinamide adenine 
dinucleotide phosphate oxidase) (102;104;105), leading to ROS production (105). The 
increased NF-κB activity downstream of Rac1 acted as a mediated signaling in 
hyperglycemia-triggered apoptosis (102).  However, the evidence for the role of Rac 
involved in the damage of hyperglycemia on pancreatic β-cells is still absent.  
1.3 Effectors act downstream of small G-protein Rac1 
There are many proteins that act downstream of Rac activation, such as 
phosphatidylinositol-4-phosphate 5-kinase (PI-4-P5K), p21 activated kinase (PAK), 
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phosphoinositide 3-kinase (PI3K), mixed lineage kinase (MLK) and POR1. Their 
functions are involved in actin organization, activation of JNK and NADPH oxidase, 
cell-cell contact, secretion, transformation and others as reviewed in (52;106). 
However, the downstream effector(s) which functions as downstream of Rac1 in the 
process of insulin secretion remains unknown. In this thesis study, interest has been 
focused on 2 effectors of Rac1: an isoenzyme of phosphatidylinositol-4-phosphate 5-
kinases (PIP5K-Iα) and an isoform (PAK1) of the P21-activated kinase. (Fig. 1) 
 
Fig. 1. Schematic diagram for the 
possible role of downstream effectors of 
Rac in insulin secretion.  
Rac has a role in the glucose stimulated 
insulin secretion probably acting on the 
translocation of insulin secretory granules 
by modifying actin cytoskeleton. A 
number of downstream effectors of Rac 
act as regulators for actin cytoskeleton. 
Among them PIP5K Iα and PAK1 were 
chosen as the candidates. 
1.3.1 Phosphatidylinositol-4-phosphate 5-kinase (PIP5K) 
1.3.1.1 Nomenclature of PIP5K 
PIP5K catalyzes biosynthesis of phosphatidylinositol-4,5-bisphosphate (PIP2) from 
phosphatidylinositol 4-phosphate (PtdIns[4]P), an important step of phosphoinositide 
cycle (107). PIP2 is directly involved in diverse fundamental cellular processes, 
including actin polymerization (108), focal adhesion assembly (109), modulation of 
ATP-sensitive K+ channels (110;111), and membrane trafficking (secretory vesicle 
cycle, regulated exocytosis and clathrin-mediated endocytosis) (112). In addition, the 
hydrolysis of PIP2 by phospholipase C (PLC) produces 2 important second 
messengers, diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3). DAG is an 
Rac
Actin cytoskeleton
Glucose induced insulin secretion
? PIP5K-Iα, PAK1
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activator of protein kinase C, while IP3 induces calcium release from the intracellular 
store (113). 
Two types of PIP5K have been identified to date. The type I PIP5K includes three 
members, α, β, and γ. In 1996, two independent groups (107;114) identified both α 
and β forms of type I PIP5K from human and mouse cells. However, the 
nomenclature for PIP5K-Iα and PIP5K-Iβ was permuted in the 2 species. In the 
present study, PIP5K-Iα was referring to the murine form, which is equivalent to 
human PIP5K-Iβ. In 1998, a third isoform, PIP5K-Iγ, was cloned (115), which has 
two splice variants (87 and 90 kDa) and selectively expressed in brain (115;116).  
The type II PIP5K (53 kDa) should be considered as PIP4K, which phosphorylates 
phosphatidylinositol 5-phosphate (PtdIns[5]P) at D-4 position to catalyzes 
biosynthesis of phosphatidylinositol-4,5-bisphosphate (PIP2), unlike type I PIP5Ks 
which phosphorylate phosphatidylinositol 4-phosphate (PtdIns[4]P) at D-5 position 
(as shown in the below flow-chart). The nomenclature of this group of PIP5Ks as type 
II PIP5K is due to an early error in characterization (117). Furthermore, unlike Type I 
PIP5Ks, type II PIP5Ks are insensitive to phosphatidic acid (107;118;119) and they 
do not interact with small G-proteins Rac and Rho (120-122). In addition, type II 
PIP5Ks are not required for the priming step of neurotransmitter exocytosis in the 
permeabilized PC 12 cells as type I PIP5K does (112;123;124). Therefore, my thesis 
study has focused on an isoform of type I PIP5Ks. 
 
1.3.1.2 Structure and distribution of PIP5K 
The three type I PIP5K isoforms have a highly conserved central kinase homology 
domain (~80% sequence identify), a region of approximately 380 amino acids 
PtdIns(4)P PIP5K PtdIns[4,5] P2 PLC DAG+Ins[1,4,5]P3
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determined by deletion mutation analysis (125).  Therefore, the divergent amino and 
carboxyl terminal extensions are likely to contribute to the isoform-specific functions 
and regulations (126-132) (Table 1). Comparing among the type I PIP5K isoforms, 
PIP5K-Iβ has the greatest Vmax value for the PtdIns(4)P kinase activity and PIP5K-Iγ 
is the most sensitive isoform towards phosphatidic acid stimulation. The carboxyl-
terminal region of each isoform was believed to give rise to such different activity. 
Interestingly, PIP5K-Iα retained its lipid kinase activity even after deletion of both 
amino- and/or carboxyl-terminal region (115). A 20-25 amino acids sequence located 
near the catalytic site was termed as activation loop, which was believed to be vital 
for the kinase’s localization on the plasma membrane and was a determinant for its 
substrate specificity (133). The PIP5Ks’ homology domain is necessary for their 
association with the plasma membrane (125). Two lysine motifs on the activation 
loop, which are evolutionary conserved in PIP5Ks from yeast to human, were shown 
to be critical for such association (125;133;134). The association of PIP5Ks with the 
plasma membrane is regulated by small G-proteins (135;136).  
Northern blot analysis revealed that type I PIP5Ks distribute ubiquitously, but varied 
considerably in expression levels (107). PIP5K-Iα is expressed moderately in 
pancreas and brain, but considerably more in heart. PIP5K-Iα is also detected in 
placenta, lung, and kidney (107). PIP5K-Iβ, also a widely distributed, is expressed 
mainly in skeletal muscle, but also in pancreas at a moderate level (107). PIP5K-Iγ 
has rather different distribution as compared to that of PIP5K-Iα or PIP5K-Iβ, since 
its expression is restricted to the brain, lung and kidneys (115). However, our previous 
study shows that PIP5K-Iα was detected and translocated upon glucose stimulation in 
INS-1 cells (137).  In the case of microcosmic view, type I PIP5Ks are present 
throughout the whole cell, including the plasma membrane, endoplasmic reticulum, 
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plasma membrane-associated cytoskeleton and nuclei (114;138) as reviewed in (139). 
Moreover a small fraction of type I PIP5K exists as a soluble protein in the cytoplasm 
(108;140).  
Table 1. PIP5K family  
Group Name Aliases Mass Cellular function 
PIP5K I α  hPIP5K I β 68kDa 
PIP5K I β hPIP5K I α 68kDa 
I 





II PIP4K (nomenclature error)  
 1.3.1.3 Regulation of PIP5K 
An important regulatory characteristic of type I PIP5Ks is their sensitivity to 
phosphatidic acid (PA) (118;141). PA is a product synthesized by both DAG kinase 
(142) and phospholipase D (PLD) (143;144). PLD in turn can be activated by PIP2 
(145;146). Thus, it establishes a positive feedback loop to amplify the intracellular 
signal, which is vital for the regulation of type I PIP5Ks. However, the physiological 
activation of PIP5Ks and function in various cellular processes are regulated tightly 
by small GTPases. 
All PIP5K isoforms are activated by small GTPases such as RhoA (120), Rac1 (147), 
and ADP-ribosylation factor (Arf)6 (148), (reviewed in (149)), thus mediating their 
regulation on actin cytoskeleton (reviewed in (135;136;150)). Rac interacts with type 
I PIP5Ks directly, which is independent of GTP (147;151). The C terminus of Rac is 
necessary and sufficient for its binding with PIP5K. The products of PIP5K are 
involved in several Rac-regulated processes, and thus they are potentially important in 
Rac activation of the NADPH oxidase, actin polymerization and other signaling 
pathways (151). RhoA also binds to PIP5K independent of activation, and PIP5K can 
be activated by GTP-bound RhoA (151). In addition, Arf6 regulates actin 
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cytoskeleton, non clathrin-derived endosomal compartment recycle, and vesicle 
priming for exocytosis through PIP5K activation and PIP2 turnover (148;152-154). 
Moreover, GTP-bounded Arf6 is also recruited and co-localized with PIP5K-Iα at 
ruffling membranes upon stimulation (144). Since Arf6 can act upstream or 
downstream of RhoA and Rac, Arf6 may coordinate with other small G proteins to 
regulate PIP5K. 
PIP5Ks are activated not only by small GTPases but also by Ser/Thr 
dephosphorylation (132;155). cAMP-dependent protein kinase A suppressed PIP5K-
Iα by phosphorylation and the Ser214 of PIP5K-Iα is the major phosphorylation site 
(155). On the other hand, lysophosphatidic acid dephosphorylated and activated 
PIP5K in a PKC-dependent manner in NIH 3T3 cells (155). Moreover, hypertonicity 
could activate PIP5K-Iα, but not other isoforms by dephosphorylation, and promoted 
its association with the plasma membrane (132). Therefore¸ the activation of PIP5K is 
regulated by a balance between protein kinases and phosphatases and PIP5Ks may 
have isoform-specific regulation and response to stimulations (107;156).  
1.3.1.4 Biological function of PIP5K and PIP2 
PIP5Ks regulate multiple fundamental cellular processes including vesicular 
trafficking, cytoskeletal organization and cell survival.   
• Actin cytoskeleton 
Since more than half of cellular PIP5K is associated with cytoskeletal proteins in 
many cell types (157), PIP5K isoforms are convinced to be critical mediators of Rac-
induced actin dynamics. Plenty of studies have been carried out in this area. The actin 
polymerization has been reported after PIP5K-Iα overexpression. However, the types 
of actin filament formation varied over cell types and may be dependant on the extent 
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of overexpression (108;109;158-160). For instance, in COS-7 cells, PIP5K-Iα induced 
massive actin polymerization resembling “pine needles”, which was abolished after 
truncation of the C-terminus of PIP5K-Iα (108). Moreover, PIP5K-Iα was recruited to 
the plasma membrane to form membrane ruffles (144). PIP5K-Iα overexpression also 
promoted various other process, such as stress fiber formation in CV1 cells (160), the 
motile actin comets formation in Swiss 3T3 cells (161), and the ezrin recruitment to 
cell adherent junctions in Rac1-dependent manner in epithelial cells (109) or to 
microvilli in Rho-dependent manner in HeLa cells (158). On the other hand, a kinase-
deficient substitution mutant of PIP5K-Iα blocked Rac mediated actin assembly in 
platelets (159). As for other isoforms of type I PIP5Ks, overexpression of either β or γ 
isoform increased the number of short actin fibers but decreased the number of actin 
stress fibers in COS-7 cells (115). In addition, PIP5K produced PIP2 was visualized to 
be concentrated in highly dynamic actin-rich regions (162-164) and was involved in 
the regulation of cytoskeleton by modulating profilin, cofilin, fascin, and gelsolin, as 
reviewed in (165). 
• Membrane trafficking 
The roles of Type I PIP5Ks in membrane trafficking have been described in several 
reviews (134), even though more studies have been done in endocytosis than in 
exocytosis previously. Hay et al has found that type I PIP5Ks were required for ATP-
dependent steps in Ca2+-activated secretion in PC12 cells, since the cytosolic PEP 1 
proteins (priming in exocytosis proteins) consists of both PIP5K-Iα and -Iβ and, 
furthermore, PIP2 specific antibody inhibited Ca2+-activated secretion (112). Other 
researchers also indicated that the central kinase domain of type I PIP5K was 
necessary and sufficient for the priming process of exocytosis (166). In addition, 
PIP5K was critical for ARF6 induced Ca2+-dependent exocytosis in PC12 cells (152). 
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On the other hand, in the type I PIP5K knockout model that was deficient in the 
expression of PIP5K-Iγ, the dominant neuronal type I PIP5K isoform, the mice 
exhibited destructions in both exo- and endocytosis of synaptic vesicles (126). 
Furthermore, defects in large dense-core vesicle (LDCV) priming and a delay in 
fusion pore expansion was revealed in chromaffin cells of knockout mice (167). As 
for the pancreatic β-cells, Waselle et al has recently shown the depletion of PIP5K-Iγ 
by RNAi (RNA interference) reduced exocytosis from INS-1 cells and MIN6 cells, in 
the presence of various stimuli including glucose, forskolin, high KCl, and isobutyl-1-
methylxanthine (168). However, the mechanism how PIP5Ks influence vesicle 
trafficking is not clear. It is believed that the actin remodeling by PIP5K may play a 
crucial role. Overexpression of PIP5K evoked actin polymerization on membrane-
bound vesicles to form actin comets, which is responsible for propelling the vesicle 
motililty (161). Additionally, PIP2 may also contribute to vesicle trafficking mediated 
by PIP5K.  As detected by immunocytochemistry, PIP2 was found to colocalize with 
secretory granules in PC12 cells (169).  The complicated cellular functions of PIP2, 
playing the role of a second messenger, will be discussed later in other sections.  
The positive role of PIP5Ks on endocytosis by modification of actin cytoskeleton has 
been thoroughly studied. Among the three isoforms of type I PIP5Ks, overexpression 
of mouse PIP5K-Iα exhibited the highest increase of PIP2 (by 180%) and increased 
the clathrin-mediated constitutive endocytosis of the transferring receptors in CV-1 
cells (140). On the other hand, the knockdown of PIP5K-Iα by siRNA inhibited 
transferrin intake in Hela cells, which made PIP5K-Iα a major contributor to the 
endocytosis (140). As for the other isoforms, PIP5K-Iβ overexpression promoted 
accumulation of PIP2 positive actin-coated vacuoles in Hela cells (148) and 
overexpression of PIP5K-Iγ induced endosomal tubules formation in COS-7 cells 
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(154) and enhanced endocytosis in neuron (170) and kidney cells (171). Furthermore, 
overexpression of either PIP5K-Iα or PIP5K-Iβ promoted actin polymerization from 
membrane-bound vesicles to generate motile actin comets in Swiss 3T3 fibroblasts 
(161). During phagocytosis, PIP5K-Iα was recruited to phagocytic cup and acted 
downstream of Rac1 to induce cytoskeletal alteration for phagosis (172;173). 
However, it was also reported that overexpression of any isoform of type I PIP5Ks 
inhibited phagocytosis which required removal of PIP2 at the plasma membrane (174).  
• Production of second messengers  
PIP2 acts as a mediator and is involved in numerous cellular processes, including actin 
dynamics at the cell cortex (175-178), actin cytoskeleton adhesion to plasma 
membrane (179;180), vesicle  trafficking (169;181;182)and cell survival (183). Ever 
since it has been confirmed by immunofluorescence staining, the existence of PIP2 
microdomains has attracted much attention of researchers, and may result in the 
discovery of the precise cellular functions (162;181). Accordingly the distinct 
functions of different isoforms of PIP5K discovered by several studies may be 
explained by the synthesis of heterogenous PIP2 microdomains. In addition, the 
hydrolysis of PIP2 catalyzed by PLC produce the another two important second 
messengers diacylglycerol (DAG) and IP3, which are involved in many cellular 
processes including exocytosis, cell growth, transformation and so on (113). 
• Ion channels 
Baukrowitz et al found that PIP2 acted on the Kir6.2 subunit and inhibited ATP 
sensitivity of KATP channel (111). And there is also evidence showing that PIP5K was 
implicated in the modulation of the KATP channel. Expressing PIP5K reduced the ATP 
sensitivity of KATP channel in CoSm6 cells whereas expressing inactive PIP5K 
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restored the ATP sensitivity (110). Overexpression of PIP5K-Iβ in INS-1 cells 
decreases the ATP sensitivity of KATP channels thus inhibiting glucose induced insulin 
sescretion (184). Besides KATP channels, PIP2 may be implicated in the regulation of 
other ion channels including non-selective cation channels such as a TRP channel 
(185;186) 
• Cell survival  
PIP2 is believed to protect cells from apoptosis. Exposure to H2O2 and UV irradiation 
triggered PIP2 depletion and induced cell apoptosis, whereas overexpression of 
PIP5K-Iα rescued cells from such stress induced cell death (183). It is also found that 
PIP2 directly inhibited initiating caspase 8, caspase 9, and executive caspase 3 during 
the apoptosis process (129). Furthermore, the overexpression of PIP5K-Iβ also 
rescued cells from apoptosis, as PIP5K-Iβ was cleaved and inactivated by caspase 3 
(129). 
• Knockout analysis 
The PIP5K-Iα -/- knockout mice are viable and fertile but exhibit enhanced passive 
cutaneous and systemic anaphylaxis (130).  The mast cells in these mice exhibited 
35% less PIP2 and diminished actin filaments polymerized at the cell cortex, which 
contributed to the hyper-responsiveness to Fcɛ receptor I signaling and downstream 
immunological responses (130). However, no other special phenotype has been 
reported.  
1.3.1.5 Potential role of PIP5K in insulin secretion 
PIP5K family is a good candidate for the further exploration of the signal cascade 
implicated in the regulation of insulin secretion by Rac1 (66). The affirmative role of 
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PIP5K in actin cytoskeleton may contribute to compel the insulin secretory granules 
to the plasma membrane of pancreatic β-cells. However, the regulation of PIP5K is 
complicated. Besides Rac1, other small GTPases, RhoA or Arf 6 are also implicated 
in exocytosis in some cell types, such as alveolar epithelial cells (187), adrenal 
chromaffin cells (188), neurons (189), PC12 cells (190), and mast cells (191). All 
regulators of PIP5K may have synergetic effect on PIP5K in insulin secretion from 
pancreatic β-cells. On the other hand, PIP2 biosynthesized by PIP5K distributes as 
spatial and temporal pools, which may result from the distinct PIP5K isoforms to 
mediate specific cellular events. Isoform-specific function of PIP5K-Iα in exocytosis 
remains unknown. As mentioned above, the knockdown of PIP5K-Iγ by RNAi 
inhibited insulin secretion in response to various stimuli in INS-1 and MIN6 cells 
(168). The possible role of other PIP5K isoforms in insulin exocytosis remains to be 
investigated. Previous study in our lab has ascertained the existence of PIP5K-Iα in 
INS-1 cells and, furthermore, translocation of PIP5K-Iα to the plasma membrane 
upon glucose and forskolin stimulation was observed (137). In this thesis study, 
PIP5K-Iα function in insulin-secreting cells was studied. 
1.3.2 P21-activated kinase (PAK) 
1.3.2.1 Nomenclature of PAK 
P21-activated kinases (PAKs) are serine/threonine protein kinases that interact with 
the activated GTP-bound forms of Cdc42 or Rac1. The first PAK, human PAK1 
(corresponding to rat 68 kDa α-PAK) was reported in 1994 (192;193) and six 
mammalian members of the PAK family were identified to date (194-203). PAK 
family was classified into two groups based on their conserved structure and the 
regulation manner. Group I has three members, PAK1-3, which are structurally very 
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similar but differ with tissue distribution. PAK2 is ubiquitous, whereas PAK1 and 
PAK 3 are tissue specific, with the highest expression level in the brain. PAK1 is also 
expressed in the muscle and spleen (192). PAK2 is corresponding to the smaller 62-
kDa γ-PAK (204;205). PAK3 (200) is essentially identical to the 65-kDa β-PAK 
(192). Group II PAKs also have three members, PAK 4-6. Their structures are distinct 
from group I PAKs (reviewed in (194)). The comparison of two groups of PAK 
family is listed in Table 2. 
Table 2. PAK family  
Group Name Aliases Mass Cellular processes 
PAK1 PAK α 68kDa 









PAK4 N/A 68kDa 
PAK5 N/A 80kDa 
II 




Cell transformation & hormone signalling 
1.3.2.2 Structure of PAK 
PAK members contain a highly conserved catalytic domain in the C-terminus and a 
distinguished regulatory domain in N-terminus. The kinase domain is located at aa 
255-529 in PAK1, aa 235-509 in PAK2, and aa 254-528 in PAK3, with at least 93% 
identity among these three isoforms (194). In addition, a conserved binding site for 
the Gβγ subunit complex of heterotrimeric G proteins exists at the extreme C-
terminus (196). In the regulatory N-terminus, there is a 95% homologous p21-binding 
domain (PBD) (aa 67-133 for PAK1) and an autoinhibitory domain (AID) (aa 83-149 
for PAK1), which overlaps with each other. (194). PAK1 exists as a homodimer in 
cytosol, where the AID of one PAK1 molecule binds and inhibits the kinase domain 
of the other.  
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1.3.2.3 Regulation and activation of PAK 
Many extracellular stimuli have been reported to activate PAKs, such as 
chemoattractant fMet-Leu-Phe (in human neutrophils), thrombin (in platelet), insulin 
(in muscle cells) and PDGF (in fibroblasts) (194). PAK1 can be activated by Rac1-3  
and Cdc42, but not by RhoA-G or other Ras superfamily members of small GTPase 
(199). Moreover, PAK1-3 can also be activated by GTPase-independent mechanisms. 
This is through the direct association of PAK with sphingosine or several other related 
long chain sphingoid bases but not with ceramides and a variety of other lipids. These 
specific lipids can induce PAK activity to a similar level by GTPase (206). On the 
other hand, some phosphatases also have been shown to dephosphorylate PAKs and 
induce the increase or decrease of PAK activity. POPX1/2, a PP2C like phosphatase, 
is a binding partner of a PAK interacting guanine exchange factor (PIX). It binds to 
various forms of PIX and thus performs dephosphorylation of PAK1, including 
Thr423 (207). Gβγ can also bind to C-terminus of PAK1 and inhibit its kinase activity 
(208).  
When the active GTP form of Cdc42 or Rac binds to CRIB (Cdc42/Rac interactive 
binding) domain, which is located at aa 75-90 in PAK1, the binding disrupts 
dimerization and leads to a series of conformational changes that destabilize the 
folded structure of the autoinhibitory domain (AID), including its dissociation from 
the catalytic domain. This rearranges the kinase active site into a catalytically 
competent state (199) and then promotes PAK autophosphorylation leading to up to 
300 fold increase of its phosphotransferase activity toward substrates (194). Active 
Rac and Cdc42 are localized on membranes via their prenylated C-terminus and this 
leads to PAK association with them at the plasma membrane where sphingolipids may 
potentially activate PAK. Once PAKs are activated, the binding of GTPase is not 
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necessary for maintenance of PAK kinase activity, although the dissociation of 
GTPase is rarely occur. Moreover, binding of PAK to Rac and/or Cdc42 inhibits their 
intrinsic and GAP-stimulated GTP hydrolysis (199). 
1.3.2.4 Downstream effectors of PAK and their biological functions 
PAK family has been implicated in the regulation of a number of cellular activities, 
including cytoskeletal dynamics, MAP kinase signaling pathways, oxidant generation 
and apoptosis. 
• Cytoskeleton dynamics (LIM kinase, myosin light chain kinase and 
filament A  
PAK is identified as a link of Rac GTPase to LIM kinase activity. Active PAK1 binds 
to LIM kinase-1 and phosphorylates it primarily at Thr508 within the activation loop, 
resulting in an increase in LIM kinase-1 activity toward cofilin/ADF (209). LIM 
kinase specifically phosphorylates cofilin, a member of actin depolymerizing factor 
(ADF) family, at Ser 3. Once phosphorylated by LIM kinase, cofilin dissociates from 
F-actin, and thus both F-actin depolymerization and severing is inhibited, which is 
critical for normal actin dynamics (210). Overexpression of PAK AID blocks LIM 
kinase-1 mediated modulation of actin assembly, whereas expression of dominant 
inhibitory LIM kinase-1 blocks the ability of overexpressed PAK1 to induce dorsal 
ruffle formation in BHK cells (211).  
PAK1 and PAK2 have been reported to directly phosphorylate R-MLC (regulatory 
myosin light chain) at the critical Ser19 resulting in the increase of contractility. 
PAK1 also modulates R-MLC via direct phosphorylation and inhibition of myosin 
light chain kinase (MLCK) at Ser 439 and Ser 991 (212).  
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PAK1 binds to the C terminus of filamin A and phosphorylates Ser 2152. Filamin A is 
a 280 kDa actin-binding protein that induces high-angle cross-linking of actin 
filaments. On the other hand, filament A binds to a region that overlaps the 
CRIB/PBD domain of PAK1 (aa 52-132) and relieves autoinhibition thereby 
enhancing intrinsic PAK1 activity (213).  Furthermore, filamin A itself can directly 
bind to Rac and Cdc42, and thus may serve both as a direct PAK activator and/or as a 
platform for GTPase-mediated activation. Filamin A is necessary for PAK-mediated 
signals to induce formation of dorsal membrane ruffles (214). 
Interestingly, the cytoskeletal and morphological effects induced by PAK1 exhibit 
both kinase-dependent and -independent components. PAK1 kinase activity is 
associated with disassembly of focal adhesions and actin stress fibers.  However, 
although expression of active PAK1 causes lamellipodia formation and membrane 
ruffling, they are independent of PAK1 catalytic activity (194;215). Expression of a 
constitutively active PAK1 mutant induces large leading edge lamellipodia and 
increases motile ability. In contrast, expression of a kinase-inactive PAK1 mutant 
induces the formation of random, multiple lamellipodia, which decreases the ability of 
movement in NIH-3T3 cells (101). PAKs have also been found to distribute between 
focal adhesions, a cytoplasmic vesicular compartment, and the leading edge of motile 
cells (216;217). It is possible that vesicular/membrane trafficking related to motile 
responses is regulated by vesicle-associated PAK1 (218). However, PAK1 action in 
vesicles trafficking is poorly studied. 
• Cell proliferation (MAPK cascades, Op18) 
PAK has been shown to be required for the increase of Jun amino terminal kinase 
(JNK) and p38 activity upon activation of the Rho family GTPases Rac and Cdc42 in 
certain types of cells. This PAK effect appears to be mediated through 
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phosphorylations of upstream components in the JNK/p38 signaling cascades to 
modulate transcriptional events which are important for response to environmental 
stresses, as well as to specific receptor-initiated signals (219-221). PAK1 is involved 
in the activation of ERK (extracellular signal-regulated kinases) by Rho GTPase and 
Ras through the ability of PAK1 to phosphorylate MEK1 on Ser 298, which is also an 
important binding site of the upstream regulatory kinase, Raf-1. PAK1 directly binds 
to Raf-1 via the C-terminal portion and is regulated by the Raf-1 N-terminal 
regulatory domain. These effects are involved in proliferation of cells (222-226). 
Evidence has revealed that PAK plays a role in the cell division through its regulation 
of microtubule dynamics and actin cytoskeleton. Phosphorylated PAK1 on Thr 212 by 
cyclin B1/Cdc2 was accumulated at the microtubule organizing centers (MTOC) and 
made microtubules less stable in mitotic cells. Although this phosphorylation was not 
associated with changes in PAK1 activity, it modulated the interaction of PAK1 with 
several unidentified proteins (227). In addition, PAK1 is implicated in the 
phosphorylation of Op18 at Ser16 when stimulated by the epidermal growth factor 
receptor in a Rac/Cdc42 dependent manner, and thus inhibits the binding of Op18 to 
microtubules and prevents its destablilizing activity (228).  
• Apoptosis or survival (BAD) 
A number of human breast cancer lines exhibit constitutively elevated PAK1 and 
PAK2 activity, in some cases associated with the presence of an activated Rac 
GTPase (229). However, PAK family members participate in both pro-apoptosis and 
anti-apoptosis. It has been reported that PAK2 but not PAK1 or PAK3 can be cleaved 
by caspase-3 at Asp212 into a 28 kDa N-terminal and a 34 kDa C-terminal fragments 
in a GTPase-independent mechanism during apoptosis (230;231). The cleaved PAK2 
is constitutively activated and may contribute to the cytoskeleton change during cell 
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apoptosis (230). In contrast, PAK1 is activated in response to survival signals such as 
IL-3, and phosphorylates Bad on Ser 112 and 136 in vitro and in vivo. This results in a 
markedly reduced interaction between Bad and Bcl-2 or Bcl-xL, and increased 
association of Bad with cytosolic adapter protein, 14-3-3. Released Bcl-2 or Bcl-xl 
could exert their anti-apoptotic actions (100). It has been also reported that 
constitutively active PAK1 could stimulate nuclear factor NF-κB activity to promote 
cell survival (232). PAK4 was reported to play protective role during apoptosis. 
Activated PAK4 induced delay in caspase activation through phosphorylation of Bad 
at Ser 112 (99) and antagonized with caspase-8 (233). PAK5 was also reported to 
protect cells from apoptosis by promoting phosphorylation of Bad (98). 
• Oxidative stress (NADPH oxidase) 
The family of NADPH oxidases (NOXes) plays an important role in the production of 
reactive oxygen species (ROS) in response to receptor agonists such as growth factors 
or inflammatory cytokines that signal through the small GTPases Rac1 or Rac2. Rac1, 
cytochrome b, p67phox and p47phox comprise the minimal components necessary for 
superoxide formation by the NADPH oxidase. PAK1 phosphorylates p47phox and 
PAK3 phosphorylates p67phox, which thus alter their conformation and drive NADPH 
oxidase translocation and assembly in the membrane. This scenario is induced during 
phagocytic activation (204;234). 
• PAK knockout mice 
PAK2-/- is lethal due to multiple developmental abnormalities, while PAK1-/- mice 
are healthy and fertile, although displaying the defective MAPK signaling pathway 
(reviewed in (198)). PAK3-/- and PAK4-/- mice showed impaired neurological 
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development (235;236), and PAK5-/- knockout mice appear normal (237). PAK5 and 
PAK6 double knockout mice have deficits in learning and locomotion (238). 
• PAK in insulin-secreting cells 
Little is known about the role of PAK in insulin-secreting cells. One study reported 
that PAK1 could be phosphorylated by Cdc42 and might mediate the link between 
Cdc42 and Rac1 activations in MIN6 cells (78). Moreover, PAK1 depletion abolished 
Rac1 activation and glucose-stimulated insulin release (78). No study has investigated 
the role of PAK in growth and death of insulin-secreting cells, although several 
critical downstream effectors of PAK, MAPKs and NADPH oxidase, are believed to 
be involved in cell viability. 
1.3.2.5 Glucotoxicity-induced pancreatic β-cell death 
The mechanisms underlying β-cell dysfunction and the resulting apoptosis via glucose 
toxicity remain to be fully characterized. Various mechanisms for glucotoxic effects 
have been proposed.  
• Production of inflammatory cytokines and modulation of Bcl family 
Exposure of human pancreatic islets, from nondiabetic organ donors, to elevated 
glucose for 1-2 days resulted in the increased production and release of interleukin 
(IL)-1β. IL-1β induced Fas expression and triggered Fas-dependent apoptosis, 
including caspase-8 and caspase-3 activation, and DNA (deoxyribonucleic acid) 
fragmentation (239). Consistent with this finding, upregulation of Fas was also 
observed in type 2 diabetic patients (240). On the other hand, the anti-apoptotic 
molecule Bcl-xl was reduced upon treatment with high glucose, but the pro-apoptotic 
molecules Bad, Bid, and Bik were overexpressed in the diabetic pancreatic islets (15). 
In addition, high glucose treatment decreased glucose kinase and increased cell death 
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that was mediated by Bax oligomerization, cytochrome C release and caspase-3 
activation in MIN6 cells (241). These observations indicate that high glucose induced 
β-cell death is highly complicated as it involves both extrinsic and intrinsic pathways 
of apoptosis.  
• Oxidative stress 
It is known that pancreatic β-cells possess weak antioxidant defense ability (242). 
Since the increased in glucose metabolism can generate oxidative stress through 
accumulation of intracellular ROS and cause mitochondrial dysfunction (243), 
chronic oxidative stress is considered as a central event for high glucose exerted toxic 
effect on pancreatic β-cells (244;245). On the other hand, indirect evidence that 
antioxidants were able to prevent chronic glucose toxicity both in vivo and in vitro 
supports this notion (246-248). 
Long term exposure to high concentrations of glucose induces the formation of 
advanced glycation end products (AGEs), an important biochemical abnormality. 
Excess glucose metabolism promotes the formation of α-ketoaldehyde and the 
hydroxyl radical and increases synthesis of diacylglycerol that activates protein kinase 
C. Moreover, AGEs increase the ratio of cytosolic NADH:NAD+, leading to 
inhibition of GAPDH activity. In addition, hexosamine metabolism pathway may also 
contribute to impaired β-cell function upon glucotoxicity. Furthermore, high 
concentrations of glucose elevate mitochondrial superoxide production and proton 
leak. All of above pathways and events can lead to ROS stress which may mediate 
glucotoxicity effect on β-cells (244). 
Culturing isolated human islets in high glucose (22 mM for 24 h) enhanced the 
expression of NADPH oxidase (249). Down-regulation of NADPH oxidase protected 
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insulin secretion and cell mass in db/db mouse islets (250). Additionally, ROS is also 
implicated in the injury of other types of cells. NADPH oxidase activated by 
hyperglycemia is a major source of superoxide in cardiovascular cells, and mediates 
oxidative stress in the process of endothelial dysfunction (105). Cultured in 30 mM 
glucose, intracellular ROS was generated rapidly through NADPH oxidase and 
mitochondrial pathways, and led to activation of p38 MAPK and caspase-3, thus 
inducing apoptosis in podocytes in vitro and in vivo (251). This suggests that NADPH 
oxidase may mediate high glucose initiated oxidative stress and function downstream 
of PAK in glucotoxicity induced cell death. 
• Activation of MAPK cascades 
Short-term incubation with high glucose induced activation of MAPK cascade. 
Several reports provided evidence that activity/phosphorylation of ERK1/2 and p38 
MAPK, but not JNK, was increased in response to glucose exposure shortly (20-30 
min) in insulin-secreting INS-1 cells (252;253) and MIN6 cells (254). Furthermore, 
both p38 MAPK and ERK were believed to regulate the insulin transcription in 
response to glucose stimulation in MIN6 cells (254;255) and INS-1 cells (253). 
However, when exposed to high glucose for a long period of time, the activation of 
MAPK cascades becomes more complicated. Accumulated evidence shows that 
oxidative stress and subsequent activation of JNK pathway play a critical role in the 
progression of pancreatic β-cell dysfunction in diabetes (256-259) and also in cell 
death in insulin-secreting cell lines: RIN-5AH and β-TC-6 (260). Overexpression of 
dominant-negative JNK protected insulin gene expression and insulin secretion from 
oxidative stress (256;261). Moreover, JNK activation led to enhanced basal islet cell 
death and increased sensitivity to cytokine-mediated cell death in isolated human 
islets (262).  
Chapter 1. Introduction 
 33 
In pancreatic β-cells, p38 MAPK was activated in response to oxidative stress (256), 
which is an important mediator of glucose toxicity (243;263;264). Therefore, the 
activation of p38 MAPK might be involved in prolonged glucotoxicity in β-cells due 
to the association of p38 MAPK with oxidative stress. Although phosphorylation of 
ERK (p44/42 MAPK) was detected at optimal glucose concentration (10 mM) for 24-
48 h in an insulin-secreting cell line (MIN6) (265), it cannot be concluded that ERK 
may retain its activation in pancreatic β-cells after prolonged exposure to higher 
glucose concentrations. 
As mentioned above, the evidence for long-term effect of high glucose on the 
activation of p38 MAPK and ERK as well as their possible roles in β-cell dysfunction 
and cell death remains limited. Nevertheless, studies of p38 MAPK and ERK 
activation upon glucotoxicity were widely performed in other cell types. Exposure to 
high level of glucose (ie. 25 mM) for a long period was reported to increase the 
activity of p38 MAPK in endothelial cell (266;267), mesangial cells (268-271), renal 
tubular cells (272), smooth muscle cells (273), and peritoneal mesothelial cells 
(274;275). Furthermore, the activation of p38 MAPK played a pro-apoptotic role in 
intestinal epithelial cell (276) and neuronal cells (277). In addition, p44/42 MAPK 
was also activated after prolonged exposure to high glucose in endothelial cell 
(267;278), mesangial (279), and myocytes (280). The activated p44/42 MAPK 
mediated oxidative damage-induced apoptosis in fibroblasts (281) but played an anti-
apoptotic role in mesangial cells (279). Thus, the role of ERK in regulation of survival 
and death of cells varies by the cell types. Taken together, the possible implication of 
p38 MAPK and ERK in the deleterious effect of chronic exposure to elevated glucose 
concentration on pancreatic β-cells needs to be investigated. 
• Others 
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Furthermore, the glycolysis metabolites, impairment of insulin gene transcription, and 
endoplasmic reticulum stress may be also involved in impaired biological function 
and survival of β-cells in the elevated glucose environment (282-286). 
1.3.2.6 Potential role of PAK in glucotoxicity-induced β cell death 
PAK family has been reported to be implicated in cell survival or cell death (98-
100;194;287;288). It seems that the role of PAK family in cell viability is isoform-
specific (199). PAK2 can be cleaved by caspase-3 thereby involved in pro-apoptotic 
pathway(289;290) whereas, PAK4 and PAK5 play roles in anti-apoptotic pathway by 
preventing caspase activation or phosphorylating Bad respectively (98;99). The roles 
for PAK1 in pro-apoptotic or survival signal cascades remain in debate. There is 
evidence that PAK1 mediates survival signals; for instance activated PAK1 upon the 
survival signaling (IL-3) protected lymphoid progenitor cells and NIH 3T3 cells from 
apoptosis by modifying Bcl family in (100). However, opposite observation also 
revealed that PAK1 contributed to procarcinogen induced apoptosis in 293T and Hela 
cells via activation of JNK (288).  
It is known that prolonged hyperglycemia in diabetic patients may result in a loss of 
pancreatic β-cell mass and thereby exacerbates the syndrome. An elevated glucose 
concentration is capable to induce oxidative stress to pancreatic β-cells which have 
weak anti-oxidative ability. On the other hand, high glucose can activate Rac1 as 
reported previously (66) that, in turn, activates PAK. As described above, many 
downstream effectors of PAK (e.g. MAPK cascades, NADPH oxidase) may be 
implicated in apoptosis, survival and oxidative stress. However, there is no direct 
evidence for the PAK involvement in glucotoxicity-induced cell death.  
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1.4 Aim and significance  
It is well known that insulin plays an essential role in the maintenance of homeostasis 
of glucose metabolism in the body. Absolute and relative deficiency of insulin leads 
to type 1 and type 2 diabetes mellitus respectively. Therefore, both the adequate mass 
and the functional secretory machinery of insulin secreting β-cell in pancreatic islets 
of Langerhans are necessary for the prompt and sufficient insulin entry into the blood 
stream for meeting the body requirements. The aim of this study is to explore the 
potential roles of two kinases, PIP5K-Iα and PAK1, in the regulation of insulin 
secretion and β-cell survival.  
To date, even after decades of vigorous studies on the regulation of insulin secretion 
from pancreatic β-cells, the complicated signaling network has not been elucidated 
completely. Not all signaling events contributing to the control of insulin secretion are 
defined. The findings that glucose stimulation activates Rac1 while the inhibition of 
Rac1 disrupts actin cytoskeleton and affects glucose-induced insulin secretion suggest 
an important role of Rac1 in these events. The studies on the effects of two Rac1 
downstream effectors, PIP5K-Iα and PAK1, on regulating cytoskeleton and 
modulating insulin secretion may help the understanding of this signaling pathway. 
On the other hand, increasing evidence emerges for the crucial role of a loss in β-cells 
due to glucotoxicity in the development of type 2 diabetes. However, the underlying 
mechanism remains unclear. It is worthy to investigate if PAK1 plays any role in 
glucotoxicity-induced damage to β-cells, given that the kinase is involved in ROS 
production and stress-induced signaling pathways that occurs also during 
glucotoxicity.   
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The comprehensive exploration of the roles of PIP5K-Iα and PAK1 in insulin 
secretion and glucotoxicity will enrich our knowledge of β-cell physiology and 
pathology that may be used to develop novel and more effective therapeutic 
approaches for diabetes mellitus.  
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2. Materials & Methods 
2.1 Materials 






D-myo-inositol-1, 4, 5-trisphosphate (IP3) [3H] assay  
D-[U-14C]Glucose 
Applied Biosystems, 
Foster city, CA, 
USA 
PAK1 target primer(FAMTM Dye/MGB probe) 
PIP5K-Iα target primer (FAMTM Dye/MGB probe) 
Rat ACTB (actin, β) endogenous control(VIC® / MGB 
Probe, Primer Limited) 
SYBR Green powerful PCR master mix 
Taqman® fast universal PCR master mix 




Acryl/bis 37.5:1, 30%Soln, 500ml 
Bio-Rad protein assay dye reagent concentrate  
BioTraceTM PVDF (polyvinylidene difluoride) 
transfer membrane 0.45 um, 30 cm*3 m roll 
Coomassie brilliant blue R-250 (protein assay dye reagent) 
Dithiothreitol (DTT) 
Extra thick blot paper (mini blot size) 
Prec Plus Std kaleidoscope  




7-Amino-4-(trifluoromethyl) coumarin (AFC) 
Ampicillin, sodium salt 
Bovine serum albumin (BSA) 
Caspase Inhibitor VI  
Caspase-3 Substrate VII, Fluorogenic  
Caspase-8 Substrate II, Fluorogenic  
Caspase-9 Substrate I, Fluorogenic  
D-glucose 
Dimethyl sulphoxide (DMSO) 
Fluo-save reagent 
Paraformaldehyde 




(to be continued) 
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Phospho-PAK1/3 (S199/204)  antibody 
Phospho-p38 MAPK (Thr180/Tyr182) antibody 
Phospho-p44/42 MAPK (Thr202/Tyr204) antibody 
Phospho-SAPK/JNK(Thr183/Tyr185)Sandwich ELISA 
(enzyme-linked immunosorbent assay)  
P38 MAPK antibody 
P44/42 MAPK antibody 
SAPK/JNK control cell extracts  
Falcon, Millville, 
NJ, USA 

















BLOCK-iT TM Fluorescent Oligo 
Gibco-fetal calf serum(FCS) 
LipofectamineTM 2000 reagent  
OPTI-MEM reduced serum media 
Penicillin-streptomycin 
Stealth RNAi negative control LO GC 
Stealth RNAi negative control MED GC 
Stealth siRNA oligo targeting PAK1 




Tris hydroxymethyl-aminomethane (Tris) 
Linco Research, St. 
Charles, MO, USA 
Insulin RIA kit 
Guinea pig anti-insulin antibody 
Macherey-nagel 
Neumann, Germany 







Ultima GoldTM XR scintillation fluid 
Pharmacia Biotech 
AB, Sweden 
Ammonium persulphate (APS) 
Bromophenol blue 
Tetramethylethylenediamine (TEMED) 
(to be continued) 
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Restore Western Blot stripping buffer 





Cell titer 96®  aqueous MTS reagent powder 









Anti goat or mouse or rabbit IgG-HRP (horseradish 
peroxidase)  
Goat polyclonal antibody PIP5K-Iα 
Mouse monoclonal antibody β-tubulin  







Bisbenzimidazole dye Hoechst 33258 
Ciprofloxacin 




DNA standard (sodium salt, from calf thymus) 
Ethanol 
Ethidium bromide (EB) 
Ethylene glycol-bis (β-aminoethyl ether) N,N,N,N, 
tetraacetic acid (EGTA) 





Kodak BioMax MR film-50EA 8in*10 
L-A-Lysophosphatidylcholine Type V  









(To be continued) 
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Sodium dodecyl sulphate (SDS) 
Sodium 4-methl-2-oxovalerate (α-ketoisocaproic acid 
sodium salt) 
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2. 2 Methods 
2.2.1 INS-1 cell culture and storage 
INS-1 cells (Passages 58-78) were cultured in RPMI 1640 supplemented with 10% 
heat-inactivated fetal bovine serum (FBS) (v/v), 10 mM HEPES, 100 U/ml penicillin, 
100 µg/ml streptomycin, 50 µM 2-mercaptoethanol and 1 mM pyruvate as previously 
described (66;74) at 37˚C in humidified air with 5% CO2. INS-1 cells were seeded at 
a concentration of 1×106/ml in culture flasks or multi-well plates. The culture medium 
was changed every 48 h. Usually, cells were sub-cultured by trypsinization weekly. 
Upon subculture, medium was discarded and cells were rinsed with 37˚C pre-warmed 
phosphate-buffered saline (PBS) followed by incubation in 0.025% trypsin [5:45:50 
of 0.5% trypsin stock: PBS (Ca/Mg-free): EDTA (0.54 mM)] at 37˚C for 5-8 min. 
Once most of cells rounded up and detached from the bottom surface of culture flasks 
after gently shake, cold RPMI 1640 with 10% new born calf serum (NBCS) was 
added to terminate trypsinization. Suspended cell clusters were dispersed by repetition 
of pipette up and down gently. Thereafter, single-cell suspension was centrifuged at 
130 g for 5 min to get cell pellet. The cell pellet was re-suspended in pre-warmed 
culture medium and mixed gently by inverting centrifuge tube several times. Re-
suspended cells were counted by using a hemocytometer before dilution into 37˚C 
pre-warmed culture medium to make an appropriate seeding concentration. 
In order to store cells for long term, cell pellets were re-suspended at 5×106/ml in 
freshly-made frozen medium (RPMI 1640 containing 20% fetal bovine serum, 7% 
DMSO) in a cryo-tube. The tube was placed in a polystyrene box packed with cotton 
wool and kept at 4˚C for half an hour, -20˚C for 2 h, -70˚C overnight, and then put in 
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liquid nitrogen tank for long term storage. When younger cells were needed, stored 
INS-1 cells were thawed quickly by transferring cryo-tube from liquid nitrogen tank 
to 37˚C water bath. After thawed, cells were cultured in dishes or flasks with pre-
warmed growth medium and kept in incubator. Once cells adhered to the bottom of 
culture dish, fresh growth medium was changed and cells were cultured for another 3 
days before cell subculture. 
2.2.2 Molecular biology 
2.2.2.1 E.Coli transformation 
Purified plasmid DNA (50 ng) was added into a sterile Eppendorf tube containing  
100 µl of competent E.Coli cells (DH5α), and mixed by swirling the tube gently to 
make a transformation mixture. The transformation mixture was placed on ice for 10 
min followed by incubation in 42˚C water bath for 90s to heat shock the E.Coli cells. 
Thereafter, the tube was quickly chilled down on ice for 2 min. Subsequently, the 
transformation mixture was topped up to 500 µl by adding LB medium and subjected 
for shaking at 200 rpm in a shaker heated to 37˚C. Afterwards, 100 µl of transformed 
cells was inoculated on a LB plate containing 100 µg/ml of ampicillin and subjected 
for incubation at 37˚C for 12-16 h. For short-term storage, the LB plate was sealed 
tightly with parafilm and kept in 4˚C up to days. 
2.2.2.2 Plasmid DNA preparation 
Plasmid purification was performed by using plasmid DNA purification kit. A single 
fresh colony was picked up from LB plate and inoculated in 2 ml of selective LB 
medium (containing 100 µg/ml ampicilin) and subjected for vigorous shaking (300 
rpm) at 37˚C for 8 h. Five µl of above starter culture medium was added into 3 ml of 
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selective LB medium in a sterile tube and incubated at 37˚C for 12-16 h with vigorous 
shaking (300 rpm). Transformed E. Coli cell pellet was harvested from 2 ml of 
selective saturated LB medium by centrifugation at 6,000 g for 15 min at 4˚C. The 
pellet of bacterial cells was re-suspended in 400 µl of buffer (S1) with RNase A 
carefully. Next, 400 µl of buffer (S2) was added into above suspension followed by 
inverting the tube 6-8 times. The mixture was incubated at room temperature for 2-3 
min before adding 400 µl of pre-cooled (4˚C) buffer (S3). Afterwards, gently mixed 
the tube by inverting it for another 6-8 times and subjected for incubation on ice for 5 
min. The bacteria suspension was centrifuged at 12,000 g for 15 min at 4˚C and 
subjected for filter in a small funnel to remove the excess precipitate left in the 
suspension. The cleared lysate was flowed through and was collected for further use. 
The Nucleobond column was equilibrated with buffer N2, and the flow-through by 
gravity flow was discarded before loading the cleared lysate onto it. The flow-through 
of lysate by gravity flow was discarded. Column was washed with 1.5 ml buffer N3 
for two times. The plasmid DNA was eluted with 1 ml buffer N5 followed by 
precipitation with 0.75 ml room-temperature isopropanol. The mixture was 
centrifuged at 15,000 g for 30 min at 4˚C to get the pellet. 500 µl of 70% ethanol was 
added to the pellet and centrifuged at 15,000 g for 10 min at room temperature to 
remove ethanol. The pellet was dried at room temperature for 5-10 min and plasmid 
DNA was reconstituted in 50 µl TE buffer. DNA concentration was measured by 
Nano-Drop spectrophotometer (NanoDrop technologies, USA) to determine the yield. 
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2.2.2.3 RNA purification 
Total RNA in 2×106 cells cultured in 6-well plates for 2-3 days was isolated by using 
RNeasy Mini Kit. Aspirated the culture medium completely and washed the cells with 
PBS thoroughly followed by adding of 350 µl of buffer RLT (lysis buffer). Cell lysate 
was collected by scraping and was transferred to sterile tube. Thereafter, the cell 
lysate was homogenized by passing through a blunt 20-gauge needle fitted to RNase-
free syringe for 5 times. Homogenized cell lysate was mixed thoroughly with 350 µl 
of 70% ethanol by pipetting. 700 µl of mixture was transferred to an RNeasy mini 
spin column, and centrifuged for 15 s at 8,000 g. The column was then washed by 
adding 350 µl of RW1 buffer and centrifuged for 15 s at 8,000 g followed by 
incubation in 20 units of RNase free-DNase for 15 min at room temperature. The 
column was washed with 350 µl of RW1 buffer again.  Thereafter, the column was 
washed twice by adding 500 µl of RPE buffer and centrifuged at 8,000 g for 15 s and 
2 min respectively. Total RNA was eluted from the column with 50 µl of RNase-free 
water. RNA concentration was measured by Nano-Drop spectrophotometer. As for 
tissue RNA isolation, a small piece (up to 30 mg) of fresh tissue was immersed into 
RNA-later stabilization reagent at room temperature for storage shortly or kept at -70˚ 
C for long-term. The small piece of tissue was transferred to a new sterile Eppendorf 
tube with 500 µl of RLT buffer (fresh prepared, containing β-mercaptoethanol). In 
order to disrupt the tissue, a surgery scissor was used to cut the tissue into tiny species 
in RLT buffer followed by sonication on ice for 10 s. The tissue suspension was 
passed through a blunt 20-gauge needle for 5 times to homogenize the tissue sample 
to get cleared lysate. 350 µl of tissue lysate was mixed with 350 µl of 70% ethanol 
and was transferred onto RNeasy mini spin column following the same steps for cell 
RNA isolation. 
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2.2.2.4 Reverse transcription, polymerase chains reaction and Real-time 
PCR 
For the first step of reverse transcription, purified total RNA (500 ng) was mixed with 
1 µl of oligo dT (500 µg/ml) and topped up by adding DEPC-treated water to get a 
final volume of 14 µl. The mixture was incubated in PCR machine (Biorad) at 70˚C 
for 5 min and was quickly chilled on ice. At the second step, the following 
ingredients, 4 µl of 5× MLT reverse transcriptase buffer, 1 µl of reverse transcriptase 
(200 U/µl) and 1 µl of dNTPs (10 mM), were added to the tube. The reverse 
transcription mixture was mixed thoroughly by shortly vortex and reverse 
transcription was performed by incubation at 42˚C for 1 h followed by inactivation of 
enzyme at 94˚C for 5 min in PCR machine. PCR reaction mixture was prepared by 
adding 2.5 µl of 10× Mg2+-free PCR buffer, 2.5 µl of MgCl2 (25 mM) buffer, 0.5 µl of 
Taq DNA polymerase (2.5 U/µl), 1 µl dNTPs (10 mM), 2 µl of RT product, and 1 µl 
of forward and reverse primers. The PCR reaction was conducted in PCR machine by 
the setting in the following Table 4.  
The knockdown level of PIP5K-Iα and PAK1 mRNA was quantified by using 
Taqman probe-based real-time RT-PCR (7500 Fast System, Applied Biosystems, 
Foster City, CA). In brief, 10 µl of 2× Taqman Master was mixed with 1 µl of 10× 
target primers and 1 µl of 10× Control (β-actin) primers. 500 ng of cDNA was added 
into above mixture, and total volume was adjusted to 20 µl by adding DEPC water. 
Experiments were carried out in triplicate and followed steps as shown in Table 4. 
The negative control was conducted by adding DEPC water, instead of cDNA 
template, into real-time PCR mixture.  
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Table 4. Programs of PCR 
Step Normal PCR SYBR green Real-time 
PCR 
Taqman Fast Real-time 
PCR 
1 94˚C 5 min 94˚C 10 min 94˚C 5 min 
2 94˚C 30 s 94˚C 15 s 94˚C 30 s 
3 60˚C 45 s 60˚C  45 s 60˚C  1 min 
4 72˚C 1 min 
go back step2  
40 cycles 
72˚C 1 min 
go back step2  
40 cycles 
72˚C 1 min 
go back step2  
40 cycles 
5 72˚C 10 min   
 
The expression of other transcripts was quantitated by SYBR green based real-time 
PCR. In brief, 10 µl of 2× SYBR green master, 1 µl of each forward and reverse 
primer (10 mM), and 500 ng cDNA template were mixed together thoroughly, and 
was topped up to 20 µl by adding DEPC water. Negative control samples contained 
water instead of cDNA template. After each run of real-time PCR, the reaction PCR 
products were analyzed by 1~2% agarose gel electrophoresis and stained with 
ethidium bromide to confirm whether there was non-specific amplification or not.  
The real-time RT-PCR running programs were detailed in Table 4. The sequences of 
primers for SYBR Green based real-time PCR were listed in Table 5. 
Quantitative results were generated by the 7500 Fast System SDS software, which 
calculated the relative gene expression levels compared to that of β-actin, which was 
used as the internal control.  
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Forward 5’-GCTCTTTTCCAGCCTTCCTT-3’ β-actin 168bp  
Reverse 5’-CTTCTGCATCCTGTCAGCAA-3’ 
Forward 5’-CCCCAGTGAAGGCAGCAA-3’ PIP5K-Iβ 75bp 
Reverse 5’-GCGACAGGTGCATAGGTCTTG-3’ 
Forward 5’-CTTCCAGGATTTCCGTTTCAAG-3’ PIP5K-Iγ 78bp 
Reverse 5’-TCCGGACGGATACCAAAGAG-3’ 
Forward 5’-TCCACCAGGTAGACATCCC -3’ Kir6.2 120bp 
Reverse 5’- TAGGAGCCAGGTCGTAGAG -3’ 
Forward 5’- GCATCAACTTGTCTGGTG -3’ SUR1 172bp 
Reverse 5’-ACTGTCCTCTTGTCATCC -3’ 
Forward 5'-CCTGAAACTGGCCAAACCAT-3' PAK2 83bp 
Reverse 5'-GACGTTAGCGGTTACTCTTCATTG-3' 
Forward 5'-AGGAGATAAAAGTGCCCATGGA-3' PAK3 74bp 
Reverse 5'-CCAAAGGAGGTTCCGAAGCT-3' 
Note: Abovementioned primers for PIP5K Iβ, PIP5K Iγ and PAK2 were designed by 
using Applied Biosystems Primer Express software. Primers for other genes were 
designed from published work: β-actin (291), PAK3 (292), Kir 6.2 (293), and SUR1 
(293). The Taqman primers for PIP5K-Iα and PAK1 were designed by Applied 
Biosystems and their sequences are not available. 
 
2.2.2.5 Transfection 
2.2.2.5.1 Reverse transfection of siRNA duplexes  
Transient transfection was performed using lipofectamineTM 2000, following the 
manufacturer’s reverse transfection protocol. In brief, a pool of 3 stealth siRNA 
duplexes targeting PIP5K-Iα or PAK1 (sequences are shown in Table 6) and 
lipofectamineTM 2000 were diluted in Opti-MEM medium separately and were 
incubated for 5 min. The aforementioned two solutions were mixed gently and 
incubated for 20 min at room temperature to allow complex formation to occur. INS-1 
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cell pellet was collected by trypsinization and was re-suspended in fresh growth 
medium. Transfection mixture and cells were added into multi-well plates or cover-
slip chambers and mixed by gently swirling. Medium used for transfection contained 
no antibiotics. The transfection medium was replaced by normal RPMI 1640 medium 
24 h later. The final concentrations of agents used were 100 nM siRNA, 5 µl/ml 
lipofectamineTM 2000 and 0.8×106 cells/ml. The same amount of scrambled siRNA 
duplexes containing similar GC content was used as negative control.  Transfection 
efficiency was determined by using fluorescent dsRNA (BLOCK-iT TM Fluorescent 
Oligo) following the manufacturer’s instruction and images were taken under laser 
fluorescence confocal microscopy.  




No. in NCBI 
Target 
site 
Anti-guide strand Guide strand 
PIP5K-
I α 
XM_219913 539-563 5’-GCU GCU GCC 
AGG CUA UUA CAU 
GAA U-3’ 
5’-AUU CAU GUA 
AUA GCC UGG 
CAG CAG C-3’ 
  908-932 5’-CCA CAU CUU 
GGA CCA UUC CCU 
CAA A-3’ 
5’-UUU GAG GGA 
AUG GUC CAA 
GAU GUG G-3’ 
  1210-
1234 
5’-CCG UUU CAG 
UUC AUA GAC CAA 
GUU U-3’ 
5’-AAA CUU GGU 
CUA UGA ACU 
GAA ACG G-3’ 
PAK-1 U_23443 359-383 5’-UUU AUC UCC 
AGC UAA GAU GGA 
UCG A-3’ 
5’-UCG AUC CAU 
CUU AGC UGG 
AGA UAA A-3’ 
  504-528 5’-UAU UUG AUG 
UUU GAA GCA AGC 
GGG C-3’ 
5’-GCC CGC UUG 
CUU CAA ACA 
UCA AAU A-3’ 
  800-824 5’-AAC AGG AAG 
UGG UUC AAU  CAC 
AGA C-3’ 
5’-GUC UGU GAU 
UGA ACC ACU 
UCC UGU U-3’ 
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2.2.2.5.2 Transient transfection of GFP-PLC plasmid and PIP2 distribution assay 
PIP2 distribution within INS-1 cells was assessed by image of fluorescence after 
transfection of a green fluorescence protein (GFP)-tagged construct leading to 
expression of the PH domain of phospholipase C-δ (PLC-δ) (a kind gift from Dr. R. 
Regazzi at University of Lausanne, Switzerland). The PH domain can bind to PIP2 
and thus increase the fluorescence signal when PIP2 is accumulated, which is a 
powerful tool for assay of PIP2 within live cells (168;294). 
Once INS-1 cells reversely transfected with either scramble siRNA or siRNA 
targeting PIP5K-Iα adhered to the coverslip chambers, culture medium was replaced 
with fresh medium without antibiotics. Two days after reverse transfection of siRNA, 
the plasmid transfection mixture was prepared by mixing 3 µl Fugene 6 reagent and  
1 µg plasmid DNA in serum-free medium in order, followed by incubation for 15 min 
at room temperature. The plasmid transfection mixture was drop-wisely added to 
coverslip chambers without changing medium, and cells were continuingly cultured in 
an incubator for 24 hrs before live-image assay. Images were taken under 
fluorescence con-focal microscopy after changing medium in the chamber to KRBH 
containing no glucose. After incubation in glucose-free KRBH buffer for 30 min, 
fluorescence images were taken again. Subsequently, 20 mM glucose was added into 
KRBH buffer and images were taken again after 30 min incubation at 37˚C. The ratio 
between the fluorescence intensity at the plasma membrane and that in cytosol in 
individual cells before and after glucose stimulation was analyzed by using software 
Image J (NIH). A series of fluorescence intensity on each pixel was obtained by 
drawing a line across the membrane and cytosol of examined cells displaying 
fluorescence within the image. The average fluorescence intensity on the plasma 
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membrane and that in the cytosol of each cell was calculated to get the ratio. At least 
10 individual cells were analyzed under each condition to get the average in each 
independent experiment.  
2.2.2.6 Measurement of DNA content 
DNA quantitation is a necessary step for normalization in data analysis for some 
experiments. Hoechst 33258 binds to the AT rich regions of double stranded DNA 
and exhibits enhanced fluorescence under high ionic strength conditions. A standard 
curve of DNA was set up by a serial dilution of standard DNA (100, 50, 25, and 12.5 
µg/ml in order). Both standard DNA and samples were topped up to 500 µl (for 24-
well microplate) with Hoechst 33258 (final concentration is 0.1 µg/ml in KRBH).  
After incubation in dark at 37˚C for 30 min, the plate was subjected for measurement 
by using a fluorescence microplate reader (Tecan M200) with excitation wavelength 
at 346 nm and emission wavelength at 460 nm. All recordings were corrected by the 
blank, and DNA content of each sample was calculated by comparison with the 
standard curve.    
2.2.3 Protein assay  
2.2.3.1 Protein extraction 
INS-1 cells were seeded in 6-well plates at a density of 1.8×106 per well. At various 
time points of culture after reverse transfection of siRNA duplexes, cells were 
harvested by scraping with cell lifter in 100 µl of ice-cold homogenizing buffer (50 
mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 0.1 mM PMSF, and 10 µg/ml 
each of aprotinin, leupeptin, and pepstatin), followed by sonication on ice for 3 times 
(5 sec each). Protein samples were centrifuged at full speed (14,000 rpm in 
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Eppendorf) for 5 min at 4˚C to discard the pellet. The supernatants were then stored at 
-70˚C if not immediately used for Western blotting. 
Cell lysates used for Phospho-SAPK/JNK ELISA were obtained by using the lysis 
buffer (provided by Cell signaling with ELISA kit) containing 20 mM Tris-HCl (pH 
7.5), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton, 2.5 mM sodium 
pyrophosphate, 1 mM β-glycerophosphate, 1 mM Na3VO4 and 1 µg/ml leupeptin. 
After the same procedures described above, cell lysates were harvested and stored in -
80˚C for further use. 
In order to extract protein for detection of phosphorylated substrates in Western 
Blotting, 100 µl of phsphoSafeTM extraction reagent containing phosphotase inhibitors 
(sodium fluoride, sodium vanadate, β-glycerophosphate, and sodium pyrophosphate) 
was used to lyze cells cultured in 6-well plates. Cells were incubated with extraction 
reagent at room temperature for 5 min before proceeding to centrifuge at 4˚C for 
16,000 g ×5 min. Supernatants were collected and stored for performing Western 
Blotting. 
2.2.3.2 Measurement of protein concentrations 
Protein concentrations were measured by using Bio-Rad assay kit based on the 
Bradford method. The Bradford method is a dye-binding assay, in which the 
absorbance of Coomassie brilliant blue G-250 dye shifts from 465 nm to 595 nm 
when binding to proteins. The Coomassie blue dye binds to primarily basic and 
aromatic amino acid residues, especially arginine and is useful for measuring proteins 
and polypeptides with molecular weight greater than 3000-5000, depending on the 
charged groups. The concentrations of protein samples were determined by setting up 
a standard curve of BSA (bovine serum albumin) protein with known concentrations. 
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The standard curve was generated by a serial dilution of standard BSA to get protein 
concentrations at 1500 ng/µl, 750 ng/µl, 375 ng/µl and 187.5 ng/µl in order. Standard 
BSA and protein samples were added into the 96-well plate individually and topped 
up to 200 µl with 20% Bio-Rad Protein Assay Dye reagent (v/v in water). Lysis 
buffer, instead of protein samples, was used to get blank readings. After incubation at 
room temperature for 20 min, the 96-well plate was subjected for absorbance 
measurement at 595 nm by an absorbance microplate reader (Tecan). For each assay, 
triplicate was conducted. And all recordings were corrected by blank readings. Protein 
concentration of each sample was quantified in comparison with the standard curve 
and calculated after taking into consideration of dilution factors. 
2.2.3.3 Western Blotting 
Aliquots of samples with equal amount (20-40 µg) of total protein were diluted with 
equal volume of 2× loading buffer (100 mM Tris-HCl, pH 6.8, 200 mM DTT, 20% 
glycerol, 4% SDS, and 0.2% bromophenol blue) and boiled at 95˚C for 5 min. Protein 
samples, as well as 10 µl of kaleidoscope prestained standard molecular weight 
marker (Bio-Rad), were separated by 10% SDS-polyacrylamide gel for 
electrophoresis (SDS-PAGE) in tank buffer (0.025 mM Tris, 0.192 M glycine, 0.1% 
SDS, pH 8.3). Polyvinylidine difluoride (PVDF) membranes (0.45 µm) were pre-
immersed with methanol followed by incubation in semi-dry buffer (25 mM Tris, 250 
mM glycine and 15% methanol) at 4˚C. The separated proteins on SDS-
polyacrylamide gels were then electro-transferred to the PVDF membrane by a semi-
dry transfer machine.  Subsequently, the membranes were blocked in TBST (Tris-
buffered saline with tween) buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl and 0.2% 
Tween-20) containing 5% dried non-fat milk for 2 h at room temperature followed by 
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blotting with the first antibody for 1-2 h at room temperature or overnight at 4˚C 
(Table 7). Thereafter, PVDF membranes were washed in TBST (5 min each) for three 
times followed by incubation in horseradish peroxidase-conjugated secondary 
antibody (anti-goat IgG, anti-rabbit Ig G or anti-mouse IgG as appropriate) for 1 h at 
room temperature. Afterwards, membranes were washed in TBST for three times (10 
min each). Finally, after incubation with chemiluminescence reagent (Supersignal®, 
Pierce chemical Co.) for 2 min, PVDF membranes were subjected for 
chemiluminescence detection by exposure X-ray films in dark room. The films were 
then scanned by EPSON 1680 scanner and the optical density of bands was analyzed 
by the gel analysis software (Bio-Rad) based on the densitometry. 
Table 7. Critical conditions for Western blotting 
Primary antibody Dilution Protein amount (µg) 
Rabbit-anti PAK1 1:500 20 
Goat-anti PIP5K-Iα 1:200 40 
Rabbit-anti phospho-p44/42 MAPK 1:1000 20 
Rabbit-anti phospho-p38 MAPK 1:1000 20 
Rabbit-anti phospho-JNK 1:1000 20 
Rabbit-anti phospho-PAK1/3 1:1000 20 
Mouse-anti β-tubulin 1:1000 20 
 
2.2.3.4 Phospho-JNK ELISA 
Phospho-SAPK/JNK (Thr183/Tyr185) Sandwich ELISA Kit has a SAPK/JNK 
antibody coated on the microwells. 100 µl of sample diluent buffer and 100 µl of cell 
lysate were mixed thoroughly in an Eppendorf tube. 100 µl of the diluted cell lysate 
was added to each well. Thereafter the microwell plate was sealed with tape tightly 
and incubated at 37 ˚C for 2 h. Both nonphospho-and phosphor-SAPK/JNK proteins 
were captured by the coated antibody. Following extensive washing with 200 µl of 
wash buffer for 4 times, 100 µl of detection antibody (phospho-SAPK/JNK antibody) 
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was added and incubated at 37˚C for 1 h to detect the captured phospho-SAPK/JNK 
protein followed by a wash step as described above. Subsequently 100 µl of HRP-
linked secondary antibody was added and incubated at 37˚C for 30 min. After wash, 
100 µl of TMB substrate was added and incubated at 37 ˚C for 30 min to develop 
color. 100 µl of STOP solution was added to stop the reaction. The microwell plate 
was subjected for absorbance measurement at 450 nm within 30 min by an 
absorbance microplate reader (Tecan). The magnitude of optical density for this 
developed color is proportional to the quantity of phosphor-SAPK/JNK protein. 
2.2.4 Measurement of insulin secretion 
Insulin secretion was measured as previously described (66). INS-1 cells, either 
transfected with scrambled or targeting siRNA duplexes, were seeded in 24-well 
culture plates and cultured for 3 days. After two washes, cells were pre-incubated in 
0.5 ml of KRBH (124 mM NaCl, 5.6 mM KCl, 2.5 mM CaCl2, 1.2 mM MgSO4, 20 
mM Hepes, pH 7.4) containing 0.1% BSA without glucose at 37˚C for 30 min. 
Subsequently, cells were incubated in 0.5 ml of KRB containing 2.8 mM glucose or 
other secretagogues for another 30 min at 37˚C. 0.4 ml of KRBH buffer in each well 
were collected in Eppendorf tubes and centrifuged at 1500 rpm at 4˚C. The 
supernatants were then diluted into RIA buffer for measurements of secreted insulin. 
For assessment of biphasic insulin secretion, supernatants in the initial 15 min were 
collected for the early phase secretion, whereas the supernatants collected 20 min 
thereafter were for the late phase secretion. The attached cells were extracted by 
adding 900 µl of acid-ethanol to determine the insulin content. All the wells were 
sealed tightly with parafilm and the plates were left for overnight at 4˚C before 
dilution of extracted insulin contents in RIA buffer. Triplicate was performed for each 
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independent experiment. The amount of secreted insulin and the insulin content of 
each sample were assayed by RIA kits. Results of insulin secretion were expressed as 
percentages of insulin content to normalize the possible influence of variance in the 
cell number among wells.  
2.2.5 Observation of cell morphology and assessment of F-actin 
filaments  
Either knockdown or control cells were cultured on glass coverslips for 3 days. 
Cellular F-actin was stained by FITC-conjugated phalloidin toxin which has much 
higher affinity to bind to filamentous actin over globular actin, as described 
previously (66). In brief, after two washes with PBS (pH 7.4), cells were fixed in 
3.7% paraformaldehyde in PBS for 10 min. Following twice washes in cold PBS, 
cells were incubated with 330 nM FITC-phalloidin and 300 ng/ml 
lysophosphatidylcholine for 20 min. Subsequently, coverslips were mounted on glass 
slides with Fluosave reagent and examined by laser confocal microscopy to detect F-
actin structures at the middle and bottom dissections of cells. For measurement of F-
actin content, INS cells cultured in 24-well plates stained with FITC-phalloidin were 
washed in PBS for two times, followed by adding 100 µl of methanol into each well 
and incubated at 4˚C for 60 min. Methanol extraction was then transferred into 96-
well microtitre plate to quantify the cellular F-actin content using Gemini EM 
microplate fluorescence reader (Molecular Devices) at excitation wavelength of 465 
nm and emission wavelength of 535 nm. Each sample was measured in triplicate.  
Same volume of methanol was added into the empty wells on the same 96-welll 
microtiter plate to obtain blank readings.  
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Insulin staining was used as internal control, and thus co-staining of insulin and F-
actin was also executed. INS-1 cells were fixed in 3.7% paraformaldehyde in PBS for 
10 min. Following twice washes in cold PBS, cells were permeabilized with 0.2% 
saponin for 10 min. After blocking with 4% BSA, coverslips were incubated with 
guinea pig anti-insulin antibody (1:100 dilution) for 2 h followed by washes and 
incubation with anti-guinea pig-TRITC (tetramethyl rhodamine isothiocyanate) for 
 1 h. Subsequently, cells on coverslips were incubated with 330 nM FITC conjugated 
phalloidin for 20 min to stain F-actin as described previously (66). Coverslips were 
mounted on glass slides with Fluosave reagent for further examination under 
fluorescence confocal microscopy (Olympus).  
2.2.6 Measurement of membrane potential  
Cell membrane potential upon various stimulations was detected in PIP5K-Iα 
knocked-down INS-1 cells by using the fluorescent probe bisoxonol (a voltage-
sensitive dye) as previously described (66;295). INS-1 cells were detached from 12-
well plates by trypsinization and centrifuged. Cell pellets were suspended in culture 
medium and incubated at 37°C in humidified air with 5% CO2 for 30 min for 
recovery. After two washes in KRBH, cells were suspended in pre-warmed 2 ml 
KRBH in a cuvette. Biosoxonol was added at a final concentration of 100 nM and 
mixed thoroughly by stirring. Fluorescent signal from bisoxonol was recorded using 
spectrofluorometer (Perkin-Elmer LS-50B) with excitation and emission wavelengths 
of 540 and 580 nm, respectively. Cells in the cuvette with stirring were incubated at 
37˚C for about 15 min to reach a stable basal line. Afterwards, agents such as high 
glucose, KCl or diazoxide were added as indicated. KRBH used for this study 
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contained no BSA. The results were expressed as the percentages of near maximal 
depolarization reached in the presence of 40 mM KCl for each individual observation. 
2.2.7 Measurement of intracellular Ca 2+ concentration at basal and 
upon glucose stimulation 
Intracellular free Ca2+ concentration ([Ca2+]i) was measured by loading with the cell-
permeable Ca2+-specific fluorescent probe fura-2/AM, a lipid soluble form of fura-2. 
Modification by acetoxymethyl at the carboxylate groups of fura-2 enables it to 
become a nonpolar compound that is permeable to cell membranes. Once entering the 
cell, these acetoxymethyl bases are hydrolyzed by intracellular esterases, resulting in 
a polar molecular that is no longer capable of freely diffusing through the cell 
membrane. Essentially being trapped inside the cell, Fura-2 is a second generation of 
dual wavelength ratiometric Ca2+ indicator, which binds Ca2+ with 1:1 stoichiometry. 
Ca2+-bound Fura-2 emits fluorescence, the density of which reflects the level of free 
Ca2+ concentrations. When excited at 340 nm, the Ca2+-sensitive emission 
fluorescence (at 505 nM) of Fura-2 is augmented with increase in [Ca2+]i. In contrary, 
an increase of [Ca2+]i  results in a decrease of the emission light when the Ca2+ dye is 
excited at 380 nm. Such features provide an excellent basis for excitation (340/380 
nm) ratiometric measurement of [Ca2+]i, which avoids the interferences resulting from 
the variety of cell number and dye concentration. 
INS-1 cells were cultured on 48-well plates for 3 days. After equilibration in pre-
warmed KRBH containing 2 µM fura-2/AM for 30 min, cells were washed thoroughly 
and subsequently incubated in KRBH containing 2.8 or 16.7 mM glucose for 30 min. 
Afterwards, fluorescence at emission of 510 nm was recorded at excitation 
wavelengths of both 340 and 380 nm using a fluorescence plate reader (Tecan M200). 
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The ratios of fluorescence intensities at 340 and 380 nm were calculated after 
subtraction of background, reflecting [Ca2+]i (296). For each assay, triplicate was run 
for each condition.  
2.2.8 Glucose metabolism 
2.2.8.1 Assessment of glucose metabolism by MTS assay 
Glucose metabolism was assessed by 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tet-razolium (MTS) assay, which 
measures the reduction potential resulting from both glycolysis and mitochondrial 
oxidation. The conversion of MTS into the aqueous soluble formazan product is 
accomplished by dehydrogenase enzymes found in metabolically active cells (297).  
INS-1 cells in 96-well culture plates were transfected either with scrambled or PIP5K-
Iα targeting siRNA duplexes, and cultured for 3 days. After washes and pre-
incubation in glucose-free KRBH for 30 min, cells were incubated with 100 µl of 
KRBH containing a range of glucose concentrations and 20 µl mixture of MTS and 
PMS [2 mg/ml MTS and 46 µg/ml PMS in DPBS (Dulbecco’s phosphate buffered 
saline), pH 6.0-6.5] at 37˚C for 1 h. Wells (without cultured cells) for blank readings 
were added with 100 µl of KRBH and MTS/PMS mixture. For each assay, triplicate 
was run for each condition. The absorbance of colored formazan product at 490 nm 
was measured in an absorbance microplate reader (Tecan, Sunrise, USA).  
2.2.8.2 Glucose oxidation 
Glucose oxidation was assayed by measuring 14C-labeled CO2 production after 
incubation with D-[U-14C]-glucose (298). Control or PIP5K-Iα knocked-down INS-1 
cells were cultured in 48-well plate for 3 days. After twice washes and pre-incubation 
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in 200 µl KRBH buffer for 30 min, cells were incubated in 100 µl KRBH buffer 
containing 2.0 µCi D-[U-14C]-glucose and 2.8, 8.3 or 16.7 mM cold D-glucose for 30 
min at 37˚C. Ten µl of the labeled KRBH buffer from each well was transferred to 
scintillation vials for counting the total radioactivity.  The remaining 90 µl KRBH 
buffer was transferred to the bottom of a scintillation vial preloaded with a PCR tube 
containing 100 µl of 1 M KOH for CO2 to dissolve in. After addition of 10 µl of 10% 
trichloroacetic acid (TCA) into the 90 µl of KRBH buffer, the scintillation vials were 
capped tightly immediately. Subsequently, vials were incubated for 2 h at 37˚C with 
occasional horizontal shaking. At the end, the 100 µl KOH from each PCR tube was 
transferred to a new scintillation vial and mixed with 5 ml scintillation cocktail 
thoroughly. The radioactivity was measured in a β-scintillation counter (Beckman). 
The amount of oxidized glucose at each condition was calculated by taking into 
consideration of the counts per min (cpm), counter efficiency, 14CO2 extraction 
efficiency, cold glucose concentration and dilution factor. Furthermore the results 
were normalized by the protein content. 
2.2.9 IP3 formation assay 
The PIP2 hydrolysis was examined by measuring one of its products (IP3). INS-cells 
transfected with scramble siRNA or siRNA targeting PIP5K-Iα were cultured in 12-
well plates. The cells were washed twice with pre-warmed (37˚C) KRBH buffer. 
Thereafter, cells were incubated in 400 µl of KRBH buffer at 37˚C for 30 min 
followed by incubation in 400 µl of KRBH buffer containing 2.8 or 16.7 mM glucose 
at 37˚C for another 30 min. The reaction was stopped by adding 100 µl ice-cold 
HClO4 (20%; v/v) and kept on ice for 30 min.  The extraction of IP3 was transferred to 
clean Eppendorf tubes and centrifuged at 2,000 g for 15 min at 4˚C to sediment 
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precipitated KClO4. Supernatants were collected and neutralized to a pH of 7.5 by 
addition of 1.5 M KOH containing 60 mM HEPES and stored at -80˚C for further 
assay.  
IP3 was measured by using a radioactive ligand binding assay following the 
manufacture’s instruction. IP3 extraction or standards were mixed thoroughly with ice 
cold assay buffer containing D-myo-[3H]insitol-1,4,5-triphosphate and IP3-binding 
protein. After centrifugation, the pellets were re-suspended in distilled water and 
transferred into scintillation vials containing 5 ml scintillation cocktail. Subsequently, 
the radioactivity was measured in a β-scintillation counter (Beckman). The counts per 
min (cpm) for each standard and sample were collected to calculate the percentage 
binding (%B/B0). The standard curve was obtained by plotting the %B/B0 against the 
standard concentration on semi-log graph paper. IP3 concentrations in the samples 
were obtained by comparison with the standard curve and normalized by protein 
content.  
2.2.10. Examination of cell growth and death 
Cell cycle was determined by propidium iodide (PI) staining and flow cytometry as 
described before(299). INS-1 cells with or without knockdown were cultured in 6-
well plates and were subjected to treatments for various periods. At the indicated time 
point, adherent cells were detached by trypsinization and collected in medium or PBS. 
After centrifugation at 200 g for 5 min, cell pellets were re-suspended in 0.5 ml of 
PBS followed by fixation in 4.5 ml of 70% ethanol at 4˚C for 2 hrs. Fixed cells were 
kept in -20˚C until performing PI staining. For the latter running, cell pellets were 
washed in 5 ml of PBS followed by re-suspension in 1 ml of fresh-prepared PI/Triton 
X-100 staining solution (20 µg/ml PI, 0.1% Triton X-100 and 0.2 mg/ml RNase A in 
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PBS) for 30 min at room temperature. Flow cytometric analysis was carried out using 
a fluorescence-activated-cells-sorter (EPICA Elite ESP, Beckman Coulter, Hialeah, 
FL). Fluorescence (excitation at 488 nm and emission at 610 nm) data were collected 
on a linear scale. Ten-thousand cells were evaluated for each sample. The flow rate 
was set to around 200 cells/sec. Cells at 4 phases of cell cycle were analyzed and 
calculated by using WinMDI software (Scripps Institute, La Jolla, CA). 
2.2.11 Caspase activity assay 
Caspase-specific peptides, conjugated to the fluorescent reporter molecule 7-amino-4-
trifluoromethyl coumarin (AFC), were used to measure caspase activity (299). 
Activated caspase is able to cleave the caspase-specific peptide to release the 
fluorochrome, which emits fluorescence at 500 nm when excited by light at 400 nm 
wavelength. The fluorescence signal detected by a fluorescence reader is proportional 
to the level of caspase activity (299). INS cells were cultured in 6-well plates and 
treated with high glucose for various periods. After one gentle rinse with 2 ml of cold 
PBS, 100 µl of lysis buffer (10 mM HEPES, pH 7.4, 2 mM EDTA, 0.1% CHAPS, 5 
mM DTT, 350 µg/ml PMSF, 10 µg/ml pepstatin A, 10 µg/ml aprotinin and 20 µg/ml 
leupeptin) was added into each well. Cell lysates were collected by scraping with cell 
lifters and subjected for 4 cycles of quickly frozen in -20˚C freezer and thawing in 
37˚C water bath. Cell lysates in Eppendorf tubes were then centrifuged at 14,000rpm 
(full speed) for 30 min at 4°C to discard the cell pellets and stored at -70˚C until 
caspase activity measurement.  
The measurement of caspase activity was carried out following the supplier’s 
instructions and a fluorogenic 7-amido-4-(trifluoromethyl) coumarin (AFC) was used 
to obtain a reference standard curve in each assay. Triplicates of each sample were 
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run in each assay. Just before measurement of caspase activity, cell lysates were 
measured for protein concentration by Bradford method. The aliquots of cell lysates 
containing 20 µg protein or equal volume of lysis buffer, which was used as blank, 
were mixed with a specific caspase substrate and 8 µl of 25× reaction buffer (250 mM 
PIPES, pH 7.4, 2.5% CHAPS, 125 mM DTT and 50 mM EDTA)  in a 96-well plate. 
The total volume in each well was topped up with water to 200 µl. After mixed gently 
by swirling, the plate was incubated at 37 °C for 1 or 3 h. Emitted fluorescence was 
measured at an excitation wavelength of 400 nm and an emission wavelength of 505 
nm by using a fluorescence plate reader (Tecan). All readings of cell lysates were 
corrected by blank readings and the caspase activity was calculated as pmol of AFC 
referred to the AFC-standard curve. The results were expressed as percentage of 
control to compare data among different caspases. 
2.2.12 ROS assay 
The accumulation of intracellular reactive oxygen species (ROS) was measured by 
dihydrofluorescein diacetate (DCFDA) assay following other’s publication (300). 
After passively diffuse into cells, the non-fluorescent dye DCFDA is cleaved by 
intracellular esterases and trapped within the cells. After oxidization by ROS, it forms 
a fluorescent 2',7'-dichlorofluorescein (DCF), which reflects the levels of intracellular 
ROS and can be quantitated by fluorescence reader (301). INS-1 cells were cultured 
in 48-well plate in the presence of high glucose for 72 h before ROS assay. INS-1 
cells were incubated with 10 µM DCFDA for 30 min at 37˚C followed by wash with 
pre-warmed KRBH buffer for three times. The intracellular ROS levels were then 
measured by using a fluorescence plate reader at an excitation wavelength of 485 nm 
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and emission wavelength of 530 nm. Samples were run in triplicate for each assay, 
and all readings were corrected by the blank. 
2.2.13 Statistical analysis 
The results were expressed as mean ± SEM and analyzed by two-tail student’s t-test 
or two-way analysis of variance (ANOVA). p<0.05 was considered statistically 
significant. 
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3. RESULTS 
3.1 The role of PIP5K-Iα in insulin secretion  
3.1.1 Knockdown of PIP5K-Iα at mRNA and protein level 
Successful knockdown of a gene using synthetic siRNA duplexes is determined by 
the transfection efficiency and appropriate amount of functional siRNA. The 
efficiency of transfection may depend on the cell type, the confluence of cells and 
the formation of siRNA-liposome complexes.  Low transfection efficiency is the 
most frequent cause of unsuccessful silencing. Furthermore, synthetic siRNAs are 
known to have difficulty in transfecting into some cell types and also vary in 
silencing efficacy. Therefore, in order to test the transfection efficiency using 
Lipofectamine 2000 in INS-1 cells, a fluorescent labeled double-stranded RNA 
duplex was used as an indicator. This fluorescein-labeled dsRNA oligomer was 
designed as a transfection control for cationic lipid-mediated delivery of dsRNA 
oligonucleotides into mammalian cells, due to its same length, charge, and 
configuration as siRNA, but not homologous to any known gene. Following the 
instructions provided by the manufacturer, fluorescence detection by laser con-focal 
microscopy was assessed at 24 h after transfection. FITC-fluorescence signal was 
detectable in majority of INS-1 cells and in some cells strong green fluorescence 
was seen in the nucleus. (Fig. 2).  




Fig. 2. Transfection efficiency of small RNA oligos in INS-1 cells.  
Scrambled fluorescent dsRNA (100 nM) was transfected into cells by using 
Lipofectamine 2000 to test its transfection efficiency. The transfection efficiency was 
assayed under laser confocal microscopy after 24 h. Majority of cells were fluorescent 
(left panel). The right panel shows an image of the same field taken under non-
fluorescence. Scale bar: 50 µm 
 
Different dosages of targeting siRNA oligos or Lipofectamine, and various 
transfection periods (24-96 h) were tested to determine the knockdown efficacy. 
Reverse transfection was carried out to perform the knockdown of interested genes 
as described in the Methods section, since conventional transfection of siRNA 
duplexes failed to significantly knock down the target transcripts.  In order to know 
a best silencing effect on target genes at the mRNA level or at protein level, the 
total RNA was isolated at three time points, 48, 72 and 96 h, after the reverse 
transfection of 3 duplexes of siRNA oligos against PIP5K-Iα (individually or in 
combination). The same amount of scrambled siRNA duplexes with similar GC 
content were used as the negative control for each assay. Transfection of PIP5K-Iα 
siRNA duplexes (individually or in combination) were able to significantly knock 
down PIP5K-Iα mRNA by 45-70% (Fig. 3A). The best knockdown (70%) was 
achieved by using pooled 3 siRNA duplexes. In order to rule out the possible off-
target effect of siRNA, the expression of other 2 isoforms of type I PIP5K, PIP5K-
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Iβ and PIP5K-Iγ, was also measured by using real-time PCR. Under transfection 
condition of PIP5K-Iα knockdown, the expression of neither PIP5K-Iβ nor PIP5K-
Iγ was altered (Fig. 3B), suggesting the specificity of used siRNA duplexes for 
targeting PIP5K-Iα. The knockdown efficacy at the protein level was determined by 
Western blotting and the strongest knockdown (by 75.2%) was observed at 72 h 
after transfection (Fig. 3C,D). As expected, transfection of scrambled siRNA 
duplexes in INS-1 cells did not affect expression of PIP5K-Iα at protein level (Fig 
3C). Therefore, all the experiments on physiological functions in PIP5K-Iα 
knocked-down INS-1 cells described below were performed under abovementioned 
silencing condition.   









          
                                                                  
Fig. 3. Knockdown of PIP5K-Iα at both mRNA and protein level in INS-1 cells.  
(A) Knockdown of PIP5K-Iα at mRNA level in INS-1 cells was obtained after reverse 
transfection of 3 siRNA duplexes targeting PIP5K-Iα individually or in combination 
for 72 h, as determined by Taqman probe-based real-time RT-PCR. The final 
concentrations were 5 µl/ml for Lipofectamine 2000 and 120 nM for 3 siRNA duplexes 
(40 nM each). Same concentrations of scrambled siRNA duplexes with similar GC 
contents were transfected in control cells. (B) The expression (mRNA) of other 2 
isoforms of type I PIP5K, PIP5K-Iβ and -Iγ was not significantly affected by 
transfection of siRNA duplexes targeting PIP5K-Iα for 72 h assayed by SYBR green-
based real-time PCR. (C) The knockdown of PIP5K-Iα at protein level was assayed by 
Western blotting 72 h after reverse transfection of the 3 siRNA duplexes in 
combination. (D) The blots were analyzed by computer-assisted densitometry. Values 
in (A), (B) and (D) are mean ± SEM from at least 4  independent experiments.  
** p<0.01 vs. control. 
 
3.1.2 Knockdown of PIP5K-Iα induces changes in cell morphology 
and cytoskeleton  
Both PIP5K and its product, phosphatidylinositol 4,5-bisphosphates (PIP2), are 
involved in cytoskeleton regulation (108;136;160). Thus the effect of PIP5K-Iα 
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siRNA targeting PIP5K-Iα or control siRNA duplexes. PIP5K-Iα knockdown 
induced dramatic changes in INS cell morphology at 48 h and such changes 
sustained for another 3-4 days. As shown in the light-contrast illustrations (Fig. 4, 
right), these PIP5K-Iα knocked-down cells grown in monolayer displayed much 
less protrusions than that seen in control cells (Fig. 4, left). Most (>70%) of these 
PIP5K-Iα depleted cells rounded up and were more easily detached upon 
trypsinization. Taken into consideration of that both the transfection efficacy and 
knockdown efficiency were more than 70%, these observations suggest that PIP5K-
Iα knockdown was attributable to a loss of, at least in part, the normal cytoskeleton 







Fig. 4. Knockdown of PIP5K-Iα induced change in cell morphology.  
INS-1 cells cultured on coverslips were transfected with scrambled siRNA (Ctrl) or 
PIP5K-Iα targeting-siRNA duplexes (PIP5k siRNA). Cell morphology was examined 
by taking images under confocal microscopy. After knockdown of PIP5K-Iα, most of 
cells rounded up. Scare bar: 20 µm. 
 
In order to further explore the effect of PIP5K-Iα knockdown on the actin 
cytoskeleton, actin-filaments were assessed by FITC-phalloidin staining (Fig. 5A). 
In addition, insulin staining was used as the reference to compare F-actin staining 
Ctrl PIP5k -Iα siRNA
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intensity between control and PIP5K-Iα knock-down cells, as PIP5K-Iα knockdown 
did not change the insulin content as shown in Fig 8. Viewing under the laser con-
focal microscopy, green fluorescence was presented mainly in the cell periphery in 
both control and PIP5K-Iα knocked-down cells (Fig. 5A). However, in general the 
PIP5K-Iα knocked-down cells displayed weaker fluorescence intensity compared 
with control cells. By adjusting the focus, the laser con-focal microscopy is capable 
to collecting a serial of optical sections from the top to the bottom of the monolayer 
cells. At the middle dissection of cells, F-actin filaments in whole cells were 
reduced obviously in PIP5K-Iα knocked-down cells (Fig. 5A, center). In addition, 
at the bottom dissection of cells, there were plenty of bundles of long-extended F-
actin filaments in control cells, which nearly disappeared after PIP5K-Iα 
knockdown (Fig. 5A, left). Those bundles of F-actin filaments may help to reinforce 
the adherent cells to the culture plate and this may explain that the knocked-down 
cells were much easier to be detached upon trypsinization. The loss of F-actin 
structure after PIP5K-Iα knockdown was also confirmed by quantitating the 
methanol-extracted F-actin content, which detected a significant decrease (by 28%) 
in cells after PIP5K-Iα knockdown (Fig. 5B).  
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Fig. 5. Disruption of F-actin structure and reduction of F-actin content in INS-1 
cells after PIP5K-Iα knockdown. 
(A) Reverse Transfection of siRNA against PIP5K-Iα enabled cells to round up and to 
display much reduced lamellipodia and F-actin filaments. Insulin staining was used as 
an internal control for comparison of fluorescence intensity between control and 
knocked-down cells. Images are viewed after adjusting the focus under confocal 
microscopy. F-actin straining was examined at both middle and bottom dissections of 
cell layer, and insulin staining was examined at the middle dissection. (B) The FITC-
phalloidin stained F-actin was extracted by methanol and measured by fluorescence 
micro-plate reader after transfection of siRNA duplexes. Values are mean ± SEM of 5 
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3.1.3. PIP5K-Iα knockdown reduces PIP2 in the plasma membrane 
and abolishes PIP2 redistribution during glucose stimulation, but 
has no effect on IP3 formation 
As a key enzyme for PIP2 synthesis, effective PIP5K-Iα knockdown may affect the 
production of PIP2, although the presence of other PIP5K isoforms could affect the 
outcome (168). PIP2 content and distribution within INS-1 cells were monitored by 
transfecting a green fluorescence protein (GFP)-tagged construct encoding the PH 
domain of phospholipase C-δ (PLC-δ) which can bind to PIP2 (168). Despite the 
relatively low transfection efficacy (10~30%), distribution of GFP fluorescence 
could be detected across the transfected INS-1 cells (Fig. 6A). The ratio of 
fluorescence intensity at the plasma membrane over that in the cytosol was 
analyzed by confocal microscopy. Such PIP2 distribution ratio was significantly 
decreased by 29% in PIP5K-Iα knocked-down cells (the ratio is 2.05 in PIP5K-Iα 
knocked-down cells and 2.88 in control) (Fig. 6A). Stimulation of control cells by 
16.7 mM glucose for 30 min caused a significant decrease of the ratio by 23%, in 
comparison with that at 2.8 mM glucose (the ratio is 2.02 in PIP5K-Iα knocked-
down cells and 2.22 in control). In contrast, PIP5K-Iα knockdown abolished this 
glucose effect (Fig. 6B).  Similar effect was also observed in dominant negative 
N17-Rac1 mutant (N17-Rac1) expressing INS-1 cells compared with cells 
expressing the empty vector, pIRES (the ratio is 2.58 in pIRES and 2.13 in N17-
Rac1 at 2.8 mM glucose) (Fig. 6A,B). Stimulation by high glucose resulted in a 
reduction in the ratio in pIRES (2.03 at 16.7 mM glucose), whereas such effect was 
not distinct in N17-Rac1 mutant expressing cells (2.06 at 16.7 mM glucose) (Fig. 
6A,B). 




   
                       
 
Fig. 6. Knockdown of PIP5K-Iα reduced PIP2 on the plasma membrane and 
suppressed the glucose effect on PIP2.  
(A) Construct expressing GFP-tagged PIP2-binding PH domain of PLC-δ was 
transiently transfected into INS-1 cells one day after reverse transfection of targeting or 
scramble siRNA duplexes. Twenty-four hours later, cells were incubated in KRBH 
buffer with 2.8 mM glucose for 30 min followed by incubation in KRBH buffer with 
2.8 or 16.7 mM glucose for another 30 min. Images were taken after the incubation 
period by confocal microscopy. A series of fluorescence intensity on each pixel 
obtained by drawing a line across the membrane and cytosol of sampling cells within 
the image was shown as the line graph next to each image. The ratio between the 
fluorescence intensity at the plasma membrane and that in cytosol in individual cells 
was analyzed by software. (B) The ratio data from more than 10 individual cells for 
each condition in every independent experiment were calculated. Values are mean ± 
SEM from 3 independent experiments. ** p< 0.01 vs. control or pIRES; # p< 0.01 vs. 
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Furthermore, the formation of IP3, a major product of PIP2 hydrolysis, was also 
examined (Fig. 7). Stimulation with 16.7 mM glucose for 30 min significantly 
increased the IP3 formation by around 2 fold in INS-1 cells. However, PIP5K-Iα 
knockdown did not significantly alter either the basal IP3 level (1.27 ± 0.23 vs.1.28 
± 0.22 pmol/mg protein in control) or the glucose stimulation-induced IP3 
production (3.37 ± 0.61 vs. 3.51 ± 0.63 pmol/mg protein in control cells).  
 Fig. 7. Production of IP3 in INS-1 
cells.  
After pre-incubation in 2.8 mM 
glucose for 30 min, INS-1 cells 
were incubated with basal (2.8 mM) 
glucose (G) or 16.7 mM glucose for 
another 30 min. Glucose 
stimulation increased IP3 formation 
significantly. Knockdown of 
PIP5K-Ia did not affect IP3 
formation at both basal and upon 
glucose stimulation. Values are 
mean ± SEM from 5 independent 
experiments. **p<0.01 and *p<0.05 
vs. basal (2.8 mM G). 
 
3.1.4 Knockdown of PIP5K-Iα affects insulin secretion  
3.1.4.1 PIP5K-Iα knockdown inhibits stimulated insulin secretion but 
augments basal insulin release 
PIP5K-Iα knockdown did not significantly alter the insulin content in INS-1 cells 
(2190 ± 498 ng/µg DNA vs.2319 ± 422 ng/µg DNA in control) (Fig. 8C). 
Therefore, the insulin secretion was expressed as the percentage of insulin content 
to avoid the possible variations in cell numbers. The insulin secretion from control 
INS-1 cells over 30 min was increased by 59% (after the exposure to 16.7 mM 
glucose) and by 2.2 folds (upon simultaneous incubation with 16.7 mM glucose 
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stimulated insulin release. After PIP5K-Iα knockdown, the basal insulin release rate 
at 2.8 mM glucose was significantly increased by doubling (2.05 ± 0.06% vs. 1.08 ± 
0.03% of insulin content in` control, p<0.01) (Fig. 8A). In addition, the total insulin 
secretion at high glucose (16.7 mM) and high KCl was also elevated after PIP5K-Iα 
knockdown, but forskolin-enhanced total insulin release was not significantly 
altered (Fig. 8A).  
The portion of basal insulin release, which was doubled in PIP5K-Iα knockdown 
cells, was included in the total insulin secretion upon stimulations. The total insulin 
secretion can not reprent the incremental insulin released by stimulators, therefore 
the basal secretion needs to be excluded. When the stimulated insulin secretion was 
expressed as the percentage over the basal, the glucose-evoked insulin secretion 
was significantly decreased. The increment of high (16.7 mM) glucose-stimulated 
insulin secretion was greatly reduced from 148% in control to 124% of basal 
(p<0.01) in cells after PIP5K-Iα knockdown (Fig. 8B). High glucose plus forskolin 
stimulated insulin secretion over basal was also markedly reduced from 303% in 
control to 203% in knocked-down cells (Fig. 8B). In contrast, high K+-stimulated 
insulin secretion over the basal in INS-1 cells was not significantly affected by 
PIP5K-Iα knockdown (Fig. 8B).  









Fig. 8. PIP5K-Iα knockdown did not alter insulin content but affected high 
glucose and forskolin induced insulin secretion in INS-1 cells. 
INS-1 cells in 24-well plates were transfected with scrambled or PIP5K-Iα targeting 
siRNA duplexes for 3 days. (A) The cells were washed and pre-incubated in 2.8 mM 
glucose for 30 min. Subsequently, the cells were incubated with different 
secretagogues for another 30 min. Secreted insulin was measured and expressed as % 
of insulin content of each well. (B) The relative insulin secretion upon stimulations 
was expressed as % increase of basal secretion at 2.8 mM glucose (Glc). Fsk; 1 µM 
forskolin. (C) Cellular insulin content was extracted with acid-ethanol and determined 
by RIA, and DNA content was measured by Hoechst staining. All data was normalized 
by DNA content in each well.  Values are mean ± SEM of 5 (in A and B) and 4 (in C) 
independent experiments. ** p<0.01 and * p<0.05 vs. control; # p<0.01 vs. control at 
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3.1.4.2 PIP5K-Iα knockdown inhibits both the early and late phase of 
insulin secretion  
Glucose is known to evoke a biphasic pattern of insulin secretion from islet β cells 
and each of the two phases may be controlled by different mechanisms (38). Both 
the early secretion (during the first 15 min) and the late secretion (over the 20 min 
thereafter) in INS-1 cells following glucose stimulation were thus also examined as 
described before (66). My results revealed that, after PIP5K-Iα knockdown, the 
augmentation of basal insulin secretion at 2.8 mM glucose was similar at both the 
early and late phases: increased from 0.55% to 1.08% at early phase, and from 
0.49% to 0.97% at late phase, when expressed as percentage of insulin content (Fig. 
9A). The total insulin secretion in cells after PIP5K-Iα knockdown was increased at 
both periods, but the percentage increment of insulin secretion upon stimulations 
over basal was reduced (Fig. 9B,C). After PIP5K-Iα knockdown, the high (16.7 
mM) glucose-induced increments of secretion at the early phase and late phase were 
reduced (110% vs. 132% in control at early phase; 128% vs. 166% in control at late 
phase; p<0.01) (Fig. 9B,C). Similarly, both the early and late insulin secretion over 
the basal induced by high glucose plus forskolin was also markedly decreased in 
PIP5K-Iα knocked-down cells (145% vs. 235% in control at early phase; 171% vs. 
288% in control at later phase) (Fig. 9A,B). In addition, it appeared that the late 
phase of secretion was more significantly affected. 
















Fig. 9. Effects of PIP5k-Iα 
knockdown on two phases of 
insulin secretion in INS-1 cells.  
INS-1 cells in 24-well plates were 
transfected with scrambled or 
PIP5K-Iα targeting siRNA 
duplexes. After 3 days, the cells 
were washed and incubated with 
different secretagogues for 30 
min. The supernatants in the 
initial 15 min and the following 
20 min incubation were collected 
for determination of the early and 
late phase of insulin secretion, 
respectively. The basal (2.8 mM 
glucose) insulin secretion was 
expressed as % of insulin content 
of each well (A). The increments 
of insulin secretion upon 
stimulations in the early phase 
(B) and later phase (C) were 
expressed as % of basal secretion. 
Although basal insulin secretion 
was increased at both phases. The 
increments of insulin secretion by 
16.7 mM glucose (Glc) alone or 
plus 1 µM forskolin (Fsk) were 
markedly reduced in cells after 
PIP5K-Iα knockdown. Values are 
mean ± SEM of 3 independent 
experiments. ** p<0.01 vs. 
control (scrambled siRNA). 
 
3.1.5 Knockdown of PIP5K-Iα affects glucose metabolism  
Glucose metabolism in pancreatic β-cells plays a critical role in glucose stimulated 
insulin secretion. I used two methods to investigate glucose metabolism after 
PIP5K-Iα knockdown. 
In MTS test, the produced soluble and colored tetrazolium (formazan) is an 
indicator of NADH- and NADPH-dependent dehydrogenase activity, thereby 
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(302). Incubation of control INS-1 cells with 16.7 mM glucose increased formazan 
formation by 2.6 folds over basal at 2.8 mM glucose. Such glucose metabolism was 
significantly inhibited by 29% in PIP5K-Iα knocked-down cells (Fig. 10A). 
However, PIP5K-Iα knockdown also significantly increased glucose metabolism at 
2.8 mM by 27% (Fig. 10A).  
Glucose metabolism was also examined by measuring radioactive CO2 production 
from D-[U-14C]glucose oxidation, which revealed similar results as assessed by 
MTS test, i.e. increased glucose metabolism at 2.8 mM glucose in PIP5K-Iα cells 
(24.02±3.60 pmol/µg protein vs. 19.97±2.14 pmol/µg protein in control, p<0.05) 
while decreased glucose oxidation at high glucose in cells upon PIP5K-Iα 
knockdown (43.79±5.35 pmol/µg protein vs. 52.68±4.52 pmol/µg protein in 
control, p<0.01) (Fig. 10B).  





Fig. 10. PIP5K-Iα knockdown 
reduced metabolism at high glucose but 
increased metabolism at basal glucose.  
(A) Metabolism status was evaluated by 
MTS assay. Control and PIP5K-Iα 
knockdown cells in 96-well micro-plates 
were incubated with MTS reagents at 
various glucose concentrations from 0 to 
22.2 mM for 1 h. PIP5K-Iα knockdown 
increased basal glucose metabolism (2.8 
mM), but significantly inhibited glucose 
metabolism at 16.7 mM or higher. (B) 
Glucose oxidation in control and 
knocked-down cells at different glucose 
concentrations was determined by 
measuring the production of radioactive 
CO2.  The rate of glucose oxidation by 
cells was normalized by protein content. 
Values are mean ± SEM from 5 (in A) 
and 4 (in B) independent experiments. * 
p<0.05 and ** p<0.01 vs. control 
3.1.6 Knockdown of PIP5K-Iα depolarizes the basal membrane 
potential 
Membrane phosphoinositides, in particular PIP2, can activate KATP channels and 
decrease the channel sensitivity to ATP inhibition (184). Therefore, PIP5K-Iα 
knockdown resulting PIP2 reduction might affect the membrane potential. Indeed, 
the resting membrane potential in PIP5K-Iα knocked-down cells was significantly 
in a more depolarized state (73.9±4.43% vs. 65.5±3.96% of maximal depolarization 
in control cells, p<0.01) (Fig. 11A,D). Stimulation of cells by 10 mM glucose 
caused depolarization of the membrane potential to the similar levels in both control 
and knock-down cells (76.9± 5.39% vs. 75.4± 3.63% in control, p>0.05) (Fig 
11B,D). However, the increased depolarization of resting membrane potential could 
not be reversed by 200 µM diazoxide, an opener of KATP channels (68.4±3.78% vs. 





























































































Fig. 11. PIP5K-Iα knockdown depolarized resting membrane potential.  
The membrane potential of INS-1 cells at resting or after stimulation was expressed as 
percentage of maximal membrane potential depolarization, which was achieved at a 
saturating concentration of KCl (40 mM). (A) At resting state (2.8 mM glucose), 4 
sequential additions of KCl (8.5 mM each) led to depolarization of membrane potential 
in both control and PIP5K-Iα knockdown cells. (B) 10 mM glucose was added at 
resting state followed by sequential additions of KCl (8.5 mM each) to get maximal 
depolarization. Glucose caused depolarization of membrane potential to the similar 
level in knocked-down cells and control cells. (C) Hyperpolarization by adding  
200 µM diazoxide (Diaz) was unable to reverse depolarized membrane potential in 
knocked-down cells. (D) Statistical analysis of membrane potential under various 
conditions in control and PIP5K-Iα knockdown cells. Results are mean ± SEM of 3 
independent experiments. ** p<0.01 vs. control.  
 
The failure of diazoxide to abolish the depolarized basal membrane potential in 
PIP5K-Iα knocked-down cells suggests that the latter phenomenon was not caused 
by the close of KATP channels. In supporting this notion, I found that PIP5K-Iα 
knockdown did not significantly alter the expression of the two subunits of KATP 
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 Fig. 12. PIP5K-Iα knockdown had no 
effect on expression of Kir6.2 and 
SUR1, two subunits of KATP channel 
at mRNA level. 
After transfection with scramble siRNA 
or targeting siRNA, mRNA was 
isolated and analyzed by SYBR green 
based real-time RT-PCR to quantify the 
expression of two critical subunits of 
KATP channel, Kir6.2 (KIR) and SUR1 
(SUR). Results are mean ± SEM of 3 
independent experiments. 
3.1.7 Knockdown of PIP5K-Iα affects intracellular [Ca2+]i 
Increased intracellular Ca2+ upon stimulations acts as a trigger signal for insulin 
secretion. I also measured [Ca2+]i using a fluorescent probe, fura-2. The ratios of 
fluorescence recorded at 2 excitation wavelengths represent the [Ca2+]i. Using this 
approach, I found that the basal [Ca2+]i was elevated slightly but significantly after 
PIP5K-Iα knockdown (0.74±0.037 vs. 0.69±0.037 in control, p<0.05). In contrast, 
high glucose (16.7 mM)-induced rises in [Ca2+]i were reduced in PIP5K-Iα 
knockdown cells (0.85±0.057 vs. 0.92±0.058 in control, p<0.01) (Fig. 13).  
 
 Fig. 13. PIP5K-Iα knockdown 
increased basal [Ca2+]i but 
decreased [Ca2+]i upon glucose 
stimulation. 
INS-1 cells cultured in 48-well plates 
were loaded with the Ca2+ probe, 
Fura-2/AM (2 µM) before incubation 
with 2.8 or 16.7 mM glucose for 30 
min. The ratio of emission 
fluorescence at 510 nm was recorded 
at excitation wavelengths of 340 and 
380 nm, reflecting changes in [Ca2+]i. 
Values are mean ± SEM from at least 
4 independent experiments. *p<0.05 
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3.1.8 Knockdown of PIP5K-Iα does not affect INS-1 cell growth and 
death 
PIP2 may be involved in the regulation of apoptosis (42). The possible effect of 
PIP5K-Iα knockdown on INS-1 cell growth and death was assessed by flow 
cytometry following propidium iodide (PI) staining. The distribution of cells fallen 
into 4 phases of cell cycle was not significantly different between control and 
knockdown cells (Fig. 14A). Most of cells were at G1 phase (75% in control vs 
78% after PIP5K-Iα knockdown) (Fig. 14B). 18% of control cells were found in S 
and G2/M phases, while 15% of knocked-down cells were at these phases (Fig. 
14B). In addition, the percentages of cells under subdiploidy apoptosis (cells at sub-
G1 phase) due to DNA fragmentation at various time points (48 to 96 h) after 
PIP5K-Iα knockdown were also not altered (Fig. 14C). These results suggest that 
PIP5K-Iα may not be involved in the control of cell cycle and apoptosis in INS-1 
cells. 













Fig. 14. PIP5K-Iα knockdown 
neither changed cell cycle nor 
induced apoptosis in INS-1 cells.  
(A) After reverse transfection of 
scramble or targeting siRNA, INS-1 
cells were cultured in 6-well plates 
for 72 h, followed by PI staining 
and flow cytometric analysis. A 
typical histogram shows 4 phases of 
cell cycle. (B) Statistical analysis of 
the percentages of cells fallen into 
G1, S and G2/M phases. (C) Cells 
harvested from 48 to 96 h after 
reverse transfection of siRNA 
duplexes targeting PIP5K-Iα were 
subjected to PI staining and flow 
cytometry. The cells whose DNA 
contents were lower than that in G1 
phase (sub-G1 fraction) due to 
apoptotic nuclear fragmentation 
were analyzed. Values in (B) and 
(C) are mean ± SEM from 4 
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3.2 The role of PAK1 in glucotoxicity-induced cell death 
3.2.1 Reverse transfection of siRNA duplexes knocks down PAK1  
In order to obtain the best silencing effect on target genes at the mRNA level 
without off-target effect after the reverse transfection of 3 duplexes of siRNA oligos 
against PAK1, the transfection conditions were optimized carefully and scrambled 
siRNA duplexes with similar GC content were used as the negative control. The 
siRNA duplexes, if transfected individually, were able to significantly decrease 
mRNA of PAK1 by 28-39%. The best knockdown efficiency (66%) for PAK1 
mRNA was achieved by using pooled 3 siRNA duplexes (Fig. 15A). Since reverse 
transfection of siRNA by liposome is a transient process, it is crucial to make sure 
that the knockdown efficacy can last through the whole experiment period. Thus the 
knockdown efficacy at the protein level was determined by Western blotting at 
various time points. We observed that a significant knockdown of PAK1 at protein 
level occurred at 24 h and was persistent till 144 h after transfection (Fig. 15B). The 
possibility that PAK1 targeting siRNA has off-target effect on other isoforms, 
which are highly homologous to PAK1, was ruled out, as the expression of PAK2 
and PAK3 at mRNA level was not altered after transfection of these siRNA 
duplexes (Fig. 15C). This demonstrated that the siRNA duplexes used in my studies 
were able to knock down PAK1 specifically. 
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Fig. 15. Knockdown of 
PAK1 in INS-1 cells.  
(A)  Knockdown of PAK1 
mRNA in INS-1 cells was 
obtained after reverse 
transfection of three siRNA 
duplexes targeting PAK1 
individually or in 
combination, as assayed by 
real-time RT-PCR. Same 
concentrations of scrambled 
siRNA duplexes (Ctrl) with 
similar GC content were 
transfected in control cells. 
Results are mean ± SEM 
from 3  independent 
experiments. * p<0.05 and 
 ** p<0.01 vs. control. (B) 
Remarkable knockdown of 
PAK1 at protein level in INS-
1 cells was determined by 
Western blotting from 24 to 
144 h. Tubulin was used as an 
internal control. (C) The 
expression of PAK2 and 
PAK3 was examined at 
mRNA level by using real-
time PCR. Transfection of 
siRNA duplexes targeting 
PAK1 did not significantly 
affect the expression of PAK2 
and PAK3.  Data are mean ± 
SEM from 5 independent 
experiments. 
 
3.2.2 PAK1 knockdown does not affect insulin secretion and actin 
cytoskeleton in INS-1 cell  
It is well known that PAK1 is a major regulator of actin cytoskeleton. However, 
PAK1 knockdown did not induce noticeable changes in INS cell morphology (Fig. 
16A). PAK1 knocked-down cells grown in monolayer adhered to culture flasks as 
tightly as control cells, as the time required for their detachment upon trypsinization 



























































24h                      48h                     72h
96h                    120h                    144h
Ctrl
PAK1 siRNA
+        - +         - +          -












































Chapter 3. Results 
 88 
accumulation was seen in the cell periphery and bunches of F-actin filaments were 
observed in the adherent surface of cells. However, PAK1 knockdown did not alter 
these F-actin structures of cells (Fig. 16A). In addition, PAK1 knockdown caused a 




Fig. 16. F-actin structure staining (A) and measurement of F-actin content (B) in 
INS-1 cells after PAK1 knockdown. 
 (A) Distinct morphological change was not observed in PAK1 knocked-down cells 
(lower row) compared with control cells (upper row).  As assessed by FITC-phalloidin 
staining, there is no change in the number of bundles of actin fibers at bottom 
dissection (left panel) after PAK1 knockdown. Additionally, the fluorescence intensity 
in PAK1 knocked-down cell was similar as in control cells (middle panel). (B) FITC-
phalloidin stained F-actin was extracted by methanol and measured by fluorescence 
micro-plate reader. Results are mean ± SEM of 4 independent experiments.   
 
PAK1 knockdown for 72 h did not significantly alter the insulin content (2189 ng/ 
µg DNA in PAK1 knockdown cell vs. 2319 ng/µg DNA in control, n=5, p>0.05) 
(Fig. 17B). Nor did PAK1 knockdown change the insulin secretion stimulated by 
high glucose (16.7 mM) and other secretagogues (forskolin, high KCl) (Fig. 17A). 
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Basal insulin secretion (2.8 mM glucose) from PAK1 knocked-down cells was 
1.38% (vs. 1.20% in control) of total insulin content. Insulin secretion over 30 min 
stimulation by 16.7 mM glucose was increased to 2.10% (vs. 1.90% in control). 
Upon incubation with 16.7 mM glucose plus 1 µM forskolin, insulin secretion was 
increased to 3.75% (vs. 3.73% in control). High (40 mM) KCl increased insulin 
secretion to 2.17% (vs. 2.26% in control) (Fig. 17A). Thus the PAK1 knockdown 
cells had the similar insulin secretion rates both at basal and upon stimulation as in 






Fig. 17. PAK1 knockdown did not affect insulin content or insulin secretion in 
INS-1 cells.  
(A) Insulin secretion at basal and upon stimulations was expressed as percentage of 
insulin content at each condition. (B) Insulin content was extracted by acid ethanol and 
measured by RIA. Data was normalized by DNA content. Data are mean ± SEM of 6 
(A) and 5 (B) independent experiments.  
 
3.2.3 Knockdown of PAK1 does not affect cell cycle at normal 
culture 
The possible effect of PAK1 knockdown on INS-1 cell growth and death was 
assessed by flow cytometry following PI staining. Cultured in normal medium 
(containing 11 mM glucose), PAK1 knockdown for 72 h did not significantly 
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18). Most cells fell into the G1 phase (74.6 % after PAK1 knockdown vs. 73.3% in 
control). The rates of subdiploidy apoptosis (cells at sub-G1 phase) due to DNA 
fragmentation after PAK1 knockdown were also not significantly altered (5.7% in 
PAK1 knocked-down cells vs. 5.4 % in control). These results indicated that at the 

















Fig. 18. No effect of PAK1 knockdown on cell cycle upon culture at regular 
glucose concentration (11 mM).  
(A) After reverse transfection of scramble or targeting siRNA, INS-1 cells were 
cultured in 6-well plates for 72 h in medium containing 11 mM glucose, followed by 
PI staining and flow cytometric analysis. The cells were fallen into four phases 
depending on their DNA content. The histogram is a typical representative. (B) 
Statistical data are mean ± SEM from 3 independent experiments. 
 
3.2.4 Glucotoxicity induces INS-1 cell apoptosis 
Consistent with the findings by other studies (241;303;304), exposure to elevated 
concentrations of glucose increased apoptosis of INS-1 β-cells. The number of cells 
with fragmented nuclei after treatment of high glucose (20 or 30 mM) for various 
periods was analyzed by flow-cytometry of PI stained cells.  A significant increase 
of apoptosis occurred after 60 h exposure to 20 mM glucose and peaked at 96 h 
(Fig. 19). When exposed to 30 mM glucose, cell apoptosis appeared 12 h ahead of 
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(46% at 20 mM glucose and 47% at 30 mM glucose) (Fig. 19). After 72 h, both 20 
and 30 mM glucose led to majority of cell to death (27% at 20 mM glucose, 33% at 




Fig. 19. Time-course of cell death induced by prolonged exposure to elevated 
glucose. 
INS-1 cells were cultured in medium containing control (11 mM) or high (20 or 30 
mM) glucose for up to 120 h. Cells were collected every 12 h. At the indicated time 
points, cells were stained with PI and subjected to flow cytometric analysis. The cells 
whose DNA content was lower than G1 phase (sub-G1) contained fragmented nuclei 
and were undergoing apoptosis. The percentage of cells in sub-G1 phase was measured 
as an indicator of apoptosis, which was increased in a time-dependent manner after 
treatment with high glucose. Results are mean ± SEM from 3 independent 
experiments. ** p<0.01, * p<0.05 vs. control (11 mM glucose). 
 
In order to obtain further evidence of apoptotic features, caspase activation assay 
was performed by using fluorescence labeled substrate for caspase-3: Ac-DEVD-
AFC. After high glucose treatment, cell homogenates were collected at various time 
points. Caspase-3 activity was significantly increased by 1.32 and 2.37 folds of 
basal after culture with 30 mM glucose for 24 h and 20 mM glucose for 36 h 
respectively (p<0.01) (Fig. 20). Moreover, both 20 and 30 mM glucose induced the 
maximal activation of caspase-3 at 48 h (6.42-fold and 4.45-fold, respectively). The 
peak of caspase-3 activation occurred around 24 h earlier than the appearance of 
apoptotic cells. Since in this study, DNA fragmentation was examined and used as 





















































Chapter 3. Results 
 92 
apoptosis is that DNA fragmentaion is a late event in apoptosis. In addition, 30 mM 
glucose induced caspase-3 activation occurred 12 h earlier than that by 20 mM 
glucose, similar to the time course of apoptosis as assessed by flow cytometry of PI 






Fig. 20. Time-course of 
glucotoxicity induced activation of 
caspase-3. 
Caspase-3 activity was assessed by 
measuring the cleavage of the 
fluorogenic specific substrates. 
Cells cultured in medium containing 
control (11 mM) or high (20 or 30 
mM) glucose were harvested at the 
indicated time points. The activity 
of caspase-3 was expressed as folds 
of basal condition (11 mM glucose 
at 24 h). High glucose activated 
caspase-3 in a time manner. Results 
are mean ± SEM of at least 3 
independent experiments. **p<0.01, 
*p<0.05 vs. control (11 mM 
glucose). 
 
The previous studies on caspases involved in glucotoxicity induced β-cell apoptosis 
are still in debate. Some reports have shown that the apoptotic process is associated 
with mitochondrial dysfunction, pointing to the intrinsic apoptotic pathway via 
cytochrome C release and caspase-9 activation (241). On the other hand, there is 
evidence that pro-inflammatory cytokines are also responsible for glucotoxicity 
induced apoptosis. IL-1β release and Fas expression were increased in islets 
cultured in elevated glucose, thus stimulating extrinsic apoptotic pathway which is 
characterized by caspase-8 activation (240). Therefore, both the extrinsic and 
intrinsic pathways of apoptosis induced by high glucose were examined in INS-1 
cells by measuring the activity of caspase-8 and caspase-9 using the synthetic 
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Glu-His-Asp-AFC (Ac-LEHD-AFC), respectively. A moderate but significant 
increase in activity of both caspase-8 and caspase-9 was observed in INS-1 cells 
after exposure to high glucose (Fig. 21 A,B). Caspase-8 was activated as early as 12 
h (1.21-fold of basal at 30 mM glucose, 1.30-fold of basal at 20 mM glucose, 
p<0.01). Caspase-9 was activated a little later than caspase-8, which is at 24 h 
(1.44-fold of basal at 30 mM glucose 1.41-fold of basal at 20 mM glucose, p<0.05). 
However, the activation of both caspase-8 (1.78-fold of basal at 30 mM glucose, 
1.63-fold of basal at 20 mM glucose) and caspase-9 (1.79-fold of basal at 30 mM 
glucose, 1.53-fold of basal at 20 mM glucose) peaked at 36 h (Fig. 21 A,B), which 
is earlier than the maximal activation of caspase-3. Interestingly, the activation of 
caspase-3 was less at 30 mM than that at 20 mM glucose after 48 h. This could be 
due to the loss of some apoptotic cells at this time point because of secondary 
necrosis, since no significant apoptosis occuured at 20 mM glucose at this time 
point. Above results suggest that both intrinsic and extrinsic pathways were 
activated and convergent on activation of caspase-3 when INS-1 cells were treated 
by chronic high glucose. 









 c occurredcontrol  
Fig. 21. Time-course of 
glucotoxicity induced activation 
of caspase-8 and caspase-9. 
Cells cultured in medium 
containing control (11 mM) or 
high (20 or 30 mM) glucose were 
harvested at the indicated time 
points. The activation of caspase-
8 (A) and caspase-9 (B) was 
examined by measuring the 
cleavage of the fluorogenic 
specific substrates at indicated 
time points. The activity of 
caspase-8 and -9 was expressed as 
fold of basal condition (11 mM 
glucose at 24 h). Maximal 
activation of both caspases 
occurred at 36 h after exposure to 
elevated glucose levels. Data are 
mean ± SEM of 3 independent 
experiments. **p<0.01 and 
*p<0.05 vs. control (11 mM 
glucose). 
 
Furthermore, a general caspase inhibitor, Z-VAD-FMK (benzyloxycarbonyl-Val-
Ala-Asp-fluoromethyl ketone), was also used to investigate glucotoxicity induced 
cell death. Measured by flow cytometry following PI staining, the percentage of 
sub-G1 cells after high glucose treatment was markedly reduced after co-incubation 
with the general caspase inhibitor between 48 and 96 h (Fig. 22). In such case, high 
glucose induced apoptosis declined from 28% to 8% at 20 mM glucose, and from 
30% to 15% at 30 mM glucose (p<0.01) at 72 h, indicating that glucotoxicity 






































































   
Fig. 22. A general caspase 
inhibitor (Z-VAD-FMK) 
blocked glucotoxicity induced 
cell death.  
(A) In the presence of a general 
caspase inhibitor (20 µM) in 
culture medium, INS-1 cells 
were cultured at 20 or 30 mM 
glucose and subjected for PI 
staining and flow cytometry.  
Cells sorting into sub-G1, G1, S 
and G2/M phase were analyzed. 
Caspase inhibitor rescued cells 
from death upon glucotoxicity. 
Typical histogram of flow 
cytometric data at 72 h is 
shown. (B)  Both 20 and 30 
mM glucose (Glc) induced cell 
death at indicated time points 
was determined by counting the 
cells in sub-G1 phase. Values 
are mean ± SEM from 3 
independent experiments.  
** p<0.01 vs. control (no 
caspase inhibitor). 
 
3.2.5 Chronic high glucose treatment increases PAK1 activation 
Our previous study has found that PAK1 was activated by acute high glucose 
stimulation (66). The activation of PAK1 after long-term culture with high glucose 
was also examined by Western blotting. Chronic culture in high glucose for 72 h 
did not change the total PAK1 mass (Fig. 23A). The activated form of PAK1 
(phosphor-PAK1) was detected by using a specific antibody targeting 
phosphorylated PAK1. After exposure to high (20 or 30 mM) glucose for 72 h, 
phosphorylated PAK1 was increased (Fig. 23B), suggesting a possible role of 
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 Fig. 23. Activation of PAK1 
after long-term exposure to 
elevated glucose. 
INS-1 cells were cultured in 6-
well plates in milieu with 
control (11 mM) or high (20 or 
30 mM) glucose (Glc) for 72 h. 
(A) Total PAK1 was assessed 
by regular Western blotting. 
(B). Protein samples were 
harvested in phospho-safe 
extraction reagent and then 
subjected to electrophoresis and 
Western blotting for detection 
of active phospho-PAK1 (68 
kDa). Tubulin was used as an 
internal control. 
 
3.2.6 Knockdown of PAK1 inhibits glucotoxicity-induced INS-1 cell 
death 
As shown above, INS-1 cells were undergoing apoptotic death after cultured in 
milieu with elevated glucose (20 or 30 mM) for a long term. In addition, before the 
majority of cell death came forth, unhealthy cells rounded up and tendered to detach 
from the bottom substratum (Fig. 24, upper images). However, such morphological 
changes were alleviated and delayed in cells upon PAK1 knockdown (Fig. 24, 
lower images). The most distinct morphology differences between control and 
PAK1 knocked-down cells were seen after 50-60 h culture at 20 or 30 mM glucose.  
B
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Fig. 24. PAK1 knockdown prevented changes of cell morphology and detachment 
induced by treatment of high glucose. 
INS-1 cells transfected with PAK1 siRNA or scrambled control siRNA were cultured 
in 6-well plates. Images were taken under light-contrast microscopy after 54 h of 
culture in medium containing control (11 mM) or high glucose (20 or 30 mM) glucose. 
The morphological change and cell detachment induced by glucotoxicity were 
alleviated by PAK1 knockdown. 
 
Furthermore, it is intriguing that PAK1 knockdown significantly reduced the cells 
fallen into sub-G1 phase undergoing apoptosis after exposure to high glucose for 72 
h (Fig. 25A). The apoptotic cells (sub-G1) were decreased significantly from 31% 
to 19% at 20 mM glucose and from 38% to 23% at 30 mM glucose upon PAK1 
knockdown (p<0.01). Such protective effect by PAK1 knockdown sustained at least 
for 96 h (Fig. 25B). In addition, PAK1 knockdown also reversed high glucose-
induced decrease of cells at G1 phase to a large extent (Fig. 25C). Glucotoxicity 
induced a markedly decrease of cell numbers sorting into G1 phase after 72 h of 
exposure to high glucose [52.5% at 20 mM and 46.2% at 30 mM glucose vs. 75.3% 
at basal (11 mM), p<0.01].  PAK1 knockdown rescued cells in G1 phase partly but 
11mMGlc              20mMGlc                 30mMGlc
Ctrl
PAK1-siRNA
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significantly (64.4% at 20 mM and 63.4% at 30 mM, p<0.01) (Fig. 25C). However, 
there is only a slightly decrease of cells in S/G2/M phases over time after treatment 
with high glucose, suggesting that most of cells fallen into sub-G1 phase shift from 
G1 phase after exposure to elevated glucose concentrations, and such pattern was 
not significantly affected by PAK1 knockdown (data not shown). 














Fig. 25. PAK1 
knockdown protected 
INS-1 cell from 
glucotoxicity induced 
cell death. 
INS-1 cells with or 
without PAK1 
knockdown were cultured 
in medium with 11, 20 or 
30 mM glucose for 
indicated time points. 
Cells were collected for 
PI staining and flow 
cytometry assay. Cells 
were distributed into sub-
G1, G1, S and G2/M 
phases. (A) A typical 
representative histogram 
of flow cytometric data at 
72 h is illustrated. (B) 
Statistical analysis of 
percentage of cells fallen 
into sub-G1 after 
exposure to control or 
high glucose (G) for 48-
96 h. (C) PAK1 
knockdown also reversed 
high glucose (Glc) 
induced reduction of cells 
in G1 phase. Results are 
means ± SEM from 3 
independent experiments.  
** p<0.01 vs. control (no 
PAK1 knockdown);  
# p<0.01 vs. 11 mM 
glucose. 
 
Additionally, the effect of PAK1 knockdown on glucotoxicity induced activation of 
caspase-3 was examined. PAK1 knockdown did not affect the caspase-3 activity 
when cells were cultured at control (11 mM) glucose (104% vs. 100% in control), 
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the number of apoptotic cells under the same condition (Fig. 26). However, the 7.1-
fold increase of caspase-3 activity in cells exposed to 20 mM glucose for 48 h was 
markedly reduced to be only 3.4-fold in cells transfected with siRNA targeting 
PAK1. Similarly, caspase-3 activation at 30 mM glucose was also relieved by 







Fig. 26. PAK1 knockdown 
suppressed caspase-3 activation.  
INS-1 cells either transfected with 
control siRNA or PAK1-siRNA 
were cultured in 6-well plate. 
Caspase-3 activity was measured 
after exposure to 11, 20 or 30 mM 
glucose (Glc) for 48 h. PAK1 
knockdown reduced caspase-3 
activation at either 20 or 30 mM 
glucose treatment. Values are mean 
± SEM from 3 independent 
experiments. * p<0.05 vs. control 
(no PAK1 knockdown). 
 
3.2.7 PAK1 knockdown blocks high glucose induced activation of 
p38 MAPK 
MAPK cascades are implicated in many cellular processes including cell survival 
and apoptosis, and there are also studies reporting their activation by high glucose 
in several cell lines (256;267;305-308). On the other hand, high glucose has a dual 
role in cell viability. Therefore, it is postulated that MAPK cascades may be 
involved in the balance of high glucose induced cell survival and apoptosis. My 
results revealed that, after long term of high glucose treatment, activation of P44/42 
MAPK and p38 MAPK (Fig. 27) but no JNK (data not shown) could be detected by 
Western blotting using antibodies specific for the activated phospho-form of 
abovementioned MAPKs. By densitometric analysis, activated p44/42 MAPK was 
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activated p38 MAPK was also significantly increased by 0.78- and 0.90-fold at 20 
and 30 mM glucose, respectively (Fig. 27).  
 
 




      
Fig. 27. High glucose induced 
activation of p44/42 MAPK and p38 
MAPK.  
INS-1 cells were exposed to 11, 20 
mM or 30 mM glucose (Glc) for 72h. 
Protein lysates were collected for 
Western blotting. Antibodies against 
phospho-p44/42 MAPK (P-P44/42 
MAPK) and phospho-p38 MAPK  
(P-P38 MAPK) were used to 
determine activation of p44/42 
MAPK and p38 MAPK respectively. 
β-tubulin was used as an internal 
control. Statistical results were 
acquired by densitometry analysis. 
Activation of MAPK was expressed 
as folds of that in control cells (11 
mM glucose), shown as bar chart. 
Treatment with high glucose induced 
activation of both p44/42 MAPK and 
p38 MAPK. Values are mean ± SEM 
from 6 independent experiments. * 
p<0.05 and ** p<0.01 vs. control (11 
mM glucose). 
 
p44/42 MAPK, p38 MAPK and JNK can be activated downstream of PAK1 (219-
226). It is thus possible that the attenuated apoptosis by PAK1 knockdown might 
result from inhibiting activation of some member(s) of MAPK cascades essential 
for glucotoxicity induced apoptosis. As shown in Fig. 27, although it seems that the 
high glucose induced activation of p44/42 MAPK in INS-1 cells was decreased 
after PAK1 knockdown at either 20 or 30 mM glucose, there was no statistic 
significance may be due to limited experiments. However, PAK1 knockdown 
completely abolished p38 MAPK activation evoked by high (both 20 and 30 mM) 
































































Fig. 28. PAK1 knockdown suppressed high glucose-induced p38 MAPK 
activation. 
INS-1 cells either transfected with scrambled siRNA (ctrl) or PAK1 siRNA (Paki) 
were cultured in 6-well plate with 11 mM or high (20 or 30 mM) glucose (Glc) for 72 
h. Protein was lysated in phosphosafe-lysis reagent followed by Western blotting. 
Activation of p38 MAPK or p44/42 MAPK was detected by using antibody against 
phorsphorylated activated MAPK. Statistical results were acquired by densitometry 
analysis (bar chart). Activation of MAPK was expressed as folds of control cell at 
11 mM glucose. High glucose caused activation of both p44/42 MAPK and p38 
MAPK but only the latter was blocked by PAK1 knockdown. Values are mean ± SEM 
of 3 independent experiments. * p<0.05 vs. control. 
 
Since no signal for phosphor-JNK was picked up in Western blotting, the JNK 
activation was also assessed by using a Phospho-SAPK/JNK ELISA, a much more 
sensitive technique than Western blotting. Following chronic high glucose for 72 h, 
JNK activity was increased by 39% at 20 mM glucose, but there was no statistical 
significance (Fig. 29). However, JNK activity was significantly increased (by 73%, 
p<0.05) after cultured at 30 mM glucose (Fig. 29). PAK1 knockdown did not 
significantly alter high glucose-induced JNK activation, suggesting that other 
regulators might mediate JNK activation in prolonged high glucose environment. 
11mMGlc        30mMGlc         20mMGlc
Ctrl                              +          - +          - +            -















































Fig. 29. JNK activation upon high 
glucose treatment. 
INS-1 cells transfected with 
scrambled siRNA (ctrl) or PAK1 
siRNA were cultured in 6-well plate 
with 11, 20 or 30 mM glucose (Glc) 
for 72h. Cell lysates were subjected 
for Phospho-SAPK/JNK Sandwich 
ELISA following the developer’s 
protocol. Data are expressed as folds 
of control cells at basal condition (11 
mM glucose). Results are mean ± 
SEM of 4 independent experiments. 
*p<0.05 vs. 11 mM glucose. 
 
3.2.8 Inhibitors of p38 MAPK and JNK protects INS-1 cells from 
glucotoxicity-induced apoptosis 
As demonstrated above, long-term of high glucose was capable of activating 
MAPK and JNK. Several specific inhibitors were used to determine if inhibition of 
MAPK activation by PAK1 knockdown is responsible for the protection of cells 
from high glucose induced cell death (SB203580 for p38 MAPK, U0126 for p44/42 
MAPK, and SP600125 for JNK). The inhibitors (10 µM each) were added to cell 
culture medium 30 min ahead of addition of 20 or 30 mM glucose and present 
throughout thereafter. Cultured in optimal glucose level (11 mM), no difference in 
apoptosis was observed in the presence of inhibitors or not (Fig. 30B). However, 
inhibitors for p38 MAPK and JNK reduced high glucose (20 or 30 mM) induced 
cell apoptosis as analyzed by PI staining and flow cytometry (Fig. 30A). SP600125, 
a JNK inhibitor, exhibited a potent protection outcome (13.1% of cells in sub-G1 
phase  vs. 27.8% in control at 20 mM glucose, 17.3% vs. 38.3% in control at 30 
mM glucose; n=3, p<0.01). A p38 MAPK inhibitor (SB203580) also blocked high 
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mM glucose and 26.4% at 30 mM glucose; n=7, p<0.01 and p<0.05 respectively) 
(Fig. 30B). However, U0126, an inhibitor of p44/42 MAPK, did not reduce rather 
even slightly exacerbated glucotoxicity induced apoptosis although without 
statistical significance (30.1% of cells in sub-G1 phase at 20 mM glucose and 









   
Fig. 30. Specific inhibitors for p38MAPK and JNK but not p44/42 MAPK 
protected INS-1 cells from high glucose induced cell death.  
INS-1 cells were exposure to 20 or 30 mM glucose (Glc) for 72 h in the presence of 10 
µM inhibitors for p38 MAPK (SB203580), p44/42 MAPK (U0126) and JNK 
(SP600125), respectively. These inhibitors were dissolved in DMSO, and same volume 
of DMSO was added into culture medium for control cells (ctrl). Cells were stained by 
PI followed by analysis of flow cytometry. (A) shows a typical histogram as a 
representative. (B) shows statistical analysis of the number of apoptotic cells at (sub-
G1) under various conditions. Data are mean ± SEM from at least 3 independent 
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3.2.9 Expression of a dominant negative Rac1 mutant aggravates 
high glucose induced cell apoptosis 
The possible role of Rac1, a critical stimulator of PAK1, in chronic high glucose 
induced apoptosis was also explored in INS-1 cells expressing its mutants. INS-1 
cells were transfected with empty vector pIRES, dominant negative mutant N17-
Rac1, or constitutively-active V12-Rac1, followed by drug selection to achieve 
stably expressing cells (66). Apoptosis was assessed by flow cytometry analysis of 
PI-stained cells. When cultured in medium containing optimal glucose (11 mM), 
there was no significant difference in apoptosis rates and distribution of cell cycle 
among the three kinds of cells (Fig. 31). The cells at sub-G1 fraction were 9.34%, 
12.73% and 10.13% in empty vector pIRES (control), N17-Rac1 and V12-Rac1 
expressing cells, respectively. High glucose induced apoptosis was enhanced in 
N17-Rac1 expressing cells (60% vs. 34% in control at 20 mM glucose and 72% vs. 
47% in control at 30 mM glucose; p<0.05) (Fig. 31). However, cells expressing 
V12-Rac1 mutant did not significantly change glucotoxicity-induced apoptosis (Fig. 
31).   
 
 Fig. 31. Expression of dominant 
negative N17-Rac1 increased high 
glucose-induced cell death. 
INS cells stably expressing empty 
vector pIRES (control), or Rac1 
mutants (dominant-negative N17-
Rac1 and constitutively-active V12-
Rac1) were cultured at 11, 20 or 30 
mM glucose (Glc) for 96 h. Cells 
were stained by PI and subjected to 
flow cytometry. Values are mean ± 
SEM from at least 3 independent 
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3.2.10 PAK1 knockdown has no effect on glucotoxicity induced 
oxidative stress 
Chronic exposure to high glucose was known to induce oxidative stress (243;261). 
Furthermore, MAPK activation was found to mediate oxidative stress’s 
deteriorating effect on apoptosis (276;281). Reactive oxygen species (ROS) assay 
was carried out to explore if PAK1 is involved in such process. My results revealed 
that ROS production was significantly increased by 76% and 48% in INS-1 cells 
after 72 h exposure to 20 and 30 mM glucose, respectively (Fig. 32). However, 
PAK1 knockdown did not alter high glucose-increased ROS formation (Fig. 32), 
indicating that PAK1 might be not directly implicated in the ROS production during 
glucotoxicity. 
 
Fig. 32. Reactive oxygen species 
(ROS) production was increased upon 
prolonged high glucose culture. 
INS-1 cells with or without PAK1 
knockdown were cultured in 48-well 
plate for 72 h at 11 mM or high (20 or 
30 mM) glucose (Glc). ROS assay was 
performed by incubation with 10 µM 
DCFDA for 30 min followed by wash 
thoroughly. Fluorescence intensity was 
measured and subtracted by blank 
reading. Data are expressed as folds of 
control (no PAK1 knockdown) cells 
cultured in 11 mM glucose. Data are 
mean ± SEM of 4 independent 
experiments. *p<0.05 and **p<0.01 vs. 







































The primary goal of this study is to examine the putative roles of two downstream 
effectors of Rac1 in insulin secretion. Both PIP5K-1α and PAK1 were selected as 
potential candidates. In this study, we used a new RNAi (RNA interference) technique 
to explore the cellular function for the targeted kinases of interest in a pancreatic β-
cell model.  
The discovery of siRNA (short interference RNA) by Andrew Fire and Craig Mello is 
a breakthrough in life science and was awarded the Nobel Prize in 2006. Recently, the 
small siRNA-mediated RNA interference (RNAi) techniques have advanced rapidly. 
At first, vectors constructed with shRNA (short hairpin RNA) specifically targeting 
interested mRNA sequence were used widely. This technique relies on the release of a 
duplex RNA, 21 bases in length with overhanging end, when the shRNA is produced 
in the cell. Later, siRNA became popular as commercially synthesized duplexes of 
siRNA were available. In the RNAi using siRNA, a strand of siRNA complexes with 
proteins to form RISC (RNA induced silencing complex) and cleaves the target site of 
mRNA where complementarity exists and hence silencing the gene. By silencing a 
target mRNA, the function of a target protein can be investigated. Several widely used 
methods have also been tried in my study to knock down the expression of the two 
interested kinases. After overcoming various difficulties, successful knockdown 
efficacy was achieved by using reverse transfection of a pool of siRNA duplexes into 
INS-1 cells. In addition, concerns about the off-target intracellular effect of siRNA 
have been brought forward recently. Short interfering RNAs were shown to induce 
unexpected and divergent changes in the levels of untargeted proteins (309). In my 
study, several isoforms have highly homogenous sequences with our interested 
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isoform for either PIP5K-1α or PAK1. To avoid possible off-target effect, the lowest 
amount of siRNA that can get the satisfied knockdown efficacy was used. In addition, 
the expression levels of other isoforms of my target genes were also analyzed by real-
time PCR. My data have demonstrated that the siRNA duplexes I used could 
specifically knock down the target kinases without significant alteration of transcript 
levels of other respective isoforms.  
4.1. Roles of PIP5K-Iα in insulin-secreting cells 
Insulin secretion from β-cells is regulated by a complex signaling network. Our earlier 
study has reported that Rac1 participates in glucose- and cAMP-induced insulin 
secretion probably via maintaining a functional actin structure for recruitment of 
insulin granules (66). Type Iα phosphatidylinositol-4-phosphate 5-kinase (PIP5K-Iα) 
is a downstream effector of Rac1 and a critical enzyme for synthesis of 
phosphatidylinositol-4,5-bisphosphate (PIP2). By using RNA interference technique, 
PIP5K-Iα in INS-1 β-cells could be specifically knocked down by 70-75%. PIP5K-Iα 
knockdown disrupted F-actin structure and caused changes in cell morphology. In 
addition, PIP2 content in the plasma membrane was reduced and glucose effect on 
PIP2 was abolished but without affecting glucose-induced formation of inositol 1,4,5-
trisphosphate. At basal conditions (2.8 mM glucose), PIP5K-Iα knockdown doubled 
insulin secretion, elevated glucose metabolic rate, depolarized resting membrane 
potential and raised cytoplasmic free Ca2+ levels ([Ca2+]i). The total insulin release at 
high glucose was increased upon PIP5K-Iα knockdown. However, the percentage 
increment of insulin secretion by high glucose and forskolin over the basal release 
was significantly reduced, an effect more apparent on the late phase of insulin 
secretion. Metabolism and [Ca2+]i rises at high glucose were also attenuated in cells 
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after PIP5K-Iα knockdown. On the other hand, PIP5K-Iα knockdown had no effect on 
cell growth and viability. Taken together, our data suggest that PIP5K-Iα may play an 
important role in both the proximal and distal steps of signaling cascades for insulin 
secretion in β-cells. 
4.1.1. Involvement of PIP5K-Iα in cell morphology and actin 
cytoskeleton organization in INS-1 cells 
In this study, marked knockdown of PIP5K-Iα by RNA interference induced 
morphological changes in INS-1 cells which were rounding up like grapes, had 
weaker ability to adhere to the substratum and lost most of their lamellipodia, a well-
known morphological marker of Rac function (310). All these morphological changes 
are similar to those observed when Rac1 was suppressed by expressing a dominant-
negative Rac1 mutant (N17Rac1) in INS-1 cells (66). In addition, F-actin was 
disrupted noticeably in PIP5K-Iα knockdown cells, though not as much as that seen in 
N17Rac1 expressed INS-1 cells, in which F-actin was almost obliterated, suggesting 
the involvement of other Rac1 effector(s) (Fig. 33).  
There are three isoforms of type I PIP5K in mammalian cells, and increasing evidence 
suggests that each isoform may have specific functions (134;135;150). Some studies 
have shown that PIP5K-Iα mediated Rac1’s effect on actin cytoskeleton in various 
cells. In permeabilized platelets, Rac is associated with PIP5K-Iα to increase actin 
assembly by uncapping actin filaments to expose barbed ends (159). Mast cells from 
PIP5K-Iα knockout mice displayed less polymerized cortex actin (130). However, the 
role of other isoforms of PIP5K in actin organization remains unclear. Silencing of 
PIP5K-Iγ in INS-1 cells by siRNA has also been reported by Waselle et al (168) but 
without mention of any morphological change. Our previous study has found that 
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glucose does induce translocation of PIP5K-1α from cytosol to plasma membrane in 
INS-1 cells (137). My current study provided further evidence that PIP5K-1α might 
be involved in regulation of actin skeleton. However, the possible involvement of 
other isoforms of type I PIP5K in regulation actin structure in β-cells could not be 
ruled out, as there is also evidence for the involvement of β or γ isoform of type I 
PIP5K in the organization of actin cytoskeleton in other cell type (115). Specific 
knockdown of other isoforms is required to verify this hypothesis. Nonetheless, my 
results revealed the important role of PIP5K-Iα in mediating Rac1’s function in the 
organization of actin cytoskeleton and morphology in INS-1 cells.  
 
 
Fig. 33. Schematic diagram for the 
role of PIP5K-1α in actin cytoskeleton 
and glucose stimulated insulin 
secretion.  
PIP5K-1α acts downstream of Rac 
mediating Rac’s role in organization of 
actin cytoskeleton and glucose 





4.1.2. Role of PIP5K-Iα in insulin secretion in INS-1 cells 
As main regulators for cytoskeleton, small G-proteins have been reported by our 
laboratory (66) and others (65;67) to be implicated in regulated exocytosis. These 
events may involve small G-proteins of Rho family, since activation of RhoA, Rac1 
and Rho GDI is involved in Ca2+-dependent exocytosis at least partly through the 
reorganization of actin filaments in PC12 cells (46;58). However, Rac1 and CDC42, 
but not RhoA, have been found implicated in glucose-stimulated insulin secretion in 
β-cells (311). Our earlier studies have provided direct evidence that glucose is able to 
Rac
Actin cytoskeleton
Glucose induced insulin secretion
PIP5K-Ia?
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activate Rac1 and that Rac1 is involved in glucose- and cAMP-mediate insulin 
secretion from INS-1 cells through regulation of reorganization of actin cytoskeletons 
(66).  
Organization of actin cytoskeleton is associated with exocytosis. Insulin secretory 
granules are known to be characterized into different pools: reserved, morphologically 
docked, and readily releasable. During exocytosis, the cortical actin cytoskeleton may 
act as a barrier to hamper or as a propeller to facilitate the approaching of secretory 
granules to fusion with the plasma membrane (312). Re-localization and 
polymerization of actin was displayed in secreting cells (67). Furthermore, the 
reorganization of the cortical actin cytoskeleton has been proved to be essential for 
translocation of insulin secretory granule (33). However, the precise regulation of 
actin cytoskeleton reorganization during exocytosis and its effect on insulin secretion 
is complicated and remains unclear. An increase of F-actin was observed in pancreatic 
β-cells when stimulated by glucose (313). Disrupting F-actin using cytochalasin B or 
latrunculin B enhanced insulin release from islet and MIN6 (47;49). However, 
inhibition of insulin secretion was also observed when Clostridium botulinum C2 
toxin was used to disrupt F-actin structure in poorly granulated HIT-T15 cells (50). 
The effects of PIP5K-Iα knockdown on stimulated insulin secretion in INS-1 cells 
appeared complex. After PIP5K-Iα knockdown, the sum of released insulin was larger 
upon stimulation by high glucose alone, but not by high glucose plus forskolin. The 
increased basal insulin secretion may result from PIP5K-Iα knockdown induced 
changes in serial cellular events of insulin secretion: the increased basal glucose 
metabolism, depolarized plasma membrane potential and elevated basal intracellular 
concentration of Ca2+. However the enhanced insulin secretion in response to high 
glucose could not be due to an increase of glucose metabolism and [Ca2+]i, as both 
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latter events were partially inhibited. This elucidation is also supported by the fact that 
the total insulin release was similarly elevated by stimulation of high KCl at basal 
glucose. The possible explanation is the disruption of F-actin filaments. As 
aforementioned, disrupting F-actin could enhance glucose-stimulated insulin release 
(47;49). However, earlier studies have demonstrated that such enhancing effect of F-
actin disruption seemed only occurring in the isolated islets and not in the transformed 
HIT or INS-1 cells (50;66), probably because the primary β-cells contain much more 
insulin granules near the F-actin web underneath the plasma membrane (50). 
Therefore, other changes than F-actin disruption after PIP5K-Iα knockdown should be 
identified to explain the enlarged total insulin release. PIP5K isozymes synthesize 
PIP2, a minor cellular phosphoinositide in discrete and compartmentalized pools, and 
thus may regulate PIP2-mediated cellular signaling events (135) including actin 
cytoskeleton organization and exocytotic membrane fusion (136;314). Elimination of 
PIP2 on plasma membrane is necessary for exocytosis (315). Therefore, the elevated 
basal insulin secretion might also attribute to the depletion of PIP2 on plasma 
membrane in PIP5K-Iα knocked-down cells.  
When stimulated insulin secretion was expressed as the percentage increment over the 
basal, however, the effects of high glucose alone or plus forskolin were significantly 
reduced by PIP5K-Iα knockdown, which is compatible with our previous results 
obtained after suppression of Rac1 function. (66). The reduction of glucose 
metabolism and consequent [Ca2+]i  at glucose stimulation after PIP5K-Iα knockdown 
might also contribute to the inhibited insulin release of glucose and forskolin 
stimulation.  Additionally, previous studies demonstrated that transient turnover of 
PIP2 on the plasma membrane is critical for insulin secretion (316). As observed in 
this study, glucose evoked PIP2 turnover on the plasma membrane was abolished in 
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PIP5K-Iα knocked-down cells. This might result in the inhibited insulin secretion 
upon glucose stimulation. However, the failure of PIP5K-Iα knockdown to 
significantly affect the insulin release stimulated by high KCl, a secretagogue 
inducing a monophasic insulin secretion only at the early stage (317), suggesting that 
the very distal steps in exocytosis remains intact.  
My current studies also revealed that PIP5K-Iα knockdown attenuated the stimulated 
insulin secretion at both the early and late phases. In addition, the late phase of 
glucose- and cAMP-stimulated insulin secretion appeared to be affected to a greater 
extent. Again, this phenomenon has also been observed in INS-1 cells after Rac1 
suppression (66) and could be explained by the disrupted organization of actin 
cytoskeleton due to PIP5K-Iα silencing.  
It is well known that glucose induces biphasic insulin secretion from pancreatic β-
cells (318). Glucose metabolism followed by closure of ATP-sensitive K+ channels 
(KATP) and elevation of intracellular Ca2+ levels results in exocytosis of an 
immediately releasable granule pool that is responsible for the early phase. During the 
late phase of insulin secretion, secretory granules need to be promoted and recruited 
to the exocytotic sites, a process that involves actin cytoskeleton (33;50;319;320). 
This process may require F-actin filaments in the deeper sites of cells which could be 
essential for sustained exocytosis (50). Based on my results from two-phase secretion 
experiments, high glucose induced insulin secretion over basal was reduced slightly 
more at the late phase than that at the early phase after PIP5K-1α knockdown. 
However, earlier studies have shown that glucose and forskolin-stimulated insulin 
secretion at late phase was inhibited more obviously after Rac1 suppression. (66). 
This could be apparently due to the fact that F-actin cytoskeleton was destroyed more 
severely in cells by Rac1 suppression than that happened to PIP5K-Iα knockdown. It 
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is likely that the F-actin structure in the deeper cell was affected by PIP5K-Iα 
knockdown to a less extent. Taken together, our results provided evidence for PIP5K-
Iα to act as the downstream effector of Rac1 at least partially to regulate glucose-
induced insulin release in INS-1 cells. 
4.1.3. Implication of PIP5K-Iα in PIP2 production in INS-1 cells 
PIP5K isozymes synthesize PIP2. PIP2 can regulate various cellular signaling events 
including actin cytoskeleton organization and exocytotic membrane fusion (134-
136;314). PIP2 was proposed to be a plasma membrane marker by distinguishing it 
from other intracellular organelles, since it was found primarily on the plasma 
membrane and accounts for approximately 1% of membrane phospholipids 
(134;321;322). In addition, visualized PIP2 was also found to concentrate in highly 
dynamic actin-rich regions (162) and lipid rafts (136;150;181). However, the subtract 
for PIP5Ks, PtdIns(4)P, is found in most of intracellular fractions such as the plasma 
membrane, endoplasmic reticulum and nuclei.(323). Furthermore, PIP5Ks are 
localized to different subcellular compartments, although little is known about the 
homogenous synthesis of PIP2 (133). Accumulating evidence now suggests that 
differential localization of distinct PIP5K isoforms allows for specific spatial and 
temporal generation of PIP2 to mediate specific cellular events and regulate non-
redundant biochemical pathways by individual PIP5K (134;135;150).  
High-resolution cell imaging of GFP-tagged PH domain of PLC-δ was widely used to 
monitor cellular PIP2 dynamics (324). By using this powerful tool, others have found 
that a plasma membrane pool of PIP2 is important in the regulation of exocytosis in 
neuroendocrine cells (152), hippocampal neurons (325) and pancreatic β-cells (326). 
PIP5K over-expression increased PIP2 levels on the plasma membrane and increased 
Chapter 4. Discussion 
 
 116 
clathrin-dependent endocytosis in Hela cells (140). Hammond et al. reported that 
plasma membrane PIP2 is transiently depleted upon activation of exocytosis in mast 
cells (315).  
Our previous study has reported that glucose stimulation was able to promote Rac1 
translocation from cytosol to the membranes in INS-1 cells (66). Furthermore, we 
observed that Rac1 might interact with and activate PIP5K at the plasma membrane, 
since transfection of a dominant negative Rac1 mutant in INS-1 cells abolished the 
stimulating effect of glucose on PIP5K-Iα translocation from cytosol to the 
membranes (137). In the present study, PIP5K-Iα knockdown not only significantly 
reduced PIP2 content on the plasma membrane but also abolished the effect of glucose 
stimulation on PIP2 distribution in the plasma membrane. Such interference with PIP2 
production might also contribute to disordered actin cytoskeleton organization and 
reduced secretory response to high glucose.  
Although high glucose stimulation of control cells for 30 min could cause similar 
reduction of PIP2 in the plasma membrane to that observed upon PIP5K-Iα 
knockdown, there was no change in cell morphology as those observed in PIP5K-Iα 
knocked-down cells. This could be due to a different dynamics of PIP2 under the 
various conditions. Glucose stimulation can increase PIP2 turnover, resulting in an 
early reduction because of hydrolysis that is followed by a recovery due to increased 
biosynthesis of PIP2 (327). Such turnover would be abolished in PIP5K-Iα knocked-
down cells. The change in cell morphology is more likely related to a disruption of F-
actin structure. But glucose stimulation seemed to mainly cause re-organization of 
cortical F-actin (49;328;329). In addition, no change or even an increase of F-actin 
content was observed when β-cells were stimulated by glucose (50;313), in contrast to 
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the significant F-actin disruption and reduction of F-actin content upon PIP5K-Iα 
knockdown.  
It is known that glucose stimulation could result in the hydrolysis of PIP2 by 
activation of phospholipase C following Ca2+ entry into the cells (315). However, 
although the current study also observed that glucose stimulation could increase IP3 
formation, such effect was not affected by PIP5K-Iα knockdown. It is possible that 
the moderate PIP2 reduction in a particular region (ie. plasma membrane) upon 
PIP5K-Iα knockdown was not enough to wipe out glucose stimulation effect. 
Alternatively, glucose stimulation might hydrolyze separate PIP2 pools which are 
maintained by other PIP5K isoforms and thus not affected by PIP5K-Iα knockdown 
(135;150;330). Unfortunately, the approach used in the current study was unable to 
detect the change of total amount of PIP2 in other cellular compartments.  
There are other reports regarding the effect of deletion of PIP5K-1α. Sasaki indicated 
that mast cells from PIP5K-Iα-deficient mice displayed reduced PIP2 levels yet, 
intriguingly, augmented degranulation (130). However, silencing of another isoform, 
PIP5K-Iγ, in INS-1 cells did not affect basal secretion but inhibited insulin release 
induced by glucose and cAMP-elevating agent (168). In the latter study, glucose 
stimulation increased PIP2 levels. The reason for the discrepancy is unclear. It could 
be due to their different measurement conditions: a 45-min stimulation of cells with 
glucose and then determination of the PIP2 distribution on the fixed cells, a time point 
when PIP2 recovery occurs (327). Alternatively, this might be associated with the 
isoform-specific function of PIP5K through synthesis of PIP2 in distinct pools 
(134;135;150). 
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Besides the regulation of cytoskeleton and membrane trafficking, PIP2 may play a 
role in the regulation of cell proliferation and survival (150). However, efficient 
knockdown of PIP5K-1α had no effect on the INS-1 cell cycle and apoptotic death. 
The majority of PIP2 on the plasma membrane remained there after PIP5K-1α 
knockdown, since only a minor reduction of PIP2 was observed. It is thus likely that 
other existing isoforms of PIP5K in INS-1 cells, which were not knocked down by 
siRNA targeting PIP5K-1α, might compensate for the synthesis of PIP2. PIP5K-Iγ 
was known to have higher Vmax than PIP5K-1α in some cells (140). On the other 
hand, Waselle et al did not mention about the cell apoptosis after silencing of PIP5K-
Iγ in INS-1 cells (168). Thereafter, the role of PIP5K in growth and death of INS-1 
cells remains uncertain and further studies need to be done to address this issue, e.g. 
by knocking down all PIP5K-1α, β and γ.  
4.1.4. Role of PIP5K-Iα in glucose metabolism and membrane 
potential  
 
Some interesting observations in this study are the enhanced basal glucose 
metabolism, a more depolarized state of resting membrane potential, elevated basal 
[Ca2+]i and doubled basal insulin secretion after knockdown of PIP5K-Iα. The 
underlying mechanism for these consequences remains to be clarified. Although the 
possibility that PIP5K-Iα is directly implicated in these processes cannot be ruled out 
(331), the changes of PIP2 distribution and reduction might be relevant. However, 
most of these phenomena did not occur in INS-1 cells expressing either a dominant-
negative or constitutively-active Rac1 mutant (66), suggesting they are not Rac1-
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related cellular processes, and thus PIP5K-1α may perform a convergent effect of 
regulators besides acting as a mediator of Rac1 activation. 
PIP5K-Iα knockdown affected glucose metabolism as assessed by both 14C-glucose 
oxidation and tetrazolium reduction test, which produced similar results: an inhibited 
metabolism at high concentrations of glucose while augmenting the basal glucose 
metabolism.  A search of the literature did not find any report on this issue and the 
precise role of PIP5K-Iα in glucose metabolism needs to be explored in the future to 
figure out what metabolic step(s) is affected. However, my findings of the effect of 
PIP5K-Iα knockdown on glucose metabolism might contribute to the depolarized 
resting membrane potential and augment of basal insulin release, in addition to the 
inhibition of high glucose stimulated insulin secretion as discussed above.   
The resting membrane potential was in a more depolarized state after knockdown of 
PIP5K-Iα. The underlying mechanisms have been explored further. It is known that 
ATP can block KATP channels, whereas PIP2 activates the channels via action on 
separate groups of residues (331). Overexpression of a PIP5K decreased the ATP 
sensitivity of KATP channels and hyperpolarized INS-1 cells, affecting high glucose-
induced insulin secretion (184). Therefore, a reduction of PIP2 synthesis upon PIP5K-
Iα knockdown would render the cells in a more depolarized state of membrane 
potential even at rest. However, introducing diazoxide at 200 µM, a potent KATP 
channel opener, was unable to reverse the depolarization of basal membrane potential 
in PIPK-Iα knockdown cells, suggesting that a change of activity of other PIP2-
regulated channels including non-selective cation channels such as a TRP channel 
might be implicated (185;186). The depolarization of basal membrane potential was 
also confirmed by patch-clamp electrophysiological studies by my colleagues (data 
not shown). The enhanced basal glucose metabolism, depolarized resting membrane 
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potential, and elevated basal [Ca2+]i would contribute to the doubled basal insulin 
secretion after knockdown of PIP5K-Iα. These observations also suggest that PIP5K-
Iα may play a role in the generation of proximal signals for insulin secretion in β-cells. 
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4.2 The role of PAK1 in glucotoxicity-induced β-cell 
apoptosis 
Effective and sustained knockdown of PAK1 in INS-1 cells by using siRNA was 
achieved in the current study. PAK1 knockdown appeared not to affect F-actin 
cytoskeleton and did not alter insulin secretion induced by various stimuli. However, 
PAK1 knockdown attenuated apoptosis and caspase-3 activation in INS-1 cells due to 
prolonged exposure to high glucose (glucotoxicity). Moreover, PAK1 knockdown 
reduced activation of p38 MAPK evoked by glucotoxicity. Thus, PAK1 may be 
involved in the glucotoxicity-induced β-cell apoptosis associated with activation of 
p38 MAPK but not participate in the regulation of insulin secretion.  
4.2.1 PAK1 knockdown has no effect on either F-actin cytoskeleton 
or insulin secretion 
Previously, our lab has observed that actin cytoskeleton is almost completely 
disrupted and F-actin content is dramatically reduced in INS-1 cells expressing a 
dominant negative Rac1, N17-Rac1. To my surprise, there was no visible 
morphological change or obvious decline in F-actin structure and content in INS-1 
cells in the present study after a specific knockdown of PAK1. It is possible that other 
isoforms of PAK compensate the loss of PAK1 for the regulation of actin 
cytoskeleton in such case. PAK2 is distributed widely and dominantly in most of cells 
(197). Whether PAK2 is also expressed abundantly and serve as the main regulator 
for actin cytoskeleton in INS-1 cells remains to be examined. Although PAK2 
expression at the mRNA level was not altered after PAK1 knockdown, it cannot be 
ruled out the possibility that its kinase activity might be increased to compensate for 
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the loss of PAK1 in these cells. On the other hand, PAKs are not the sole downstream 
effector of Rac1, and thus other effectors may also mediate the effect of Rac1 on actin 
cytoskeleton. In addition, the sole knockdown of PIP5K-Iα induced only moderate 
decrease of F-actin content, which also cannot account for the dramatic effect of 
expressing a dominant negative Rac1 on F-actin cytoskeleton. Therefore, other 
isoforms of PIP5K, such as PIP5K-Iγ which is certainly expressed in INS-1 cells, as 
well as additional Rac1 downstream effectors may also contribute to the regulation of 
actin cytoskeleton.  
The role of PAK1 implicated in exocytosis remains in debate. Overexpression of 
PAK1 promoted evoked secretion in bovine chromaffin cells (58).On the other hand, 
siRNA mediated depletion PAK1 inhibited insulin secretion from MIN6 cells (78). 
However, expression of a wild-type PAK1 or a constitutively active PAK1E423 or the 
kinase-dead PAK1R299 mutants produced no effect on secretion in PC12 Cells (332). 
My study is consistent with the latter finding. Knockdown of PAK1 by using siRNA 
had no effect on insulin secretion at basal status or upon various stimulations in INS-1 
cells, including glucose alone or plus forskolin, and high potassium. In contrast, our 
previous study has demonstrated that Rac1, an activator of PAK1, play an important 
role in insulin secretion through organization of F-actin cytoskeleton (66). In addition, 
CDC42, another activator of PAK, was also considered as a proximal transmitter of 
the glucose signal in stimulus-secretion in MIN6 β-cells (77;78). The regulation of 
insulin secretion appears to be a highly complicated process, which is implicated by 
many small G proteins, kinases, phospholipases etc. (65;333-336). However, my 
observation that PAK1 knockdown failed to affect insulin secretion suggests other 
downstream effectors may mediate the role of Rac1 in the regulation of insulin 
secretion in INS-1 cells.  
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4.2.2 The protective role of PAK1 knockdown from glucotoxicity 
induced β-cell death 
Activation of PAK was observed after long-term culture in high glucose environment, 
even though I have not observed an alteration of total PAK1 mass. Intriguingly, I 
found that PAK1 knockdown by using siRNA reduced chronic high glucose induced 
INS-1 cell apoptosis, as assessed by the measurement of the hypodiploid. It is 
generally accepted that medium containing 11 mM glucose is optimal for culturing of 
pancreatic β-cell (337). However, moderate or severe hyperglycemia can lead to the 
loss of β-cell mass. There is evidence showing that the effect of chronic elevation of 
moderate glucose (≥ 16.7 mM) was associated with features of apoptosis in islets and 
insulin-secreting cells (241;303;304). In addition, more cells may die by necrotic cell 
death at severe glucose (i.e. 27 mM glucose) (304). Thereafter, in this study INS-1 
cells were cultured in 20 or 30 mM glucose to study the deteriorating effect of long 
term exposure to moderate and severe high glucose. Using PI staining followed by 
flow cytometry to calculate the hypodiploid events is a quantitative methodology that 
allows estimation of both apoptosis and secondary necrosis (338;339). Consistent 
with others’ findings in insulin-secreting cells (241) and pancreatic islets (303;304), 
my study demonstrated that incubation with elevated glucose provoked apoptosis in a 
time- and dose-dependent manner in INS-1 cells, even though their apoptosis needs 
longer period of exposure to high glucose compared with islets.  It is understandable 
that INS-1 cells were less susceptible to high glucose treatment compared with islets 
due to the frail character of isolated islet cultured in vitro. Although significant cell 
apoptosis induced by 20 mM glucose treatment occurred 12 h later than that happened 
to 30 mM glucose treatment, apoptosis in both cases peaked roughly at the same level 
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(around 50%) simultaneously. PAK1 knockdown reduced cells undergoing apoptosis 
with either 20 or 30 mM glucose by nearly 50% up to 96 h of treatment. 
It has been demonstrated that PAK members play isoform-specific role in either pro-
apoptosis or anti-apoptosis (199). PAK2 was generally accepted to be activated 
downstream of caspase-3, thus contributing to the morphological change during the 
late stage of apoptosis (289;290). However, the role of PAK1 in cell survival or 
apoptosis is controversial. The protective role of PAK1 is believed to result from its 
activation upon survival signals and attenuation of apoptosis via its activating  
NFκ-B or by promoting degradation of Bad in some cell types (100;340).  On the 
other hand, there is also evidence for PAK1’s role in the signaling pathway towards 
apoptosis. Procarcinogen, Benzo[a]pyrene, was shown to promote apoptosis by 
activating Rac1, PAK1, and JNK pathway in 293T and Hela cells (288). Moreover, 
expression of constitutive active mutant of PAK1 accelerated Benzo[a]pyrene induced 
apoptosis, whereas dominant negative PAK1 inhibited Benzo[a]pyrene induced cell 
apoptosis (288). Therefore, the role of PAK1 in the cell viability may be dependent on 
the extracellular stimuli and cell types.  Although more evidence is inclined to the 
anti-apoptotic effect of PAK1, my results support the latter notion that PAK1 is also 
implicated in the signaling network for apoptosis. In addition, above observations 
raised a question on the knockdown specificity. However, my real-time PCR results 
have ruled out the possibility that the siRNA pools may knock down other isoforms of 
PAK due to off-target effect. Therefore, the anti-apoptotic effect of PAK1 knockdown 
in my studies could not be a result from depletion of PAK2, which is extensively 
believed to play an apoptotic role in several cell types (230;231;289;290;341).  
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4.2.3 PAK1 knockdown attenuated glucotoxicity-induced caspase-3 
activation  
The attenuation of high glucose induced apoptosis by PAK1 depletion were further 
confirmed by reduced caspase-3 activity. Herein, I reported for the first time the role 
of PAK1 in glucotoxicity-induced apoptosis and PAK1 acts upstream of caspase-3 in 
insulin-secreting cells. My time-course study revealed that capase-3 was activated by 
glucotoxicity with the maximal activation happened at 48 h after exposure to high 
glucose, which is 48 h ahead of the peak of apoptosis.  Thereafter, caspase-3 activity 
decreased gradually. On the other hand, caspase-3 activation in cells cultured in 20 
mM glucose is higher than that in 30 mM glucose, although the highest cell death rate 
was similar in either high glucose concentrations, implying that more cells died in a 
caspase-independent manner when incubated with severe high glucose level (30 mM 
glucose). It suggests that there may be a transition from caspase-dependent to 
caspase-independent cell death accordingly to glucose concentrations. 
The initiative caspases that acted upstream of caspase-3 in the glucotoxicity to induce 
a series of apoptotic signaling events in pancreatic β-cells remained unclear. The 
activation of extrinsic pathway was supported by the fact that exposure of islets from 
non-diabetic organ donors to high glucose resulted in increased production and 
release of IL-1β, followed by Fas upregulation, activation of caspase-8 and -3 
(239;240;308). On the other hand, chronic exposure to hyperglycemic environment 
caused mitochondria dysfunction and cytochrome C release in MIN6 cells (241) and 
INS-1 cells (342). In addition, the anti-apoptotic members of Bcl family were 
suppressed whereas pro-apoptotic members increased in human islets after long-term 
culture in 16.7 mM glucose (15), which implied the involvement of intrinsic pathway.  
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My present study supports the notion that both extrinsic and intrinsic pathways are 
related to glucotoxicity induced apoptosis of INS-1 cells, as activation of both 
caspase-8 and -9 was observed. Though the activity of caspase-8 and -9 was 
moderately increased, the peak activation of both initiative caspases occurred nearly 
at the same time point, 36 h after high glucose treatment, which was prior to the 
activation of caspase-3. However, involvement PAK1 in either the intrinsic or 
extrinsic pathways leading to activation of caspase-8 and -9 during glucotoxicity-
induced β-cell death needs to be explored. The possibility that other initiative 
caspase(s) may contribute to caspase-3 activation in this scenario also cannot be ruled 
out.  
Furthermore, cells rounded up and got detached from the bottom of substratum after 
chronic high glucose culture. This occurred after the peak activation of caspase-3 and 
persisted until the most of cells suffered from apoptosis. However, the occurrence of 
morphological change was delayed in cells after PAK1 knockdown, consistent with 
the anti-apoptotic observations of inhibiting glucotoxicity-induced caspase activation 
and apoptosis in these cells.  
4.2.4 The role of PAK1 activators in glucotoxicity  
Our previous study has shown that acute glucose stimulation can activate Rac1, a 
critical regulator for PAK1 activation (66). However, in my study the constitutively 
active mutant V12-Rac1 caused no significant change in cell apoptosis cultured either 
with optimal or high glucose. In contrast, the dominant negative mutant of Rac1 
(N17-Rac1) aggravated glucotoxicity-induced INS-1 cell apoptosis, even though it 
had no effect on cells cultured at optimal glucose. Nevertheless, the expression of 
dominant negative mutant of Rac1 may be not an ideal depletion technique to study 
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the function of a protein. Recently, a pro-apoptotic role of Rac1 has been revealed by 
using RNA interference to obtain Rac1 silencing in cancer cell and lymphocyte 
(88;343). Knockdown of Rac1 by RNA interference protected cell from apoptosis via 
reducing drug induced ROS generation (343) or impeding Fas translocation to lipid 
raft micro-domain (88). Increased oxidative stress and Fas expression have been 
proved to participate in the glucotoxicity induced apoptosis in β-cells (240;244;344). 
Therefore, the effects of expression of a negative Rac1 mutant in high glucose 
induced apoptosis need to be further clarified. 
Besides Rac, CDC42 is another critical activator for PAK1. Several investigations 
have demonstrated the involvement of CDC42 in apoptosis. By overexpression or 
knockdown, CDC42 was shown to be required for growth factor withdrawal or other 
stress induced neuronal apoptosis via JNK activation (345-347). Moreover, CDC42 
was also activated by high glucose (78). Although both PAK1 activators, Rac1 and 
CDC42, may be involved in pancreatic β-cell apoptosis due to glucotoxicity, the 
relevant evidence is still scant. 
4.2.5 PAK1 knockdown blocked p38MAPK activation upon 
prolonged exposure to high glucose  
The downstream effectors of PAK1 were explored in my study to find the critical one 
that mediates PAK1’s protective effect on high glucose induced β-cell apoptosis. 
Among various downstream effectors, intracellular signaling pathways such as 
mitogen-activation protein (MAP) kinase pathways appear to act as the focal points in 
response to a variety of extracellular stimuli (348). MAP kinase family contains four 
subgroups:  1) extracellular signal-regulated kinases (ERKs); 2) c-jun-N-terminal or 
stress-activated protein kinases (JNK/SAPK); 3) the p38 group of protein kinases; and 
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4) ERK/big MAP kinase 1 (BMK1) (349;350). ERK, p38 MAPK and JNK are all 
activated downstream of PAK1 and exert multiple cellular functions to react to 
extrinsic stress (199;351;352). 
In my study, distinct activation of p38MAPK and ERK as well as moderate activation 
of JNK was observed after chronic treatment with high glucose for several days. 
Other researchers have demonstrated that ERK, p38 MAPK, and JNK were activated 
by chronic hyperglycemia in some cell types other than β-cells (6;267;272;274). In 
pancreatic β-cells, transient incubation with high glucose (16 mM for less than 30 
min) has been reported to evoke activation of ERK and p38 MAPK but not JNK in 
INS-1 cells (252) and MIN6 (254). My study also revealed that activation of  
p38 MAPK and ERK could be activated by chronic high glucose, which could sustain 
for up to 72 h.  In contrast, activation of JNK was barely observed after prolonged 
treatment with glucose.  
Chronic hyperglycemia induced imbalance of pro-apoptotic and anti-apoptotic forces, 
which led to the lethal destiny. In the current study, I found that PAK1 knockdown by 
siRNA attenuated chronic high glucose-induced activation of p38 MAPK 
significantly but had no obvious effect on activation of ERK upon high glucose. ERK 
was widely considered as a survival mediator, which exerts protective role via 
suppressing Akt, the anti-apoptotic signaling pathway (352;353). Even though some 
recent studies have challenged it and provided evidence that activation of ERK 
contributes to cell death in some cell types, for instance in neuronal and renal 
epithelial cells upon stimulation by oxidative stress or deprivation of growth factors 
(354), and in cytokine (IL-1β and IFN-γ)-induced apoptosis of rat islets (355). The 
results from my studies support the survival role of ERK in glucotoxicity induced cell 
apoptosis. Although chronic activation of ERK was detected, inhibitors of ERK 
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(U0126), a widely used ERK inhibitor (356), did not attenuate cell apoptosis. In 
contrast, the glucotoxicity-induced cell apoptosis was slightly increased in the 
presence of U1206. Therefore, ERK might play a protective role for INS-1 cells after 
long term treatment with high glucose. Furthermore, glucotoxicity-activated ERK was 
not blocked by PAK1 knockdown significantly, suggesting that the stimuli other than 
PAK1 may be responsible for ERK activation induced by glucotoxicity in INS-1 cells.  
I observed that PAK1 knockdown by siRNA blocked high glucose-induced activation 
of p38 MAPK significantly. Furthermore, the glucotoxicity-evoked cell apoptosis was 
reduced by a specific inhibitor for p38 MAPK, SB203580 (357). To date, the role of 
p38 MAPK in apoptosis is still in debate. Although activation of p38 MAPK was 
reported to be a signal for mediating cell survival (307), accumulating evidence 
illustrated that p38 MAPK was implicated in oxidative stress, growth factor 
deprivation and inflammation cytokines induced cell death in insulin secreting cell 
lines such as RIN-5AH cells (358) and others (352;359-361). Mcginn et al found that 
although both p38 MAPK and ERK were activated after treatment of 25 mM glucose 
for 72 h, it is p38 MAPK that mediated high glucose-induced anti-proliferatative 
growth response in endothelial cells (267). This is in line with my findings in INS-1 
cells that p38 MAPK might act as a mediator acting downstream of PAK1 upon 
glucotoxicity. The inhibitors of p38MAPK attenuated high glucose induced INS-1 
cell apoptosis, thereby indicating a critical role of p38 MAPK in this scenario. 
However, it seems that PAK1 knockdown is more potent than p38 MAPK inhibitor 
for blockage of glucotoxicity-induced β-cell apoptosis. A possible explanation is that 
some effectors of PAK1 other than p38 MAPK may also mediate its role in cell 
apoptosis due to glucotoxicity.  
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Similar to ERK and p38 MAPK, JNK plays a role in both pro- and anti-apoptotic 
processes, depending on cell types, death stimulus and its activation extent. JNK 
suppressed apoptosis via phosphorylation of Bad in hematopoietic cells (362). 
Nonetheless, accumulating evidence has against its anti-apoptotic role. JNK, a stress-
activated protein kinase, was advised as a new therapeutic target for diabetes (363). 
JNK was activated by hyperglycemia and triggered caspase-3 activation thus 
facilitating cell apoptosis in HUVECs (6). JNK was also activated by oxidative stress 
and mediated its deteriorating role in islet dysfunction (259;270). Furthermore, 
suppression of JNK pathway protected β-cells from oxidative stress, ER stress, 
inflammatory cytokine damage, and toxic effect of hyperglycemia as reviewed 
previously (259). It is generally assumed that glucotoxicity on β-cells may, at least in 
part, result from generation of protracted oxidative stress and subsequent JNK 
activation (364). In current study an increase of ROS following chronic exposure to 
high glucose in INS-1 cells was observed. Although only weak activation of JNK 
evoked by chronic high glucose was detected using current methods in my study, the 
JNK inhibitor was able to promote prominent alleviation of glucotoxicity-induced 
apoptosis of INS-1 cell. In addition, such protective effect by JNK inhibitor is much 
stronger than that by knockdown of PAK1. These findings in my study suggest that 
JNK might also be implicated in apoptotic pathway in cells suffering from 
glucotoxicity, although the association between JNK activation and PAK1 remains 
unclear. (Fig. 34) 
 






Fig. 34. Schematic diagram for the role 
of MAPKs and PAK1 in glucotoxicity-
induced β-cell apoptosis.  
Knockdown of PAK1 by siRNA 
attenuated β-cell apoptosis due to chronic 
exposure to high glucose. Glucotoxicity 
evoked activation of p38 MAPK, 
ERK1/2 and JNK. Knockdown of PAK1 
blocked such activation of p38 MAPK 
but not ERK1/2 or JNK. Specific 
inhibitors for either p38 MAPK or JNK 
reduced glucotoxicity-induced apoptosis, 
whereas inhibitors for ERK1/2 
aggravated it. All together, p38 MAPK 
may mediate, at least partly, PAK1’s role 
in glucotoxicity-induced β-cell apoptosis.  
 
4.3 Conclusions 
Knockdown of PIP5K-Iα induced not only disruption of F-actin cytoskeleton but also 
alteration of insulin secretion, which is, at least in part, responsible for Rac1’s role in 
INS-1 cells as hypothesized. Furthermore, PIP5K-Iα silencing resulted in increased 
basal glucose metabolism, depolarized resting membrane potential, increased basal 
intracellular Ca2+ concentration and doubled basal insulin secretion, which are not 
related to Rac1’s effect. Therefore, my data suggest a complicated involvement of 
PIP5K-Iα in various cellular signaling events in β-cells.  
Knockdown of PAK1 by siRNA had no effect on F-actin cytoskeleton and insulin 
secretion in INS-1 β-cells. However, my results for the first time demonstrated that 
PAK1 was involved in INS-1 cell apoptosis induced by chronic exposure to high 
glucose. Knockdown of PAK1 also attenuated caspase-3 activation evoked by high 
glucose, indicating that PAK1 is required for the caspase-dependent apoptotic cascade 
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chronic exposure to high glucose, only p38 MAPK was involved, at least partly, in the 
role of PAK1 knockdown in protecting β-cells from glucotoxicity-induced apoptosis.  
4.4 Future work 
This study investigated the potential role of two downstream effectors of Rac1, 
PIP5K-Iα and PAK1, in insulin-secreting INS-1 cells. My thesis study has revealed 
that the former plays a role in reorganization of F-actin cytoskeleton and insulin 
secretion, while the latter contributes to cell apoptosis provoked by chronic exposure 
to high glucose. However, the present study has a limitation because of the use of 
transformed insulin-secreting cell line, whose properties are different from primary 
pancreatic β-cells to various degrees (74) which, for example, have extremely low 
ability to proliferate. The techniques of islet isolation, β-cell purification and long-
term culture in vitro have been advanced significantly. In addition, the development 
of lentivirus-based transfection system makes it feasible for knockdown of target 
proteins in purified β-cells. Therefore, the major findings on knockdown of PIP5K-Iα 
and PAK1 in INS-1 cells need to be verified in the primary β-cells in the near future. 
Moreover, all the present results were obtained based on depletion study. 
Consequently, overexpression of native PIP5K-Iα and PAK1 or their constitutively 
active mutants to rescue the knockdown outcomes may rule out any possible non-
specific effects by siNRA.  
4.4.1 Future work for the study of PIP5K-Iα  
This study has identified a role of PIP5K-Iα in the regulation of actin cytoskeleton 
and insulin secretion in INS-1 cells. However, there are some issues that remain to be 
further investigated.  
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1) PIP5K-Iα knockdown altered glucose metabolism. It would be interesting to 
examine if PIP5K-Iα knockdown causes the expression of some metabolic enzymes 
such as Glut2 (glucose transporter 2) and Gck (glucokinase) (365;366), as well as 
other critical enzymes for glucose metabolism by arrays. 
2) PIP5K-Iα knockdown depolarized membrane potential. This effect was verified by 
collaborators using electrophysiology based on patch-clamp experiment (367). It is 
required to define the underlying ion channel whose activity is modified by PIP5K-Iα 
knockdown. This could be due to the involvement of closing a non KATP channel or 
opening a cation channel. Both electrophysiological and pharmacological experiments 
can be performed to explore this issue.   
3) PIP2 dynamics and F-actin dynamics. Glucose stimulation may induce spatial 
redistribution of PIP2 and F-actin, which could be affected by knockdown of PIP5K 
Iα. F-actin staining in live cells could be acquired by microinjection of fluorescence-
labeled phalloidin (368) into cells transfected with a GFP-PLCδ construct as 
described in chapter 2. Thus cells with co-staining of PIP2 and F-actin can be 
subjected for live-image of fluorescence con-focal microscopy. 
4) Role of other PIP5Ks.  The implication of PIP5K-Iγ has been reported previously, 
and different findings have been reported (168). It would be also important to see the 
effects of knockdown of 2 or more PIP5Ks on β-cell functions.  
5) Possible role of PIP5K-Iα in glucotoxicity. When isolated islets or β-cell lines were 
exposed to very high glucose (glucotoxicity), similar results were obtained, i.e. altered 
glucose metabolism, enhanced basal insulin release but reduced glucose-stimulated 
insulin secretion (369-371). It would be interesting to know if PIP5K-Iα could be 
implicated in such pathological development in β-cells.  
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4.4.2 Future work for the investigation of PAK1 
My study on PAK1 has revealed its important role in glucotoxicity-evoked apoptosis 
of INS-1 β-cells. Despite that, further work is required to address some unsolved 
issues and extend the findings.  
1) Regulation of actin cytoskeleton by PAK. In the current study, PAK1 knockdown 
had no apparent effect on F-actin cytoskeleton or insulin secretion, unlike the effects 
of inhibition of its upstream activator, Rac1. The expression of other isoforms of PAK 
at protein level needs to be examined in INS-1 cells. Furthermore, it would be worthy 
to examine the effect of knockdown of other PAK isoforms on F-actin cytoskeleton or 
insulin secretion in β-cells.  
2) Role of PAK1 in activation of caspase-8 and -9. I have found that PAK1 
knockdown partially blocked activation of caspase-3, which plays a central role in the 
executive-phase of apoptosis. Activation of caspase-8 and -9 in glucotoxicity 
represents the involvement of extrinsic and intrinsic pathway respectively. However, 
whether PAK1 plays any role in either or both the pathways needed to be further 
investigated. 
3) Relationship between activation of caspases and stimulation of MAPKs. Although I 
observed that glucotoxicity led to activation of caspases and also some MAPKs, it is 
unclear about their potential interactions. In addition, it is also unknown how PAK1 
might be implicated in these relations. The activation of MAPKs or PAK1 can be 
measured after exposure to high glucose in the presence of caspase inhibitor. On the 
other hand, caspase activation can be examined by using specific inhibitors for p38 
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